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CHAPTER 1
DYNAMICAL ANALYSIS OF BLOOD-BASED SYSTEMS 
BIOMARKERS OF CENTRAL NERVOUS SYSTEM DRUGS
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Scope and intent of investigations
The body is a complex of interacting networks, and therefore the disciplines of pathology 
and pharmacology are shifting from a purely reductionist approach to a method that also 
includes an holistic approach [1–3]. Moreover, the biological processes related to these 
networks behave dynamically in response to drugs. The understanding of the dynamics 
of the biological processes improves the success rates in drug development [4,5]. In this 
thesis, we will focus on central nervous system (CNS) drug development as an example of 
a complex system that may suffer from a large series of serious pathologies. Neurological 
disorders and mental illnesses, hereafter named CNS diseases, are among the main con-
tributors to the global burden of disease affecting millions of people worldwide [6–8]. 
Yet, CNS drug development is hampered by low success rates (<10%) and long duration of 
development (~12.6 years) [9,10]. Among other reasons, this can be attributed to lack of 
understanding of underlying pathological and pharmacological processes and the lack of 
validated biomarkers that represent these processes. Indeed, biochemical pathway analy-
sis in cerebrospinal fluid (CSF) show a multitude of pathways involved in CNS diseases, with 
large overlap among CNS diseases [11]. In silico evaluation predicted that schizophrenia 
is characterized by a disbalance among the different neurochemical pathways throughout 
the brain that could partly be restored by antipsychotic drug treatment [12]. One of the 
questions is how we can translate these insights into methodologies that can be applied 
in CNS drug development, also considering the limitations of sampling from the human 
brain. In this thesis, we will therefore focus on two questions:
1. How can the relation between drug dose and the dynamic systems response be quanti-
fied in vivo?
2. How can blood-based markers that represent central drug effect be obtained?
Section I – General introduction
In Chapter 2 we first give a general introduction into the fields of pharmacokinetic/phar-
macodynamic (PK/PD) modeling and pharmacometabolomics and how these approaches 
have been applied in CNS drug development. As an example, PK/PD modeling enabled 
interspecies translation of the prolactin response, which is a biomarker of dopamine D2 
receptor antagonist effect [13]. Another example showed how pharmacometabolomics 
reveals new lipid biomarkers to evaluate and understand the relation between D2 antago-
nist treatment and weight gain [14]. The chapter subsequently discusses the challenges of 
integrating PK/PD modeling and pharmacometabolomics to enable the dynamic evaluation 
of the systems response upon drug treatment. A specific attention is paid to interspecies 
scaling in translational drug development.
Chapter 3 describes an overview of biochemical and endocrine markers in the brain and 
in plasma that have been associated with dopaminergic agents. Dopamine drugs are, for 
Scope and intent of investigations 9
example, used to treat schizophrenia (D2 antagonists) or Parkinson’s disease (D2 agonists). 
In addition to their interference with the dopamine pathway they also influence other 
neurochemical pathways [15]. Furthermore, since the D2 system is involved in the control 
of hormone release of the pituitary, peripheral hormone concentrations are expected to 
change upon administration of dopaminergic agents [16–18]. Finally, the D2 system is not 
only functional in the brain, in fact, it is widely distributed throughout the body being 
expressed in, for example, the gut, the adrenal glands and the kidney [19]. The aim of this 
chapter is to obtain an overview of the different biochemical and endocrine pathways in 
the brain and in plasma that are perturbed by these agents, to subsequently point direc-
tions to further improve biomarker-driven CNS drug development. Special attention will 
be paid to potential blood-based biomarkers that reflect drug effects in the brain.
Section II – The dynamical neuroendocrine systems response to study 
dopamine D2 drug effects
The neuroendocrine system provides a tight connection between the brain and the pe-
riphery. Its biological function is to control peripheral processes from the brain, such as 
stress and reproductive function. One of these neuronal pathways is the dopaminergic 
tuberoinfundibular pathway. It is well-known that activation of this pathway leads to 
enhanced release of dopamine into the pituitary, where it inhibits the prolactin release 
from the lactotrophs [17]. With regard to CNS drug development, this connection has 
received much attention for the discovery of blood-based biomarkers that reflect central 
drug effect [16].
In Chapter 4 we use the selective dopamine D2 antagonist remoxipride as a paradigm 
compound to evaluate the effect of D2 antagonism on the release of pituitary hormones 
and neuropeptides. While prolactin has been widely used to dynamically evaluate D2 
antagonistic drug effects [13,16,20], the other pituitary hormones and neuropeptides are 
not so often used for such evaluation. Given the biological relation between dopamine and 
multiple hormones, the aim of this chapter is to dynamically evaluate the neuroendocrine 
systems response upon remoxipride treatment in rats.
To place the results of remoxipride into perspective, in Chapter 5, the neuroendocrine 
systems response is evaluated with the selective D2 agonist quinpirole as paradigm com-
pound. D2 agonists may be expected to interact with the neuroendocrine system inversely 
to D2 antagonists, but this is not necessarily the case (Chapter 3). Comparing agonistic 
with antagonistic interactions is envisioned to provide more insight into the dopamine 
specific effects. While single administration dynamics provide insight into the short-term 
mechanistic interaction between the drug and the biological system, it does not take into 
account longer-term processes, such as tolerance and sensitization. As these processes 
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involve behavioral changes upon quinpirole treatment in rats [21], the neuroendocrine 
systems dynamics are evaluated with single and multiple quinpirole administration.
Section III – The dynamical biochemical systems response to study dopamine D2 
drug effects
The neuroendocrine system only represents a small part of the system-wide dopami-
nergic effects. Moreover, it utilizes one of the mechanisms through which blood-based 
biomarkers of neurological effects can be obtained. Indeed, neurochemical markers may 
also distribute from the brain into plasma to be discovered as blood-based biomarker. 
Pharmacometabolomics has proven useful for discovery of systems biomarkers of CNS 
drug effects and diseases [22,23]. For example, schizophrenia involves disturbances mul-
tiple metabolic pathways, including energy metabolism, neurotransmitter metabolism, 
fatty acid biosynthesis, and phospholipid metabolism, that are partially restored following 
risperidone treatment. Biomarkers such as myo-inositol, uric acid, and tryptophan were 
found important to distinguish disease and treatment groups [24]. Thus, pharmacome-
tabolomics provides a powerful approach for CNS drug biomarker discovery. At the same 
time, there is no methodology available that quantifies the dynamical pharmacometabo-
lomics response upon drug treatment. A logical step is the integration of PK/PD modeling 
and pharmacometabolomics, as is discussed in Chapter 2.
In Chapter 6 a methodology is developed to describe the pharmacometabolomics data by 
a PK/PD model, in order to reveal the systems-wide pharmacodynamics of remoxipride in 
plasma. The aim of this chapter is to quantify the multiple dose-response relationships un-
derlying the systems-wide effects of remoxipride in terms of pharmacologically meaning-
ful parameters such as potency (EC50), maximal effect (EMAX) and endogenous metabolite 
turnover rate (kOUT). Here, it is important to describe the pharmacokinetics of remoxipride 
simultaneously with the pharmacodynamics, in order to account for potential temporal 
delays between drug concentration and biomarker profile. Additionally, biomarkers that 
represent the diverse response patterns are presented for future validation.
The PK/PD-metabolomics method is taken a step further in Chapter 7 in which we de-
scribe multiple biomarker responses in plasma as well as in brain extracellular fluid upon 
administration with quinpirole. Again, it is important to describe the pharmacokinetics 
and the pharmacodynamics simultaneously, but now with an additional layer of complex-
ity: biomarker responses in brain as well as in plasma. This provides us the opportunity to 
identify response patterns that are specific for the brain or the periphery. Moreover, for 
biomarkers that show a response in brain as well as in plasma, we can indicate the target 
site of action by comparing the temporal response patterns in both biofluids. We show that 
multiple biomarkers respond in the brain and in plasma with different pharmacodynamic 
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characteristics (e.g. EC50, EMAX, kOUT). We also present potential (blood-based) biomarkers 
of quinpirole effects for future validation.
Section IV – General discussion and conclusion
In Chapter 8 we give an overall reflection on the results in the different chapters, discuss 
the implications of our findings, and provide directions for future research on the integra-
tion of PK/PD modeling and pharmacometabolomics in CNS drug development.
12 CHAPTER 1
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CHAPTER 2
BUNDLING ARROWS: IMPROVING TRANSLATIONAL 
CNS DRUG DEVELOPMENT BY INTEGRATED PK/PD-
METABOLOMICS
W.J. van den Brink, T. Hankemeier, P.H. van der Graaf, E.C.M. de Lange
Expert Opinion on Drug Discovery 2018 13(6):539-550
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Abstract
Introduction: Central nervous system (CNS) diseases affect millions of people worldwide, 
and the number of people is quickly growing. Unfortunately, the success of new CNS drugs 
in clinical development is less than 10%, and this has been contributed to the complexity 
of the CNS, unexpected side effects, difficulties for drugs to penetrate the brain and the 
lack of biomarkers.
Areas covered: First, we discuss how pharmacokinetic/pharmacodynamic (PK/PD) models 
are designed to predict the dose-dependent time course of effect, and how they are used 
to translate drug effects from animal to men. Then, we discuss how pharmacometabolo-
mics provides insight into system-wide pharmacological effects and why it is a promising 
method to study interspecies differences. Third, we advocate the application of PK/PD-
metabolomics modeling to advance translational CNS drug development by discussing its 
opportunities and challenges.
Expert opinion: It is envisioned that PK/PD-metabolomics will increase understanding of 
CNS drug effects and improves translational CNS drug development to increase success 
rates. Successful further development of this concept will need multi-level and longitu-
dinal biomarker evaluation over a large dose range, multi-tissue biomarker evaluation, 
and the generation of a proof of principle by application to multiple CNS drugs in multiple 
species.
Key words: Biomarkers; CNS drug development; Interspecies scaling; Pharmacometabolo-
mics; PK/PD modeling; Systems pharmacology
Highlights
1. Translational CNS drug development is shifting from an empirical to a mechanistic ap-
proach
2. PK/PD modeling in conjunction with scaling principles enables the interspecies transla-
tion of pharmacological CNS effects
3. Pharmacometabolomics provides a mean to compare the system-wide pharmacologi-
cal CNS effects in multiple species
4. An integrated PK/PD-metabolomics is envisioned to increase understanding of CNS 
drug effects and improve translational CNS drug development
5. To achieve an integrated PK/PD-metabolomics approach, we need multi-level bio-
marker evaluations, to study a large dose range, and longitudinal sampling from the 
brain, plasma, and CSF.
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1. Introduction
Central nervous system (CNS) diseases affect millions of people worldwide, and the num-
ber of people with such disease is quickly growing [1]. They are characterized by their high 
complexity as multiple neurotransmitter systems and biochemical pathways are involved 
[2–4]. It is therefore not surprising that CNS drug development suffers from low success 
rates (< 10%) and long duration (~12.6 years) [5,6]. Moreover, it is hampered by CNS medi-
ated side effects (e.g. nausea, dizziness), the presence of the BBB, lack of effective animal 
models and/or lack of integrative investigations in animals to investigate the mechanisms 
of CNS pathology and pharmacology, and the lack of biomarkers representing these 
mechanisms [6–9]. In particular, the translation from preclinical to early clinical studies 
is difficult.
Clearly, there is a need to improve the current methodologies within CNS drug develop-
ment. Two promising methods in this regard are pharmacokinetic/pharmacodynamic (PK/
PD) modeling and pharmacometabolomics [10–12]. PK/PD modeling allows to “charac-
terize and predict the time course of drug effects under (patho)physiological conditions” 
[13]. Pharmacometabolomics involves the “determination of the metabolic state to define 
signatures before and aſter drug exposure that might inform treatment outcomes” [14]. 
This review discusses how translational CNS drug development can be improved by the 
integrated application of PK/PD modeling and pharmacometabolomics. An overview will 
be provided of the role of both fields in translational CNS drug development, after which 
the opportunities and challenges of an integrated approach will be discussed.
2. Biomarker-driven development of central nervous system 
drugs
Current translational CNS drug development highly relies on behavioral endpoints, such as 
the 5-choice serial reaction time task. While these endpoints may provide reasonable con-
struct validity, their predictive validity is low [15,16]. Predictive validity, which includes a 
mechanistic rationale between the drug effect and the endpoint, is important to translate 
the preclinical to the clinical pharmacology [17]. It is therefore that biomarkers are in-
creasingly recognized as an essential element of CNS drug development [7,18–20]. Indeed, 
biomarkers have been defined as indicators of specific pharmacological or physiological 
processes [21,22]. Current biomarker strategies include receptor occupancy [23–25], 
functional imaging [26,27], biochemical measures in CSF [20], EEG [28,29], or physiological 
measures such as hormone release [30]. Biomarkers have been classified into multiple 
pharmacological levels following the causal relation of the drug dose to the clinical effect 
[31]. These are i) genotype or phenotype, ii) drug exposure, iii) target occupancy, iv) target 
activation, v) physiological/laboratory measures, vi) disease processes, vii) clinical scales. 
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Such classifi cati on provides a framework for rati onal drug development. In parti cular, as 
depicted in Figure 1, confi dence in the drug exposure, target binding, and target acti vati on 
are key components to guarantee successful translati onal drug development [12].
Figure 1. The conceptualizati on of an integrati ve approach. The plasma and brain drug exposure profi le are 
determined by the pharmacokineti cs, to drive the target binding and acti vati on of potenti ally multi ple tar-
gets. The acti vati on (or inhibiti on) of these targets elicits multi ple downstream biochemical eff ects, which 
can be evaluated by proteomics or metabolomics. These processes are described by mathemati cal expres-
sions as developed in the fi eld of PK/PD modeling.
3. PK/PD modeling in biomarker-driven CNS drug 
development
Not only the measurement of biomarkers is important for predicti on of the dose-eff ect 
relati on. It is also important to quanti fy the non-linear and ti me-dependent relati ons 
between the biomarkers to obtain insight into the dynamics of the pharmacological pro-
cesses. PK/PD modeling is used to mathemati cally describe these processes in terms of PK 
and PD parameters, for example, clearance, volume of distributi on, maximal drug eff ect or 
in vivo potency. Biomarkers thus enable the quanti tati ve characterizati on of the processes 
that are on the causal path between dose and eff ect. More specifi cally, biomarker data 
gives insight into pharmacokineti c (PK) parameters such as clearance and volume of distri-
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bution, or pharmacodynamic (PD) parameters such as maximal effect and in vivo potency. 
As such, PK/PD parameters provide a quantitative and scalable perspective on interspecies 
differences, thereby allowing the prediction of the first-in-human dose [17,30,32]. The 
components of a PK/PD model are the i) PK model that describes the exposure of the 
drug in the body; ii) the PD model that captures the relation between the drug concentra-
tion and the effect and iii) the link model that accounts for the possible delay between 
the concentration-time and the effect-time profile [13]. These components are further 
described in the next section.
3.1 PK/PD models
3.1.1 PK models
A crucial aspect of successful CNS drug development is the understanding of the distribu-
tion of the drug into the brain [33–35]. The intensity, onset, and duration of CNS drug 
effects depend on the concentration-time profile at the site of drug action. This brain is 
separated from the plasma by the blood-brain-barrier (BBB), which often influences the 
rate and extent of drug distribution into the brain. The transport over this barrier may be 
passive (driven by concentration gradient) and active (driven by transporters). In addition 
to the BBB, other factors, such as plasma protein binding, brain tissue binding, cellular 
uptake, brain metabolism, CSF flow, and physicochemical properties of the drug influence 
the drug exposure profile in the brain (for reviews and key research on this topic see refer-
ences [36–41]). Although classical PK modeling still often is used, physiology-based PK 
(PBPK) modeling is increasingly applied to predict the time course of drug concentrations 
at the site of drug action.
3.1.2. PD models
Whereas the understanding of the drug exposure at the target site is a crucial aspect in 
CNS drug development, the subsequent linkage to the PD (i.e. target binding and activa-
tion, and downstream physiological responses) is equally important for understanding 
drug effects [11,12]. Among others, receptor occupancy [23,25], EEG measures [28,42], 
hormone release [30] have been used to characterize the pharmacodynamic response 
of CNS drugs. The mathematical linkage of PD responses to the drug exposure has been 
extensively reviewed by Danhof et al. (2007) [43]. Still, in practice, an integrative approach 
including PK and PD in one study is often lacking. A widely used equation to link PK to PD 





where Emax is the maximal observed drug effect, EC50 is the in vivo potency and C is the 
concentration around the target (e.g. brainECF).
3.1.3 Link models
The effect-time profile is often delayed as compared to the drug concentration-time 
profile. If only plasma drug concentrations are known, one may assume that the delay is 
caused by slow distribution from plasma to the site of drug action. In such case, an effect 
compartment model is used to account for the delay [44]. Slow target binding kinetics may 
also cause a delay between PK and PD, and in such case, these can be explicitly included in 
the model [45]. Finally, downstream signal transduction may be relatively slow compared 
to the plasma PK, drug distribution, and the target binding kinetics, being responsible for 
the delay of the effect-time profile. This is often accounted for by a turnover model [46]. 
It assumes a continuous process of production and degradation (turnover) that drives the 
basal biomarker levels. The drug effect influences either the production or the degrada-
tion rates through inhibition or stimulation, thereby causing an increase or a decrease of 
the biomarkers levels.
3.2 Interspecies scaling
PK/PD modeling enables the rational extrapolation of drug effects between animal and 
men [47]. It does so by explicitly distinguishing the drug- and system-specific parameters 
[17,32]. Typical drug-specific parameters are plasma protein binding, target-binding affin-
ity, and intrinsic efficacy, while examples of system-specific parameters are tissue volumes, 
clearances, receptor expression, and turnover rate constants. While drug-specific param-
eters can be obtained from in vitro experiments, system-specific parameters can only be 
estimated from in vivo data and may be species-dependent. The interspecies scaling of 
these parameters follows two principles: allometric scaling and physiology-based scaling. 
With allometric scaling it is assumed that the parameters are dependent on bodyweight 






where P is the mathematical model parameter, BW is the bodyweight, and b is the species-
independent scaling exponent. Typically, allometric scaling is applied to clearance, volume 
of distribution, and turnover rate constants. The scaling exponent generally is 0.75 for 
the clearance, 1 for the drug distribution volume and -0.25 for the turnover rate constant 
[50,51]. As an illustrative example, the acetaminophen clearance extrapolates over a large 
range of species, including zebrafish larvae, rat and human, using allometric scaling [52]. 
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In another study, the prolactin effects of remoxipride were successfully scaled from rat to 
man, by applying allometric scaling on the turnover rate of prolactin in plasma [30].
The principle of physiology-based scaling is to replace the animal parameters by the hu-
man parameters [53]. While the physiology-based scaling of CNS PK is well developed, for 
example to predict the human CSF drug concentrations of acetaminophen and morphine 
[37,39,54,55], it has only started to emerge for PD. Some studies have shown that PD 
parameters such as Emax and EC50 may be similar across species for a series of drugs, for 
example for opioids and their effect on electrocardiogram output [29,56]. In contrast, 
other studies showed species-dependent PD parameters. A recent evaluation of a Tran-
sient Receptor Potential Melastatin-8 blocker showed 3-fold cross-species (mouse versus 
dog) differences in its potency, resulting in clinically important differences in core body 
temperature predictions [57]. In another study, the Emax and EC50 for prolonging the QT-
interval were found to differ between humans and dogs [58]. A third publication showed 
that the affinity of psychoactive drugs differed significantly between, for example, the D1rat 
and 5HT2rat, and D1human and 5HT2human receptors [9]. Also, the Emax and the EC50 of prolactin 
to control its own release was found different between rats and humans [30].
Overall, these examples show that the interspecies translation of CNS drug effects needs 
to be driven by the mechanistic understanding of drug- and system-specific properties at 
the level of PK and PD. Both allometric scaling and physiology-based scaling of PK/PD pa-
rameters can be used to support interspecies translation on basis of in vitro (drug-specific) 
and in vivo (system-specific) parameters. If clinical data is not available from same-in-class 
drugs, multiple species can be evaluated for these properties and simulations of worst-
to-best case scenarios can be used to guide the dosing strategies during early clinical 
development [57].
4. Pharmacometabolomics in biomarker-driven CNS drug 
development
Although PK/PD modeling aims to predict single biomarker time courses, it appears 
that CNS drugs typically affect multiple biochemical pathways [59,60]. For example, ris-
peridone affected multiple pathways including energy metabolism, antioxidant defense 
systems, neurotransmitter metabolism, fatty acid biosynthesis, and phospholipid metabo-
lism [61]. In fact, many successful CNS drugs were identified by serendipity on basis of 
phenotypic changes in vivo [62]. Indeed, the efficacy of neurological drugs is associated 
with multi-target affinity [63–65]. As an example, antipsychotics typically have interactions 
with multiple targets (up to 26 for clozapine and quetiapine) [63,64]. A comparison of 
haloperidol and clozapine showed that they caused a different biochemical phenotype, 
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that of clozapine close to that of the 5-HT2A antagonist M100907 [66]. However, although 
multi-target pharmacology may be related to the efficacy of e.g. clozapine, it is also as-
sociated with unwanted effects, for example cardiovascular disease [63]. Good insight 
into the systems behavior of multi-target drugs is essential to anticipate the (post-)clinical 
benefit-risk balance of drugs during early development. As such, pharmacometabolomics 
is suggested as an important method in drug development to biochemically understand 
in vivo neuropharmacological effects [67–69]. For example, using lipidomics, the underly-
ing pathways were identified that may explain antipsychotic-induced weight gain [70]. 
Metabolomics analyzes hundreds of biochemical molecules in biological samples, and 
as such, it can provide system-wide pharmacological biomarkers [14]. By measuring the 
biochemical end-products of cellular reactions it provides an intermediate metabolic 
phenotype between gene expression and drug effects on one hand, and clinical outcome 
on the other hand. In other words, it fulfills the definition of a type 4 biomarker [31] and 
can provide insights into the pharmacological pathways relevant to the clinical outcome. 
For example, a urinary metabolomics fingerprint could be used to predict the Kellgren-
Lawrence grade as a clinical endpoint for osteoarthritis [71]. As compared to other 
biomarker types, such as functional imaging, pharmacometabolomics is relatively cheap 
and easy to apply in preclinical and early clinical studies. Moreover, biochemical path-
ways are relatively similar across mammalian species, suggesting potential for applying 
pharmacometabolomics in translational drug development [72,73]. The main analytical 
tools that are used for metabolomics are nuclear magnetic resonance (NMR) technology 
and liquid chromatography-tandem mass spectrometry (LC-MS/MS). Both technologies 
have the advantage that they can identify a wide range of small molecules, providing a 
comprehensive picture of the metabolome. The metabolome contains more than 40000 
molecules, which typically have a molecular weight below 2 kD [74].
Of interest for the CNS-pharmacology are the energy substrates, neurotransmitters, amino 
acids and structural lipids, all of which are involved in cell viability, signaling, and cell 
membrane function [2]. It was specifically observed that the corresponding pathways were 
overlapping among CNS drugs and diseases, indicating that multi-biomarker approaches 
are important for the evaluation of drug effects [2,59]. Several clinical studies have been 
performed utilizing pharmacometabolomics for the study of CNS drug effects, although 
the main focus has been on the disease rather than on the treatment [75]. These studies 
showed that pharmacometabolomics has the potential to reveal new insights into lipid-
related side effects of antipsychotics [70,61], enable the early prediction of antidepressant 
effects on multiple biochemical pathways [76], or identify systems biomarkers of motor 
neuron disease treatment [77] and antiparkinson drugs [78].
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4.1 Multivariate analysis of pharmacometabolomics data
The endogenous metabolites are members of biologically highly connected pathways. 
Pharmacometabolomics data is therefore often evaluated by multivariate data analysis, 
which takes into account the connectivity among the individual metabolites. The purpose 
is to identify biomarkers that classify subgroups (e.g. treated vs. non-treated), and to 
elucidate the biochemical pathways that are perturbed with drug treatment. There are 
roughly three types of multivariate analyses: descriptive analyses (e.g. correlations), 
unsupervised methods, and supervised methods. (for review see [79]). An example of 
descriptive analysis is correlations between metabolite levels. These can be used to define 
a network with metabolites as nodes, while edges are drawn if the correlation coefficient 
exceeds a certain threshold (e.g. 0.8). In addition to correlation-based networks, more 
sophisticated methods have been developed, such as Gaussian graphical networks. These 
networks eliminate the direct correlations that are explained by indirect correlations, 
providing a much cleaner network [80,81]. The power of network analysis is that it shows 
a clear picture of the multifactorial changes under particular conditions, for example, 
treated vs. non-treated. In particular, it can identify the key metabolite pathways that 
underlie the pharmacological effects [82], as well as their synergistic or resilient charac-
teristics [83]. A network approach was, for example, used to understand the systems-wide 
effects of sertraline, showing that the tricarboxylic acid and the urea cycle, fatty acids and 
intermediates of lipid biosynthesis, amino acids, sugars and gut-derived metabolites were 
changed with four-week treatment [76]. A well-known unsupervised method is cluster 
analysis, which classifies samples or metabolites on basis of the proximity to each other 
with regard to, for example, the metabolite levels or the chemical similarity. This can 
reveal interesting patterns in the data, such as clusters of genes or metabolites that have 
similar biological functions [84]. Another well-known unsupervised method is principal 
component analysis (PCA), which identifies the latent variables (principal components) 
underlying pharmacometabolomics data [85]. These latent variables then represent the 
‘overall’ effect of a treatment in case of a pharmacometabolomics study. Closely related 
to PCA is the supervised partial least squares regression (PLS). This method optimizes a 
model to predict a certain output variable, for example, disease status or dose [77]. Both 
PCA and PLS elucidate which metabolites are most influential in explaining the variation 
between the subgroups.
4.2 Translational pharmacometabolomics to study CNS drug effects
The specific application of metabolomics in translational drug development has gained 
attention more than 10 years ago [72]. Metabolomics has an advantage over other ‘omics’ 
approaches with regard to interspecies translation. Indeed, endogenous metabolite path-
ways are highly identical among mammalian species. A recent study thoroughly compared 
the biochemical reaction network of rat and human, showing a strong overlap [73]. There 
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are, however, only a few studies that applied metabolomics in vivo to compare different 
species. Some studies showed how the metabolic phenotype of animal disease models 
for osteoarthritis and multiple sclerosis overlapped with the patients’ metabolic pheno-
type, indicating the potential of metabolomics for interspecies translation [72,86,71,87]. 
Although no efforts have yet been made to compare the animal and human metabolic 
phenotypes after drug treatment in vivo, the rat and mouse metabolic phenotypes were 
compared to study their differential sensitivity to cocaine [88]. It was found that the aryl 
hydroxylation pathway was dominant in rats, causing increased excretion of cocaine, 
which was not the case in mice. Interestingly, when comparing microsomes of humans 
versus these two species, the human cocaine metabolism showed a closer resemblance 
to the mice cocaine metabolism, indicating that the mouse is a better animal model for 
evaluation of cocaine sensitivity in humans. This study shows how pharmacometabolomics 
could be used to guide interspecies translation of CNS drug effects. Nevertheless, care 
should be taken with regard to the assumption that the biochemical reaction networks are 
species independent. The bile acid, carbohydrate, glycine-serine-threonine, purine and 
ascorbic acid pathways were found to have reactions specific for rats, while the glycan 
and sphingolipid pathways included human specific reactions, as measured in hepatic 
cells. These species differences may result in large differences in even opposite effects on 
certain endogenous metabolites [73]. In such case, further information on the pathway 
is important to extrapolate the preclinical findings. The ascorbic acid change in rats, for 
example, reflects a change in the glucuronic acid metabolism, which is also present in 
humans [89]. This information can then be used for the interspecies translation.
5. The integration of pharmacometabolomics and PK/PD 
modeling in translational CNS drug development
Translational CNS drug development can thus potentially profit from both PK/PD model-
ing and pharmacometabolomics; both are envisioned to contribute to biomarker-driven 
development. An integration of PK/PD modeling and pharmacometabolomics is envi-
sioned to provide scalable system-specific parameters for multiple biochemical pathways 
that are potentially relevant for the clinical drug effects. A conceptual workflow of such 
translational approach is depicted in Figure 2. Recent suggestions have been made to 
use pharmacometabolomics in PK/PD frameworks as static or dynamic markers [90,91]. 
While static metabolic phenotypes can be used as a predictor for treatment responses, 
dynamic metabolic phenotypes allow to follow the treatment effect over time to evaluate 
the system-wide dynamics [90,92,93].
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Figure 2. The integrati ve approach of metabolomics and PK/PD modeling as applied to interspecies scaling 
in CNS drug development. Such approach starts with animal experiments to collect longitudinal brainECF and 
plasma samples during treatment with a CNS drug. These samples are analyzed for drug concentrati ons and 
metabolomics to subsequently develop a multi variate PK/PD model. By applying the principles of interspe-
cies scaling a humanized model is defi ned to select doses for the clinical study. Plasma drug concentrati ons 
and metabolomics data of the clinical study will be used to recalibrate the model and increase the under-
standing of interspecies diff erences.
5.1 Longitudinal analysis of pharmacometabolomics responses
A longitudinal multi variate evaluati on of pharmacometabolomics data was performed by 
Rasmussen and colleagues, who were one of the fi rst doing that in the fi eld of clinical 
pharmacology [94]. This multi variate fi ngerprint was suitable for guiding dose selecti on of 
recombinant interleukin-21 in pati ents with metastati c melanoma.
5.2 PK/PD based analysis of pharmacometabolomics responses
In additi on to longitudinal evaluati on of the pharmacometabolomics response, the inte-
grati on with PK/PD modeling has been shown in a few studies. Clustering of longitudinal 
transcriptomics data formed the basis for the 6 turnover models in one study. Together, 
these turnover models formed a complex PK/PD model that described the gene-expression 
signaling cascade in the rat liver aft er corti costeroid treatment [84]. In another study, clus-
tering was applied to the PK/PD parameters identi fi ed from pharmacometabolomics data 
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in rats aft er remoxipride treatment [95]. This analysis revealed 6 unique PK/PD relati ons, 
18 potenti al biomarkers and two perturbed pathways (Figure 3). It has the potenti al to 
defi ne a therapeuti c window on basis of multi ple biomarkers, provides a list of biomark-
ers to take into account in additi onal studies, and gives insight into biological eff ects of 
remoxipride. The applicati on of such analysis in multi ple species will give insights into 
species-diff erences on the PK/PD parameters that describe the longitudinal pharmaco-
metabolomics response. Depending on the diff erences in parameters, dosing strategies 
can be defi ned following simulati on of worst-to-best case scenarios as was performed by 
Gosset et al. [57] for the eff ect of a Transient Receptor Potenti al Melastati n-8 (TRPM8) 
blocker on a single marker (core body temperature). Eventually, pharmacometabolomics 
data analysis methods can aid the development of quanti tati ve systems pharmacology 
(QSP) models which aim to mathemati cally describe the interacti ons between multi ple 
elements of the biological system (e.g. biomolecules, cells, ti ssues) in order to understand 
the impact of drugs on the system as a whole [91,96,97]. Quanti tati ve metabolic networks 
can provide a topological basis of QSP models to be integrated with organ-level networks, 
receptor binding kineti cs and PK [91,97]. QSP models are promising for interspecies trans-
lati on by humanizing the animal-based model parameters [9,98,99].
Figure 3. A metabolomics study combined with multi variate PK/PD modeling revealed 6 diverse response 
patt erns (middle) for remoxipride in rats. These response patt erns were represented by 18 metabolites that 
could potenti ally functi on as biomarker (right), rendering further validati on. The response clusters were 
associated with 2 known biological pathways (left ). Modifi ed from reference 95.
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5.3 Predicti on of the human brain pharmacometabolomics responses
In vivo pharmacometabolomics studies typically use plasma samples to characterize the 
system-wide drug eff ects. The plasma metabolic phenotype is a composite extracti on of 
all individual ti ssue metabolic phenotypes. Although this provides the opportunity to 
evaluate whole-body treatment eff ects in an easily accessible body fl uid, it can limit the 
quanti tati ve interpretati on of the treatment response that originates in a specifi c ti ssue. 
This is parti cularly true for CNS treatments, for which the metabolic biomarkers have to 
distribute over the BBB (Figure 4). This was illustrated by the fact that plasma monoamine 
levels were decreased with CNS drug treatment, whereas CSF levels were not aff ected 
[20,78]. Likely, the eff ects were caused in the periphery, and did not provide informati on 
on the central brain eff ects of these drugs.
Figure 4. Brain metabolic phenotypes are refl ected in the periphery via three mechanisms: i) individual 
metabolites distribute to CSF, plasma and urine, and become integrated in the peripheral metabolic phe-
notype; ii) the brain metabolic phenotype aff ects the peripheral nervous signaling, thereby controlling 
the release of peripheral metabolites, such as acetylcholine or norepinephrine; iii) the brain metabolic 
phenotype infl uences the neuroendocrine system via the hypothalamus, modifying the pituitary hormone 
release. Modifi ed from reference 59.
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A useful technique that has been used to study CNS drug PK and PD is intracerebral mi-
crodialysis [100–103]. It allows longitudinal sampling within a single individual to follow 
the treatment response over time. Moreover, since microdialysis allows the collection 
of molecules with a molecular weight below 20 kD, it is highly suitable for pharmaco-
metabolomics analysis [104,105]. Notably, microdialysis, for ethical reasons, is limited in 
humans. Animals are therefore typically used to characterize the relation between the 
brain- the CSF- and the plasma metabolic phenotypes. Following the translation PK/PD-
metabolomics workflow depicted in Figure 2, the human brain metabolic phenotype can 
subsequently be predicted using the principles of interspecies scaling and calibrated with 
the human plasma and CSF metabolic phenotypes.
5.4 Disease dependent PK/PD-metabolomics approach
This review has mainly focused on the treatment, rather than on the disease. Here, we 
would like to spend a few words on the influence of pathology on the pharmacology; a 
patient may respond differently to a treatment than a healthy individual. Both the CNS 
drug PK and PD can be affected by the disease, and this influence is drug-specific. For 
example, the morphine PK changed with traumatic brain injury [39], and the rate of dopa-
mine metabolism was higher in a rotenone rat model of Parkinson’s Disease as compared 
to control [103]. Thus, the understanding of the two-way interaction between pathology 
and pharmacology in the context of translational CNS drug development is important. 
Metabolomics was found useful to understand species differences with regard to pathol-
ogy [72]. As such, it has potential to translate the pathology-dependent pharmacology 
from animal to men [106].
6. Conclusion
This review discussed the merits of PK/PD modeling and pharmacometabolomics in the 
field of translational CNS drug development. PK/PD models can predict human biomarker 
time courses on basis of animal data using the principles of interspecies scaling. Phar-
macometabolomics can measure the biochemical responses to evaluate the system-wide 
CNS drug effects among species. The integration of PK/PD modeling and pharmacome-
tabolomics studies is envisioned to enable the prediction of longitudinal, dose-dependent 
system-wide responses, and has begun to receive attention [90,91,95]. The opportunities 
and challenges of such integration were discussed with regard to translational CNS drug 
development. Although we are still at the stage of early conceptual development, such 
integration is envisioned to increase understanding of system-wide pharmacology and to 
improve the interspecies translation of CNS drug effects.
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7. Expert opinion
7.1 The potential of integrated PK/PD and pharmacometabolomics in 
translational CNS drug development
CNS drug development is suffering from low success rates, which, for a large part, can 
be attributed to the empirical approach in translational development [6,12]. This led to 
the realization to shift towards mechanism-based prediction of clinical on basis of pre-
clinical pharmacology. In particular, PBPK and PK/PD modeling are increasingly applied 
in drug development to guide dosing strategies for early clinical studies [39,47,57,107]. 
The strength of these models is that they describe the dynamics of pharmacological 
processes, which can be scaled from animals to humans. While the PD models typically 
describe the drug effect on a single biological pathway, pharmacometabolomics provides 
a means to evaluate multiple pathways obtaining a comprehensive insight into the system-
wide pharmacology of a CNS drug [69,108]. Interestingly, the metabolome is structurally 
very similar among mammalian species, enabling a direct comparison of their metabolic 
phenotypes, although there are a few differences that need caution (e.g. ascorbic acid 
production in rats, but not in humans) [72,73]. At this moment, only very few studies have 
been performed to investigate the interspecies correlations of metabolic phenotypes. 
Moreover, pharmacometabolomics is mostly applied in a static manner, although dynamic 
approaches are emerging [90,94,95].
PK/PD modeling and pharmacometabolomics are thus complementary to each other. 
Since both fields have a potential for translational CNS drug development, their integra-
tion is promising. It has the potential to identify the pharmacologically relevant param-
eters of the system-wide drug effects [95]. Using the principles of interspecies scaling, 
these parameters can be humanized, and predict the clinical on basis of the preclinical 
pharmacology. The model can subsequently be validated on basis of the clinical metabolic 
phenotype (Figure 2).
7.2 Challenges and recommendations for the integration of PK/PD modeling 
and pharmacometabolomics
Several aspects of study design and data analysis need consideration to achieve an inte-
gration of PK/PD modeling and pharmacometabolomics.
7.2.1 Multi-level biomarker evaluation
To achieve an integrative understanding of the pharmacological action, multi-level bio-
marker data needs to be collected, for example, plasma drug concentrations, brain drug 
concentrations, (multiple) target occupancies, biochemical biomarkers. Eventually, these 
biomarkers will be linked to physiological measures and clinical outcome during clinical 
development.
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7.2.2 Longitudinal sampling over a large dose range
To capture the dynamics of the PK/PD response, longitudinal data is essential. Serial plasma 
sampling and intracerebral microdialysis are useful methods to obtain time courses of CNS 
drug concentrations, as well as biochemical markers, in plasma and brain. Of interest, 
isotope-labeling based metabolomics (also called flux-based metabolomics) is an emerg-
ing discipline that enables the capturing of network dynamics when applied in combina-
tion with longitudinal sampling [109,110]. Additionally, a large drug concentration range is 
needed to have information on all parts of the non-linear concentration-response curve. 
This is particularly important with a comprehensive pharmacometabolomics evaluation, 
since individual metabolites may have a different position on the concentration-response 
curve [95].
7.2.3 Integrated PK/PD-metabolomics analysis
Longitudinal pharmacometabolomics data in conjunction with drug concentration data 
needs to be described using PK/PD modeling in order to identify a fingerprint of pharma-
cologically relevant parameters such as the in vivo potencies, the maximal drug effects or 
the turnover rates [90,95] (Figure 2, 3). 
7.2.4 Multi-tissue biomarker evaluation
Drug concentrations and endogenous metabolites must be analyzed in multiple biofluids, 
such as plasma, brainECF, and CSF to understand how the plasma metabolic phenotype 
relates to the target site effect (Figure 4).
7.2.5 Generate proof of principle for an integrated PK/PD-metabolomics approach in 
translational CNS drug development
A primary challenge will be the generation of proof of principle for the integrated PK/
PD-metabolomics approach.
First of all, multiple same-in-class drugs are to be compared biochemically using a phar-
macometabolomics approach. Haloperidol and clozapine showed different efficacy on 
basis of a multivariate analysis with 58 different components of movement, as well as a 
multivariate evaluation with monoamines [66]. Although both analyses marked the fact 
that haloperidol and clozapine showed different efficacy, the pattern was not similar for 
the behavioral and the monoamine analysis. This indicates two things: 1) a multivariate 
biochemical is promising with regard to understanding differences between same-in-class 
drugs. 2) The abovementioned analysis showed that the monoamine based evaluation, 
although recognizing the pharmacological complexity, still is oversimplified to explain the 
behavioral outcome.
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A second aspect that needs to be included to provide proof of principle is the application 
of longitudinal metabolomics in multiple species, including humans. Taking into account 
the known species-differences, the interspecies metabolomes should be compared to 
understand and map species differences and evaluate applicability of pharmacometabo-
lomics in translational CNS drug development [73]. In particular, it will be important to 
validate the scaled PK/PD models in humans.
A third aspect is to relate the metabolic fingerprint to relevant clinical (side) effects. Kad-
durah-Daouk et al. [70] nicely showed this for risperidone, olanzapine and aripiprazole, 
comparing their lipidomic profiles. Interestingly, aripiprazole showed less impact on lipids, 
which was associated with the absence of weight gain as a side effect. Further studies will 
indicate whether such approach is generally applicable in drug development.
7.3 The future of translational CNS drug development with an integrated PK/
PD-metabolomics approach
It is envisioned that the integration of PK/PD and pharmacometabolomics will increase the 
understanding of system-wide pharmacology and improve the interspecies translation of 
CNS drugs. Specifically, it is envisioned to enable the extraction of system-wide pharma-
cologically relevant parameters that can be scaled to humans. Additionally, information 
on biomarkers and pathways is obtained. This advancement must be seen together with 
the developments in the field of QSP [91,96,97]. The integrated PK/PD-metabolomics ap-
proach reveals a PK/PD fingerprint biomarker representing the dynamics of known and 
unknown pathways. QSP aims to connect the cellular pathway response with the organ- or 
system-level response. On one hand, the integrated PK/PD-metabolomics approach can 
thus inform QSP models on relevant pharmacological pathways. On the other hand, QSP 
models can identify the mechanistic relationship between the single metabolites described 
by an integrated PK/PD-metabolomics model.
Altogether, an integrated PK/PD-metabolomics approach is envisioned to have a promising 
role in translational CNS drug development by providing a method to scale system-wide 
effects from animal to men (Figure 2).
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Abstract
Despite substantial research carried out over the last decades, it remains difficult to 
understand the wide range of pharmacological effects of dopaminergic agents. The 
dopaminergic system is involved in several neurological disorders, such as Parkinson’s 
disease and schizophrenia. This complex system features multiple pathways implicated in 
emotion and cognition, psychomotor functions and endocrine control through activation 
of G protein-coupled dopamine receptors. This review focuses on the system-wide effects 
of dopaminergic agents on the multiple biochemical and endocrine pathways, in particular 
the biomarkers (i.e., indicators of a pharmacological process) that reflect these effects. 
Dopaminergic treatments developed over the last decades were found to be associated 
with numerous biochemical pathways in the brain, including the norepinephrine and 
the kynurenine pathway. Additionally, they have shown to affect peripheral systems, for 
example the hypothalamus-pituitary-adrenal (HPA) axis. Dopaminergic agents thus have 
a complex and broad pharmacological profile, rendering drug development challenging.
Considering the complex system-wide pharmacological profile of dopaminergic agents, 
this review underlines the needs for systems pharmacology studies that include: i) pro-
teomics and metabolomics analysis; ii) longitudinal data evaluation and mathematical 
modeling; iii) pharmacokinetics-based interpretation of drug effects; iv) simultaneous 
biomarker evaluation in the brain, the cerebrospinal fluid (CSF) and plasma; and v) specific 
attention to condition-dependent (e.g., disease) pharmacology. Such approach is consid-
ered essential to increase our understanding of central nervous system (CNS) drug effects 
and substantially improve CNS drug development.
Keywords: dopaminergic agents; biomarkers; systems pharmacology; CNS drug development
Abbreviations
3-MT: 3-methoxytyramine; 5-HT: serotonin; 5-HIAA: 5-hydroxyindoleacetic acid; α-MSH: 
alpha-melanocyte stimulating hormone; ACh: acetylcholine; ACTH: adenocorticotropic 
hormone; BBB: blood-brain-barrier; BrainECF: brain extracellular fluid;; CNS: central nervous 
system; CRH: corticotropin releasing hormone; CSF: cerebrospinal fluid; DOPAC: 3,4-di-
hydroxyphenylacetic acid; DRN: dorse raphe nucleus; EPN: entopeduncular nucleus; EPS: 
extrapyramidal symptom; FSH: follicle stimulating hormone; GABA: gamma-aminobutyric 
acid; GnRH: gonadotropin releasing hormone; GPe: external globus pallidum; GPi: internal 
globus pallidum; HPA: hypothalamic-pituitary-axis; HVA: homovanillic acid; LH: luteinizing 
hormone; MSN: medium spiny neuron; NAc: nucleus accumbens; NMDA: N-methyl-D-
aspartate; NOS: nitric oxide synthase; PFC: prefrontal cortex; PNS: peripheral nervous 
system; PVN: paraventricular nucleus; SN: substantia nigra; VMAT: vesicular monoamine 
transporter; VTA: ventral tegmental area
Biomarker strategies for dopaminergic treatments 39
Introduction
Over the last decades, the development of therapies targeting diseases affecting the 
central nervous system (CNS) has been facing numerous challenges while the number 
of people suffering from CNS disorders has tremendously grown, exceeding one billion 
worldwide nowadays [1,2]. The challenges mostly rely on the insufficient knowledge of 
biomolecular mechanisms underlying many CNS-related diseases, as well as the poor un-
derstanding of mechanisms of action of many CNS drugs. In order to improve drug efficacy, 
both pharmaceutical industry and academic community have fostered the implementation 
of biomarker-based approaches for translational pharmacology and dose decision-making 
in clinical settings. A biological or biochemical marker represents a measurable sign with 
regard to a pharmacological or pathological process, providing a clinically meaningful 
endpoint in predicting the effect of a chosen treatment [3–5]. Biological markers are 
recognized as a valuable tool in drug development, allowing for further elucidation of 
both drug efficacy and side effects. CNS drug discovery and development faces multiple 
challenges, including the large number of drugs that fail in late phases of clinical trials 
due to poor understanding of processes underlying the dose response relation [6]. In this 
context, biomarkers represent an attractive alternative approach to support identification 
of most promising compounds, guide the dosing strategies in early clinical trials, and help 
recognizing a patient population that is most likely to benefit from a specific treatment.
This systematic and exhaustive review presents all biochemical indicators that have been 
previously reported as being related to dopaminergic drug effects, as well as their poten-
tial role in biomarker-driven CNS drug development, focusing on biomarkers in rodents 
biofluids, specifically brain extracellular fluid (brainECF), cerebrospinal fluid (CSF), plasma 
and urine.
Anatomy and physiology of the dopaminergic system
Dopamine is a neurotransmitter that belongs to the catecholamine family and is primarily 
synthesized in the brain and the kidneys. In the brain, dopamine is produced in the cell 
bodies of dopaminergic neurons located in the substantia nigra (SN), the ventral tegmental 
area (VTA) and the hypothalamus. These neurons send projections to multiple brain areas 
where dopamine is stored and released, including the striatum (nigrostriatal pathway), the 
prefrontal cortex (PFC) (mesocortical pathway), the nucleus accumbens (NAc) (mesolimbic 
pathway) and the pituitary gland (tuberoinfundibular pathway), as illustrated in Figure 
1. It should be noted that these pathways do not represent all dopamine systems in the 
brain. Other systems, such as the thalamic dopamine system, are increasingly recognized 
as important additional components of the brain dopamine pathways [7]. The presence 
of dopamine in the mesolimbic pathway is related to positive reinforcement, reward and/
or pleasure, while in mesocortical pathway it is involved in cognitive control of behavior. 
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Furthermore, the role of dopamine in the nigrostriatal pathway, transmitt ed from the SN 
(midbrain) to the putamen in the dorsal striatum, is to simulate reward-related cogniti ve 
processes as well as psychomotor functi on. The tuberoinfundibular pathway projects 
dopaminergic neurons from the hypothalamus to the pituitary gland to modulate secre-
ti on of hormones, including prolacti n. Dopaminergic pathways also project from the VTA 
(midbrain) to the amygdala, the hippocampus, and the cingulate cortex. As such, dopa-
mine is simultaneously involved in both emoti onal and memory processing. Dopaminergic 
neurons form a ti ght network with a number of other neuronal pathways, including cho-
line, glutamate and gamma-aminobutyric acid (GABA) systems, showing its possible role 
in multi ple complex processes. Therefore, any drug targeti ng the dopaminergic neurons 
may infl uence multi ple transducti on pathways including both the dopaminergic and other 
systems.
Figure 1. Overview of the dopaminergic system. A. Representati on of the dopamine pathway architecture 
in the brain. B. Illustrati on of the dopamine producti on and degradati on, as well as the synapti c signaling.
Five dopamine receptor subtypes, oft en referred to as D1–5 receptors, have been reported 
in the CNS, all being G-protein coupled receptors that may functi on independently but of 
which the downstream pathways may also interact [8]. Dopamine receptors are divided 
into D1- and D2-like receptor classes, the D1 receptor class including D1 and D5 receptors 
while D2 receptor class includes D2, D3, and D4 receptors. D1 receptor and D2 receptor class-
es have opposing eff ects with regard to adenylyl cyclase acti vity, cAMP concentrati ons, as 
well as phosphorylati on of proteins, resulti ng in either sti mulatory or inhibitory acti on on 
voltage-gated and ion channels in synapses [9]. D1 receptor are highly expressed in the 
striatum, NAc, SN, frontal cortex and amygdala, while lower expression of D1 receptor is 
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found in the hippocampus, thalamus, and cerebellum. D2 receptor are mainly localized in 
the striatum, NAc, SN, hypothalamus, cortical areas, amygdala and hippocampus. Although 
dopamine receptors are most densely expressed in the brain, they are also found in the 
periphery in different patterns of expression [10], highlighting the system-wide effects of 
dopamine that are crucial in maintaining homeostasis.
Dopaminergic agents for treatment of neurological disorders
The dopaminergic system has been exploited for treatment opportunities in a large variety 
of disorders. Due to its broad implication in pathophysiology, the current pharmacological 
efforts mostly focus on targeting both the dopamine receptors and subsequent post-
receptor mechanisms. Different types of dopaminergic drugs have been developed so far, 
primarily dopamine agonists and dopamine antagonists.
Dopamine agonists
dopamine agonists have been developed for treating Parkinson’s disease, a progressive 
neurodegenerative disorder presenting both motor and non-motor symptoms. The pathol-
ogy of the Parkinson’s disease is characterized with an extensive loss of dopamine neurons 
in the SN and accumulation of the protein α-synuclein in Lewy bodies within nerve cells 
in specific brain regions [11]. Although the underlying mechanisms leading to Parkinson’s 
disease remain poorly understood, a strong association between low dopamine brain 
levels and Parkinson’s disease symptoms has been frequently reported [12]. Dopamine 
receptor agonists, introduced first in 1970 for the treatment of Parkinson’s disease, act 
directly on dopamine receptors to mimic endogenous neurotransmission. Levodopa (L-
DOPA), a pro-drug crossing the blood-brain barrier (BBB), was the first therapeutic option 
available for treating Parkinson’s disease. Various other agonists, e.g., apomorphine, 
bromocriptine and pramipexole, have been later developed and commercialized, showing 
comparable effectiveness [13].
Dopamine antagonists
While most of the currently available dopamine agonists are used for Parkinson’s disease, 
the vast majority of dopamine antagonists have been developed for the treatment of 
schizophrenia. Multiple studies using animal models of schizophrenia have elucidated a 
pattern of persistent hyperdopaminergic state, accompanied with altered stimulus recruits 
of dopamine in different brain regions. Cognitive impairments during psychosis might thus 
be explained by a rapid release of dopamine into the mesolimbic and the nigrostriatal 
regions [14]. Chlorpromazine was the first and extremely potent antagonist of D2 receptor 
discovered, which considerably fostered antipsychotic drug development. Nevertheless, 
chlorpromazine treatment is accompanied with pronounced adverse effects, including 
neuroleptic malignant syndrome and extrapyramidal symptoms (EPS) such as tardive 
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dyskinesia. Other D2 receptor antagonists, e.g., haloperidol, risperidone and clozapine, 
have been developed to exhibit comparable or greater effectiveness with fewer of these 
side effects, in particular EPS [15,16].
Many of dopaminergic agents were discovered with incomplete understanding of their 
modes of action, often resulting in unpredictable side effects and/or off-target effects. It 
is only after having been introduced to market that studies were conducted to elucidate 
their modes of actions, which revealed multiple pathways affected [17–19].
Selectivity of dopaminergic drugs
Clozapine is currently the “gold standard” for the treatment of schizophrenia[15]. Interest-
ingly, this is one of the least selective D2 receptor antagonists [16,20]. Indeed, schizophre-
nia is a polygenic disease, and therefore a ‘shotgun-approach’ may be more successful 
than a ‘magic-bullet approach’ [16]. Many D2 receptor antagonists have therefore affinity 
for more receptors, including serotoninergic, adrenergic, muscarinic, and histaminergic 
receptors [16,20]. Also many D2 receptor agonists were found non-selective, with affinity 
for other dopaminergic, serotonergic, adrenergic and histaminergic receptors [21]. This 
should be taken into consideration when evaluating the effects of these agents on the 
system-wide biochemical pathways.
This review aims to further improve the understanding of mechanisms of action by provid-
ing an extensive overview of the pathways that are affected by dopaminergic agents, with 
the hope to increase our understanding of system-wide dopaminergic pharmacology, as 
well as to provide directions on how to improve pharmacological biomarker strategies 
during early drug development.
Methods
A systematic overview of literature over the past 25 years has been built, focusing on 
dopaminergic treatment effects on central and peripheral biomolecular pathways in rats. 
A search of the PubMed database was conducted in September 2017 by using the follow-
ing key words: dopamine antagonists, dopamine agonists, biogenic amine, amino acid, 
hormone, cytokine, lipid, neurotransmitter, cerebrospinal fluid, intracerebral microdialy-
sate, plasma, urine, rat (see Supplementary Data S1 for the exact search code), yielding 
to 1058 articles (English only). Only studies describing the effects of dopaminergic agents 
and elucidating a potential biochemical indicator of drug action in rats were included. In 
vitro studies, experimental studies focusing only on behavioral changes and/or reactions, 
studies of cognition patterns or event-related potentials, and studies that only included 
pharmacokinetic information were excluded. Furthermore, studies including functional 
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imaging techniques or electroencephalography, investigating dopamine receptor affini-
ties, functions, and synthesis, exploring the effect of dopaminergic agents in combination 
with other pharmacological agents, under pathological conditions, after surgical proce-
dures such as adrenalectomy or ovariectomy, with pregnant or lactating animals, and with 
animals under long-term food restriction were excluded as well. Finally, prolactin, being 
considered a standard marker of dopaminergic activity with well-explored functions and 
relationship with dopamine [22–24], has been excluded. After selection, 260 articles were 
included.
Dopaminergic treatment effects on endogenous metabolites levels in the CNS
The CNS-wide effects of dopamine receptor agonists and antagonists reported in 
the selected studies are shown in Table I and Figure 2. Although information was also 
gathered from studies involving intracerebral administration, only data after systemic 
administration is presented to obtain insights into clinically relevant effects. Moreover, 
a distinction is made between short-term and long-term treatment effects. Most of the 
effects reported in the CNS have been mainly observed in brainECF, using microdialysis, 
leading to deeper insights into neurotransmitter pathways. Overall, the reported literature 
emphasizes the CNS-wide effects of dopaminergic agents, including dopamine pathway 
but also norepinephrine, cholinergic, GABA-glutamate, serotonin, kynurenine, nitric oxide 
and endocannabinoid pathways.
Several considerations have to be taken into account for the discovery of easily accessible 
biomarkers that reflect these systematic effects, notably (Figure 3):
i) detectability in CSF, plasma or/and urine;
ii) simultaneous evaluation together with other markers of the pathway of interest to 
understand the dynamics between the drug and the pathway;
iii) Sufficient understanding of central and peripheral response
iv) Identification of distribution rates between brain, CSF, plasma and urine to understand 
the temporal relation between the biomarker peripheral concentration and effects in 
the brain.
Effects on the dopamine pathway
Metabolism and signaling of the dopamine pathway
The synthesis of dopamine involves the conversion of tyrosine into L-DOPA, the precur-
sor of dopamine. It is stored into vesicles in the presynaptic neuron, following uptake 
via the vesicular monoamine transporter (VMAT). These vesicles release dopamine into 
the synaptic cleft, where it may bind to pre- or postsynaptic dopamine receptors to pass 
on neuronal signals to the post-synaptic neuron. The dopamine present in the synaptic 






































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































hydroxyphenylaceti c acid (DOPAC) or 3-methoxytyramine (3-MT), or by uptake into the 
presynapti c neuron via the dopamine transporter. In the latt er case, dopamine is stored 
into vesicles, or degraded to HVA or DOPAC.
Figure 3. Conceptual considerati ons for the use of accessible biomarkers in CSF, plasma or urine to refl ect 
dopamine drug eff ects in the brain. The grey solid lines represent the distributi on of biochemical pathway 
components to CSF, plasma and urine. Since only part of the pathway components may distribute to these 
biofl uids, some of the nodes are fi lled blank. The grey dashed line represents the peripheral nervous system 
(PNS) that may infl uence the peripheral release of biochemical markers through electrical signaling. The 
grey dott ed lines represent the neuroendocrine system (NES), which is electrically controlled at the level of 
the hypothalamus and the pituitary, causing the release of hormones into plasma. Feedback mechanisms 
of these hormones on their own release may complicate the interpretati on of their responses in plasma. 
The black dashed lines represent the levels at which dopamine drugs may interact with these systems.
Eff ects of dopaminergic agents on the dopamine pathway
Dopamine receptors are located pre- and postsynapti cally, thereby infl uencing local 
concentrati ons of dopamine and its metabolites upon the presence of agonists and an-
tagonists (Table I, Figure 2). Short-term treatments with D2 receptor antagonists such as 
haloperidol, sulpiride, risperidone, olanzapine and clozapine have shown to sti mulate the 
dopamine pathway [25,26], whereas administrati on of D2 receptor agonists like quinpirole, 
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quinelorane, 7-OH-DPAT, and apomorphine inhibit this pathway [27–29]. This has been 
observed in brainECF for dopamine as well as for its major metabolites DOPAC, HVA, 3-MT 
(Table I). The infl uence of D1 receptor agents on the dopamine pathway remains poorly 
investi gated. Only one study was identi fi ed, showing an increase in dopamine levels aft er 
intraperitoneal treatment with the D1 receptor antagonist SCH23390 [30], while no stud-
ies reported the eff ects aft er systemically injected D1 receptor agonists. The eff ects of D2 
receptor antagonists and agonists on the dopamine pathway may be explained by the 
modulati on of presynapti c D2 autoreceptors that provide a negati ve feedback functi on on 
dopamine release [31]. Moreover, many of these drugs have affi  nity for 5-HT receptors 
[16,21], which also contribute to the control of dopamine release [32,33].
Aft er long-term treatment with D2 receptor agonists, the basal dopamine pathway acti vity 
is decreased, similar to the eff ect observed aft er short-term treatment [27,34]. Interest-
ingly, D2 receptor antagonists inhibit the dopamine levels aft er long-term treatment, while 
the levels of the dopamine metabolites are increased [35–37]. This may, fi rst of all, be 
explained by the upregulati on of D2 receptor expression aft er long-term treatment [38], 
thereby leading to an enhanced inhibiti on of dopamine release via the D2 autoreceptor. 
Second, the monoamine oxidase (MAO) and the catechol-O-methyl transferase (COMT), 
that metabolize dopamine into DOPAC, HVA and 3-MT, were upregulated [39], providing 
another explanati on, also supporti ng the increased concentrati ons of dopamine metabo-
lites that are observed with long-term treatment.
Biomarkers for the dopamine pathway
dopamine and its metabolites can be detected in CSF, plasma and urine [40,41]. In 
contrast to dopamine, HVA is able to cross the BBB, providing a way to evaluate central 
dopaminergic acti vity in plasma. The diffi  cult aspect is to disti nguish between the central 
and the peripheral eff ects, since the dopaminergic system is also peripherally acti ve in, 
for example, the kidney and the adrenal glands. The origin of the HVA response in urine 
aft er long-term treatment with haloperidol and clozapine [40,42] is therefore not known. 
Surprisingly, no further studies were identi fi ed that investi gated CSF, plasma or urine 
biomarkers of the dopamine pathway aft er dopaminergic treatment.
Eff ects on the norepinephrine pathway
Metabolism and signaling of the norepinephrine pathway
The largest concentrati ons of norepinephrine in the brain are found in neurons in the 
locus coeruleus. Outside the brain, it is found in the postganglionic sympatheti c adrenal 
fi bers and the chromaffi  n cells in the adrenal glands. Within the norepinephrine neurons, 
VMAT stores dopamine into synapti c vesicles, where it is converted to norepinephrine 
through dopamine beta-hydroxylase, and released into the synapti c cleft . Norepinephrine 
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may bind to alpha- or beta-adrenergic receptors, the former being mostly inhibitory and 
located presynaptically, while the latter are stimulatory and located postsynaptically. From 
the synaptic cleft, norepinephrine undergoes reuptake into the presynaptic neuron via the 
norepinephrine transporter, or is metabolized to epinephrine, dihydroxyphenylglycine and 
methoxyhydroxyphenylglycol. In the presynaptic neuron, it may be stored into vesicles, or 
degraded into its metabolites.
Effects of dopaminergic agents on the norepinephrine pathway
Norepinephrine release is stimulated by D2 receptor antagonists such as clozapine, olan-
zapine and risperidone, although this has not been reported for haloperidol [43,44] (Table 
I, Figure 2). While this may be explained by dopaminergic modulation of norepinephrine 
release [45], these drugs also exhibit affinity for the adrenergic receptors [16]. Interest-
ingly, in contrast to haloperidol, the other D2 receptor antagonists showed affinity for 
the α2 adrenergic receptor. After long-term treatment, haloperidol caused a reduction of 
norepinephrine levels in the striatum [46], which may be explained by reduced conver-
sion from dopamine to norepinephrine, since long-term D2 receptor antagonist treatment 
decreased dopamine levels (Table I, Figure 2).
Plasma norepinephrine concentrations were decreased after D2 receptor stimulation 
with the agonist bromocriptine [47]. This effect was blocked by administration of the D2 
receptor antagonist domperidone, which does not cross the BBB, suggesting the effect 
to be peripheral [48]. Furthermore, plasma levels of epinephrine were increased upon 
stimulation of D2 receptor, although likely elicited through direct peripheral action on the 
adrenal gland and independent of the effect on norepinephrine [47,49].
Biomarkers for the norepinephrine pathway
norepinephrine and its metabolites have been already analyzed in CSF, plasma and urine 
[40,41,47], indicating that the latter biofluids can be used to estimate the central norepi-
nephrine pathway activity. Indeed, reduced levels of the most downstream norepineph-
rine metabolite vanillylmandelic acid were found in urine after long-term treatment with 
haloperidol or clozapine [40,42]. However, as discussed in the previous paragraph, the 
effect on plasma (and thus also urine) norepinephrine concentrations are at least partly 
caused by peripheral effects. Further understanding of the relative central and peripheral 
effects of dopaminergic agents on the plasma or urine norepinephrine pathway responses 
is needed to conclude whether they can be used as biomarker for central activity. The CSF 
levels are likely more representative; however, the evaluation of longitudinal norepineph-
rine pathway responses upon dopaminergic treatment is still lacking.
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Effects on the acetylcholine pathway
Metabolism and signaling of the acetylcholine pathway
Acetylcholine (ACh) is produced from choline in the presynaptic neurons and stored into 
vesicles via the vesicular acetylcholine transporter. These vesicles release ACh into the 
synaptic cleft where it binds to the postsynaptic ACh receptors, which are subclassified into 
nicotinic receptors that modulate neuronal activity and muscarinic receptors that elicit 
G-protein dependent signaling. ACh is degraded to choline and acetate, the former being 
recycled into the presynaptic neuron by the sodium-dependent choline transporter. Inter-
estingly, anticholinergic drugs are typically prescribed to decrease the EPS accompanying 
antipsychotic treatments, suggesting that the dopaminergic and the cholinergic system 
are tightly connected. Cholinergic interneurons in the striatum represent only 1-2% of 
all neurons, yet they play an important role in the integration of multiple neurotransmit-
ter signals [50], thereby contributing to the stabilization of dopaminergic signaling in the 
psychomotor circuit (also cortico-basal ganglionic system) [51].
Effects of dopaminergic agents on the acetylcholine pathway
As listed in Table I and Figure 2, ACh release from cholinergic interneurons in the striatum 
is inversely related to D2 receptor stimulation or inhibition. On the other hand, choline, 
the precursor of ACh, was reduced after D2 receptor antagonist treatment, probably as 
a consequence of ACh release, since the uptake of choline was increased to support ACh 
production [52,53].
Contrary to their effect in the striatum, D2 receptor agonists increased ACh levels in the 
hippocampus and the frontal cortex [54–57]. Furthermore, ACh in the PFC and the hip-
pocampus was increased after treatment with second-generation D2 receptor antagonists, 
which was not the case for first-generation D2 receptor antagonists [26,56,58–61]. ACh 
levels in the NAc were not affected by D2 receptor antagonism [26]. Overall, this indicates 
that the relation between the dopaminergic system and cholinergic signaling is region-
specific. Indeed, there is evidence for D2 receptor specific regulation of ACh in the stria-
tum, while for other regions the results are conflicting. D1 and D2 receptors are certainly 
involved, taking into account that several of the D2 receptor binding drugs discussed here 
also exhibit affinity for the muscarinic receptors [16,56,59].
D1 receptor agonists have consistently been reported to lead to increased ACh levels in 
several brain regions, including the striatum [55,62–65], while D1 receptor antagonism 
led to decreased ACh concentrations [63], or had no effect [55,56]. Cholinergic neurons 































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Biomarkers for the acetylcholine pathway
Both ACh and choline can be detected in CSF and plasma with state-of-the-art analytical 
methods [66–69]. Furthermore, the plasma levels of these molecules may reflect central 
cholinergic activity, since they both can cross the BBB [70]. However, ACh is an important 
neurotransmitter of the PNS, sending signals from neural endfeet to muscle cells. This 
might confound the plasma levels as a marker of central activity. Quantitative understand-
ing of the BBB distribution relative to the PNS response is essential to be able to interpret 
the plasma levels. Moreover, the relation between dopamine treatment and the cholin-
ergic system appeared brain region specific, which may limit the usefulness of CSF and 
plasma for cholinergic biomarker detection. No studies have investigated cholinergic CSF 
and plasma in relation to dopaminergic treatment so far. Therefore, it is not possible to 
conclude whether it is possible to use these biofluids for biomarker evaluation.
Effects on the GABA-glutamate pathways
Metabolism and signaling of the GABA-glutamate pathways
GABA and glutamate are the main inhibitory and excitatory neurotransmitters, respec-
tively, in the brain. Glutamate is synthesized from glutamine by the enzyme glutaminase 
and is stored in vesicles in glutamatergic neurons via the action of vesicular glutamate 
transporters. These vesicles release glutamate into the synaptic cleft where it binds to 
the glutamate receptors, i.e., metabotropic receptor and ionotropic receptors (NMDA, 
kainate,and AMPA receptors). From the synaptic cleft, glutamate distributes into glial 
cells, using the glutamate transporter 1 or the glutamate aspartate transporter, where it 
is metabolized into glutamine. Glutamine is subsequently released from the glial cells and 
recycled into glutamatergic neurons. Also in GABAergic neurons, glutamate is produced 
from glutamine. However, these neurons also contain the enzyme glutamate decarbox-
ylase that converts glutamate into GABA. Vesicular GABA transporters store GABA into 
vesicles which release it into the synaptic cleft. There, it binds to the GABA receptors to 
inhibit the activity of the postsynaptic neuron. GABA diffuses to the glial cells via the GABA 
transporter where it is metabolized to glutamate via the Krebs cycle, and subsequently 
converted to glutamine. Glutamine is recycled into the presynaptic GABAergic neurons. 
Although glutamate and GABA have many roles in the brain and are distinct neurotrans-
mitters, we discuss here their interconnection in relation to two dopaminergic pathways: 
the nigrostriatal pathway and the mesocorticolimbic pathway. These pathways belong to 
the so-called circuits that connect multiple brain regions by neuronal fibers. Concretely, 
in the nigrostriatal pathway, activation of the striatal D1 receptor leads to release of GABA 
into the internal globus pallidum (GPi) and the substantia nigra reticula (SNr). This sub-
sequently reduces the release of GABA into the thalamus. Activation of the striatal D2 
receptor inhibits the release of GABA into the external globus pallidum (GPe), which then 
stimulates the release of GABA into the subthalamic nucleus and the GPi. This also reduces 
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the release of GABA into the thalamus. As such, these two pathways, also referred to 
direct and indirect pathway, enhance the thalamic release of glutamate into the PFC. Since 
cortical glutamatergic neurons project to multiple regions in the midbrain, amongst which 
the striatum and the substantia nigra, many functionalities are stimulated. In the meso-
corticolimbic pathway, activation of D2 receptors in the VTA stimulates GABAergic neurons 
in the NAc. This leads to enhancement of GABA release into the other brain regions such 
as VTA and ventral pallidum. Additionally, D2 receptor activation in the VTA stimulates the 
release of dopamine into the PFC. This enhances the activity of the pyramidal neurons that 
release glutamate into other brain regions, including NAc and VTA.
Effects of dopaminergic agents on the GABA-glutamate pathways
While these circuits for a large part were unraveled by local injection of dopaminergic, 
GABAergic and glutamatergic agents [71–73], not many studies have been performed 
showing the effect of systemically injected dopaminergic agents (Table I, Figure 2). 
Only one D1 receptor agent, an antagonist, was systemically injected to show no effect 
on glutamate levels in the entopeduncular nucleus (EPN) [74]. The cortical GABA levels 
were increased with systemic injection of D2 receptor agonists, while glutamate levels 
in the NAc or EPN were decreased [27,74,75], contrasting the response expected from 
the above-described circuits. D2 receptor antagonists typically did not show an effect on 
GABA levels in the ST, the GPe, the PFC and the NAc [26,76–78], or glutamate levels in the 
ST, EPN, PFC or NAc [26,74,77,79–81]. It should be noted that the results are not always 
consistent, since some studies with D2 receptor antagonists found reduced GABA levels in 
the GP, NAc or PFC [76,78,82,83], increased GABA concentrations in the GP or the striatum 
[84,85], or increased glutamate levels in the SN, ST, EPN, PFC, or NAc [79,81,86,87]. These 
contradictions highlight the delicate balance of this circuit, which is affected by multiple 
factors (e.g., target site exposure, experiment time, off-target effects, etc.) that can cause 
concentration-, time-, or drug-dependent differences among the studies. Moreover, with 
systemic injection, these circuits are perturbed at multiple regions, rendering its pharma-
cological interpretation non-intuitive. Systematic studies that account for these factors, 
and that evaluate glutamate, GABA and dopamine in multiple brain regions simultane-
ously, are warranted to obtain a deeper insight into the effects of systemic administration 
of dopaminergic agents on such circuits.
Biomarkers for the GABA-glutamate pathways
Although GABA and glutamate concentrations are well measurable with modern analytical 
approaches [88], it is not known how the levels relate to dopaminergic treatment. GABA 
and glutamate responses have shown to be region-dependent, which may confound 
the CSF and plasma response. Further experimental evidence needs to be collected to 
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evaluate the potenti al of CSF and plasma to assess the GABA-glutamate pathway acti vity 
in relati on to dopaminergic agents.
Eff ects on the serotonin pathway
Metabolism and signaling of the serotonin pathway
Serotonin is produced from the amino acid tryptophan via 5-hydroxytryptophan and 
stored into vesicles by VMAT. When it is released from these vesicles into the synapti c 
cleft , it binds to diff erent classes of 5-HT receptors (5-HT1 – 5-HT7). It is recycled into the 
presynapti c neuron by the serotonin transporter, where it is stored into vesicles or me-
tabolized to 5-hydroxyindoleaceti c acid (5-HIAA).
Eff ects of dopaminergic agents on the serotonin pathway
In contrast, the modulati on of serotonin circuits by dopamine is mainly restricted to D2 
receptor mediated sti mulati on of serotonin neuron cell bodies in the dorsal raphe nucleus 
(DRN) that control motor acti vity. This leads to increased serotonin release in the DRN 
and other regions such as the striatum [32], as identi fi ed with systemic administrati on 
of D2 receptor agonists [89,90] (Table I, Figure 2). No eff ects of dopamine agonists were 
found on the levels of the metabolite 5-HIAA [91,92]. Additi onally, it was suggested that D2 
receptor agonists modulate serotonin aff erents presynapti cally in the hippocampus [93] or 
the SN [94]. D2 receptor antagonists did not show an eff ect on serotonin levels [26,95,96], 
except for atypical anti psychoti cs such as risperidone and clozapine, likely elicited through 
presynapti c serotonin receptors [16,20,95–97]. Moreover, 5-HIAA was found increased 
aft er risperidone in but not all studies [83,98–102].
Biomarkers for the serotonin pathway
The serotonin metabolite 5-HIAA, but not serotonin itself, has been already detected in 
CSF [41]. serotonin, 5-HIAA and the precursor tryptophan can be also detected in plasma. 
Although serotonin cannot pass the BBB, the central serotonin pathway acti vity may be 
inferred from the tryptophan and 5-HIAA responses. It is, however, important to realize 
that the serotonin pathway is also present in peripheral systems, for example in platelets. 
Moreover, tryptophan is provided via food intake. These factors may confound the plasma 
biomarker response to refl ect central acti vity. Experimental evidence is further needed to 
investi gate the relati on between dopaminergic treatments, central serotonin acti vity and 
CSF or plasma biomarker responses.
Interacti ons among neurotransmitt er systems
The above-described eff ects of dopaminergic agents clearly show that the neurotransmit-
ter systems of dopamine, norepinephrine, GABA, serotonin, glutamate and ACh are highly 
interconnected. Moreover, many of these agents also infl uence these neurotransmitt er 
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systems via binding to other receptors, such as serotonineric and adrenergic receptors. 
Therefore, in order to understand the eff ects of these agents, neurotransmitt er responses 
should be evaluated altogether. Qi et al. (2016) established a network of the connecti ons 
between these neurotransmitt ers, taking into account the spati al and functi onal organiza-
ti on of their neurons and interacti ons [103] (Figure 4). This network was used to under-
stand the neurotransmitt er disbalances in schizophrenia and their normalizati on upon 
anti psychoti c treatment. Indeed, disease pathology and drug acti on must understood in 
terms of a disbalance among multi ple signaling pathways, rather than describing pathol-
ogy and pharmacology as a single pathway disrupti on.
Figure 4. Mathemati cal model containing expressions for the interacti ons between the diff erent neurotrans-
mitt er systems in multi ple brain regions. Rather than looking at single biomarkers, this model enables the 
predicti on of disbalances among the neurotransmitt er systems under conditi ons of drug administrati on. 
Adapted from reference (168) with permission.
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Biomarkers that reflect the balance among the neurotransmitter systems
It will become important to identify accessible biomarkers in CSF, plasma or urine that 
can reflect the balance among the neurotransmitter systems. While such approach has 
been followed for a glutamate receptor agonist, identifying the turnover of the dopamine, 
norepinephrine and serotonin pathway in CSF [41], there has not been such attempt for 
dopaminergic agents.
Effects on the kynurenine pathway
Metabolism and signaling of the kynurenine pathway
Similar to serotonin, kynurenine is a metabolite of tryptophan. In fact, about 95% of 
tryptophan in the brain is metabolized via the kynurenine pathway, further leading to 
kynurenic acid, quinolinic acid and 3-OH-kynurenine [104,105]. Whereas quinolinic acid 
is a pro-glutamatergic molecule, kynurenic acid has several anti-glutamatergic properties, 
such as the antagonism of the NMDA receptor and the inhibition of glutamate release 
through ACh receptors. 3-OH-kynurenine is involved in the generation of free radicals, 
independent of the glutamate system [104]. 3-OH-kynurenine and quinolinic acid have 
neurotoxic properties, while kynurenic acid has proven to be neuroprotective [106]. A 
disbalance in the kynurenine metabolism was therefore associated with several neurologi-
cal disorders, amongst which Parkinson’s disease and schizophrenia [104,107,108].
Effects of dopaminergic agents on the kynurenine pathway
Kynurenic acid was reduced after long-term (1 – 12 months), but not after shorter-term 
(1 week) administration of clozapine, raclopride and haloperidol [109] (Table I, Figure 2). 
D2 receptor antagonists may potentially interfere with the kynurenine amino transferase 
(KAT) enzyme, which converts kynurenine to kynurenic acid. Indeed, kynurenine and its 
metabolites other than kynurenic acid were not altered after treatment with D2 receptor 
antagonists [109]. It is likely that this effect is D2 receptor specific, given that raclopride is 
a highly selective D2 receptor antagonist [110]. D2 receptor antagonists thus likely inhibit 
the neuroprotective branch of the kynurenine metabolism, which could be a potential 
unwanted effect in the long term.
Biomarkers for the kynurenine pathway
Kynurenine and kynurenic acid are present in sufficient concentration in CSF to be quanti-
fied [107,108]. Moreover, 40% of the kynurenine synthesis occurs in the brain, while 60% 
takes place in the blood and is transported over the BBB. It is thus likely that kynurenine 
and kynurenic acid in CSF and plasma reflect the levels in the brain; however, it is not 
known to which extent. CSF and plasma levels changes upon dopaminergic treatment 
remain to be investigated.
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Effects on the nitric oxide pathway
Metabolism and signaling of the nitric oxide pathway
Nitric oxide is generated by nitric oxide synthase (NOS) through the conversion of arginine 
to citrulline. Nitric oxide has a short half-life (i.e., few seconds) and is readily oxidized to 
nitrite and nitrate, which can then be measured as an indication of NOS activity. By binding 
to soluble guanylyl cyclase, nitric oxide stimulates local postsynaptic excitability via modu-
lation of voltage-gated ion channels and possibly also presynaptic neurotransmitter re-
lease, thereby modulating synaptic plasticity [111,112]. Nitric oxide is tightly connected to 
glutamatergic signaling. Moreover, it contributes to gonadotrophin and oxytocin release, 
circadian and respiratory rhythms, locomotor and thalamocortical oscillation, as well as 
learning process and memory [111]. The nitric oxide pathway is downregulated in Parkin-
son’s disease and schizophrenia, indicating a connection with dopamine [111,113,114].
Effects of dopaminergic agents on the nitric oxide pathway
Citrulline, nitrite and nitrate have shown to be upregulated after short-term treatment 
with D1 receptor and D2 receptor agonists (Table I, Figure 2). Only two studies with sys-
temic administration have been reported [115,116], while other studies focused on the 
effects after intracerebral injections [117,118]. A possible hypothesis for this upregulation 
is the stimulation of NOS activity by dopamine, thereby augmenting the production of 
citrulline and nitric oxide [117]. The effect on the nitric oxide pathway was proven to be 
D2 receptor-specific in the striatum [118], while the D1 receptor was involved in the NAc 
[117]. Although D2 receptor antagonists blocked the effect of D2 receptor agonists on nitric 
oxide concentrations [119], they did not exhibit a significant effect when administered 
alone [118,120]. However, long-term treatment with haloperidol led to an upregulation of 
neuronal NOS in the hypothalamus [38].
Biomarkers for the nitric oxide pathway
Nitrite and nitrate have been measured in the CSF of patients suffering from neurologi-
cal disorders [113,114], indicating their potential as easily-accessible biomarkers. Nitrate 
urine levels were found increased after intravenous administration of fenoldopam, a D1 
receptor agonist, although this effect might have been exerted via D1 receptors present 
in the kidney, rendering difficult to discriminate between peripheral and central effects 
[115].
Effects on the endocannabinoid system
Metabolism and signaling of the endocannabinoid system
The most well-known components of the endocannabinoid system are anandamide, which 
is synthesized from N-arachidonoyl phosphatidylethanolamine, and 2-arachidonyl glycerol 
(2-AG), that is produced from phosphatidylinositol [121]. Anandamide is degraded to 
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ethanolamine and arachidonic acid by fatty acid amide hydrolase, while 2-AG is broken 
down to arachidonic acid by monoglyceride lipase [121]. Arachidonic acid is the precursor 
of a wide range of biologically and clinically important eicosanoids and respective metabo-
lites, including prostaglandins and leukotrienes. The endocannabinoid system is widely 
distributed in the CNS where it reduces synaptic input through retrograde signaling via 
cannabinoid receptors, in the brain mainly the CB1 receptor subclass [121].
Effects of dopaminergic agents on the endocannabinoid system
dopamine influences the endocannabinoid system mainly in the nigrostriatal pathway by 
upregulation of endocannabinoid system in the striatum and downregulation in the GPe 
in a D2 receptor dependent manner [122]. Indeed, quinpirole stimulated the release of 
anandamide in the striatum [123], an effect that was blocked by raclopride (Table I, Figure 
2). This provides evidence for D2 receptor-dependent involvement of the dopaminergic 
system in endocannabinoid signaling. Furthermore, although the D1 receptor agonist 
SKF38393 did not cause an effect on anandamide [123], it was found that, with impaired 
dopamine release, the striatal D1 receptor may also affect the endocannabinoid system 
[122].
Biomarkers for the endocannabinoid system
Even though anandamide can be detected and quantified in the brain, its levels in CSF 
and plasma are very low [124], rendering its quantitation challenging. Moreover, 2-AG 
is chemically unstable in aqueous solution, leading to the formation of its isomer 1-AG. 
Nevertheless, ethanolamine levels can be measured in CSF suggesting this compound as a 
potential biomarker candidate to reflect the activity of the endocannabinoid system [125].
Dopaminergic treatment effects on the neuroendocrine and the energy 
systems
Additional to its role in the CNS, the dopamine system is widely expressed in peripheral 
tissues [10], supporting the importance of evaluating the peripheral effects of dopami-
nergic agents. The CNS is connected to the periphery via the PNS and the neuroendocrine 
system, allowing for the opportunity to capture the consequence of central drug effects 
in the periphery, as done for instance with prolactin [23,24]. A significant influence on the 
hypothalamic-pituitary-adrenal (HPA) axis, the reproductive system, insulin signaling and 
the lipid metabolism has been found in this systematic review (Table II, Figure 2). With 
regards to biomarker discovery, two important aspects can be highlighted (Figure 3):
i) Biomarkers need to be evaluated together with other markers of the pathway of inter-
est to understand its interaction with the drug;
ii) The connection between brain and target pathway must be quantitatively understood 
to allow for estimation on how the biomarker response reflects the central effect.
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Effects on the hypothalamic-pituitary-adrenal (HPA) axis
Signaling in the HPA axis
The hypothalamo-pituitary-adrenal (HPA) axis is involved in the homeostasis of meta-
bolic and cardiovascular systems, stress response, reproductive system, as well as im-
mune system. It is a complex system of signals and feedback mechanisms between the 
hypothalamus, the pituitary gland and the adrenal glands. The hypothalamus releases 
corticotrophin releasing hormone (CRH) and vasopressin to modulate the secretion of 
adenocorticotropin hormone (ACTH) by the pituitary gland. ACTH subsequently stimulates 
the release of glucocorticoids (corticosterone in rodents, cortisol in humans) and catechol-
amines, which control CRH and ACTH release via a negative feedback loop. ACTH is cleaved 
from the prohormone pro-opiomelanocortin, which also yields to a number of different 
peptides including alpha-melanocyte stimulating hormone (α-MSH), beta-endorphin and 
a few other peptides that are also secreted from the pituitary gland.
Effects of dopaminergic agents on the HPA axis
A wide range of neural systems influence the HPA axis [126], including dopaminergic 
system, both in a D1 and D2 receptor dependent manner (Table II, Figure 2) [127–129]. 
This effect is mainly observed after short-term treatment with D1 and D2 receptor agonists, 
while long-term treatment did not show a significant effect on basal ACTH levels [130].
Surprisingly, in contrast to haloperidol, the D2 receptor antagonists eticlopride and remoxi-
pride have been reported to increase ACTH plasma levels [24,131]. However, remoxipride 
was 40 times less potent to elicit the ACTH response than to induce the prolactin response 
[24], suggesting that these observations are explained by off-target effects.
Contrary to their conflicting results for ACTH release, D2 receptor antagonists showed a 
consistent stimulation of corticosterone plasma levels (Table II, Figure 2), indicating that 
glucocorticoid release is not only mediated via a central mechanism of ACTH secretion. Ad-
ditionally, the stimulation of the PNS was suggested to control the sensitivity of the adrenal 
medulla to ACTH, thereby enhancing the release of corticosterone. It is not certain whether 
this process is under dopaminergic control, but catecholamines certainly play a role [132]. 
Furthermore, D2 receptor antagonists might directly modulate the release of corticosterone, 
given that D2 receptors have been found on the adrenal cortex [133]. It is worth mentioning 
that investigations on dopaminergic innervation in the glucocorticoid release focused on 
aldosterone release from the zona glomerula, and not on corticosterone release from the 
zona fasciculate and reticularis [133]. Whether the effects of dopaminergic drugs are pri-
marily mediated via dopamine receptors is not fully elucidated. While the ACTH response to 
D2 agonist quinpirole was blocked by the D2 antagonist sulpiride, indicating the involvement 
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In addition to ACTH and corticosterone, α-MSH secretion from the intermediate lobe of 
the pituitary gland is also controlled by the dopaminergic system [134]. α-MSH levels 
were increased after D2 receptor antagonist treatment [135,136] but changed not after D2 
receptor agonist treatment [135], suggesting that α-MSH release is under maximal inhibi-
tory control of dopamine.
Biomarkers of the HPA axis
Although the basal mechanisms of the HPA axis are very well understood, it remains 
unclear at which levels dopamine drugs interfere. The dopamine system is active in the 
hypothalamus, the pituitary gland, as well as the adrenal gland. While α-MSH and ACTH 
reflect the response in the pituitary gland upon hypothalamic stimuli, the corticosterone 
response is secondary to ACTH, or elicited at the adrenal gland directly. Therefore, the 
interpretation of biomarker responses should rely simultaneous evaluation of α-MSH, 
ACTH and corticosterone in a longitudinal manner to enable the evaluation of dopamine 
drug effects at the different levels of the HPA axis.
Effects on the reproductive system
Signaling in the reproductive system
The reproductive system also involves communication between the brain and the periph-
ery. It is controlled by the neuroendocrine system through the release of gonadotropin 
releasing hormone (GnRH) from the hypothalamus, which stimulates the secretion of lu-
teinizing hormone (LH) and follicle stimulating hormone (FSH) in the pituitary gland. These 
hormones subsequently modulate the release of progesterone and estrogens (estrone, 
estradiol and estriol) in females, as well as testosterone in males from the reproductive 
glands, which act as a negative feedback on GnRH release.
Effects of dopaminergic agents on the reproductive system
The role of the dopaminergic system in the reproductive system is supported by a well-
known side effect of D2 receptor antagonists, i.e., sexual dysfunction [137,138]. Further-
more, dopamine release in the nigrostriatal, mesolimbic and medial preoptic area plays 
a crucial role in mating behavior and copulation [139,140], providing a mechanistic basis 
for the involvement of dopamine in sexual function. Other studies have investigated the 
dopaminergic drug effects on the sex hormones testosterone, progesterone and estrogen 
in plasma (Table II, Figure 2). prolactin was excluded from our analysis because of its well-
known relation with dopaminergic agents; however, it is an important mediator of sexual 
function, supported by the higher frequencies of sexual disorders observed with strong 
inducers of prolactin (classical antipsychotics and risperidone) compared to weak inducers 
(e.g., clozapine and olanzapine) [138]. The antipsychotic drug-induced disorders are at 
least partially mediated via peripheral mechanisms, since the peripherally acting D2 recep-
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tor antagonist domperidone also caused significant changes in reproductive hormones 
[141].
The results observed for testosterone plasma concentrations were conflicting and mainly 
associated with high dose levels [142–144]. Furthermore, while the D2 receptor antagonists 
chlorpromazine and metoclopramide caused a reduction in progesterone and estrogen 
levels [145–147], sulpiride, clozapine, risperidone, and haloperidol led to enhanced con-
centrations [148–151]. Similarly, LH and FSH were reduced after long-term chlorpromazine 
and fluphenazine treatment [146,152], while there was no effect observed after long-term 
sulpiride, risperidone and haloperidol treatment [143,149]. After short-term haloperidol 
treatment, however, increased levels of LH and FSH were observed [153]. Interestingly, the 
effect of short-term D2 receptor antagonist treatment was observed in female but not in 
male rats [24,153].
The non-selective characteristics of the abovementioned D2 receptor antagonists may 
explain these conflicting results, particularly since the effects were associated with large 
dose levels [16,20]. Moreover, sex hormones show a high degree of intra-individual vari-
ability and impact of treatment duration, the latter being illustrated by the increased 
testosterone levels observed after 5 days of domperidone treatment, while it was reduced 
after 30 days [141]. This dual effect highlights the importance of longitudinal sampling 
upon dopaminergic treatment.
Finally, in addition to the effects of dopaminergic drugs on prolactin and the sex hormones, 
D2 receptor agonists enhanced oxytocin secretion, likely in a D3R-specific manner [154].
Biomarkers of the reproductive system
The reproductive system has multiple levels, i.e., the hypothalamus, the pituitary and 
the endocrine glands, where further understanding is required to develop an effective 
biomarker strategy. The prolactin response is already difficult to interpret. Although 
some studies indicated that it correlates to drug exposure in the brain [23,155], another 
study found plasma exposure a better predictor [156]. A prolactin response has been also 
observed with domperidone, which does not cross the BBB [141]. These observations sug-
gest that the prolactin response is a composite of central and peripheral effects. Similarly, 
it is not known to which extent LH and FSH represent a central or a peripheral effect. 
oxytocin, however, represents a biomarker for central effects only, given that the release is 
solely controlled by the hypothalamus. The testosterone and progesterone responses are 
secondary to LH and FSH responses, although they may also have been elicited through a 
peripheral mechanism. Overall, similar to the HPA axis, the longitudinal evaluation of such 
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possible biomarkers is essential to understand the interaction between dopamine drugs 
and the reproductive system.
Effects on the insulin system
Signaling in the insulin system
It is well known that many antipsychotics, especially atypical, increase the risks for com-
plicated disorders such as metabolic syndrome and type 2 diabetes mellitus [157]. Blood 
glucose levels are controlled by mainly two hormones; insulin and glucagon. Upon a rise in 
glucose levels, insulin is secreted from pancreatic β-cells, leading to the glucose uptake in 
the muscles and storage as glycogen in the liver. As a consequence, the insulin secretion is 
reduced. When blood glucose levels fall, glucagon is released from the pancreatic α-cells, 
causing glucose release from the liver.
Effects of dopaminergic agents on the insulin system
Although insulin signaling is under PNS control [158], the role of dopamine is mainly at 
the periphery. It is argued that dopamine and insulin are co-secreted from the pancreatic 
beta cells, with dopamine providing a negative feedback on insulin secretion in a D2-like 
receptor dependent manner [159]. However, both insulin and glucagon levels were not in-
fluence by short-term D2 receptor agonist treatment (Table II, Figure 2) [160], highlighting 
that this mechanism does not play a major role. In contrast, glucose concentrations were 
increased after treatment with the D3 agonist 7-OH-DPAT, which was antagonized by ra-
clopride. Interestingly, this effect was confirmed for quinpirole, but not for bromocriptine 
[160]. Possibly, off-target mechanisms of bromocriptine normalize the D3 receptor medi-
ated effect on glucose. Both glucose and insulin levels were increased with D2 receptor 
antagonists (Table II, Figure 2). Typically, the dose required to elicit a short-term glucose 
response was higher than the one needed for a corticosterone response [161], indicating 
that an off-target effect explains this response.
The results of long-term treatment are conflicting, with in general no effect on basal fast-
ing glucose or insulin levels [36,144,148,162], although for some D2 receptor antagonists 
a stimulation of the insulin system has been observed [36,144,163,164]. Given the large 
variation in experimental design (sex, strain, fasting protocol, dose levels), it is difficult 
to identify the source of this discrepancy. Moreover, many D2 receptor antagonists were 
found to share the off-target affinity for other receptors, such as serotonine, muscarinic 
and the histamine receptor, all involved in weight gain which is associated with insulin 
resistance and hyperglycemia [16,157,165]. Interestingly, the M3 muscarinic receptor was 
found to be crucial in the control of insulin release [166]. It is thus likely that the short- and 
the long-term effects of D2 receptor antagonists on the insulin system are mediated via 
other receptors than the D2 receptor only.
64 CHAPTER 3
Biomarkers of the insulin system
The insulin system has been well described in terms of biomarkers, including fasting plasma 
glucose, fasting serum insulin and glycated hemoglobin. Systematic and well-controlled 
studies that longitudinally evaluate these biomarkers in combination with dopamine 
treatment are needed to better understand their potential interaction.
Effects on the lipid metabolism
Metabolism and signaling in the lipid system
Phospholipid and cholesterol pathways are the main pathways of lipid metabolism. Both 
pathways start with acetyl CoA, and depending on whether the enzyme SREB-1 or SREB-2 
is present, the fatty acid or the cholesterol pathway is activated [148]. Fatty acids are 
subsequently converted to triglycerides or phospholipids, amongst others. Cholesterol 
and phospholipids are notably essential to maintain the cell membrane integrity [167]. 
A distorted lipid metabolism can lead to the loss of neural transmission and is involved 
in brain several disorders, including schizophrenia [168]. Moreover, misbalances in the 
lipid homeostasis may, for example, cause weight gain, atherosclerosis and cardiovascular 
problems. In this regard, the relation between dopaminergic drugs and the lipid metabo-
lism is closely related to what is observed with the insulin system [157,169]. 
Effects of dopaminergic agents on the lipid system
The lipid metabolism has shown to be significantly altered after long-term treatment, 
while no studies were identified for short-term treatment (Table II, Figure 2). For instance, 
2-3 week treatment with the D2 receptor antagonists risperidone and olanzapine caused 
an increase in triacylglycerols and a decrease in free fatty acids plasma levels, which was 
not the case for the partial D2 receptor agonist aripiprazole [18]. Another study showed 
that 4 weeks of treatment with clozapine and risperidone, but not haloperidol, raised the 
serum levels of total cholesterol, free fatty acids and triglycerides via modulation of the 
pathway that is responsible for their biosynthesis [148]. The fact that the D2 receptor ago-
nist ergocryptine, although relatively unselective for this receptor, has been reported to 
decrease total cholesterol and triglycerides concentrations [170], may indicate that these 
effects are mediated via D2 receptors. However, given that not all D2 receptor antagonists 
affect the lipid metabolism, other receptors than the D2 receptor may be involved. Further 
investigations are needed to investigate through which mechanism dopaminergic agents 
affect the lipid metabolism.
Biomarkers of the lipid metabolism
Cholesterol, free fatty acids, triacylglycerols and triglycerides can be used as biomarker to 
evaluate dopamine treatment effect on the lipid metabolism. Additionally, a lipidomics-
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based approach also revealed an increase of phosphatidylethanolamine as biomarker for 
antipsychotic efficacy [18].
Recommendations for biochemical biomarker strategies in CNS drug 
development
This review provides an extensive overview into the effects of dopaminergic agents on 
multiple biological pathways in the CNS and the periphery, as well as the potential of 
easily accessible biomarkers to reflect these effects. Overall, there is a strong need for 
systematic searches for biomarkers that together can represent the system-wide effects 
of dopaminergic agents. Here, we provide the following recommendations to account for 
system-wide effects in early CNS drug development.
1. Use proteomics and metabolomics-based biomarkers discovery for CNS drug effects
We envision a crucial role for proteomics and metabolomics approach to further elucidate 
known and unknown pathways and to identify drug effect-related biomarkers [171]. Con-
sidering the potential lack of insights into the system-wide effects of a new compound in 
early drug development, these methodologies enable preclinical anticipation of wanted 
and unwanted effects [172]. This information can then be used to optimize the future 
dosing strategies. Also, using a targeted metabolomics approach with monoamines in 
the brain, it was shown that risperidone and clozapine are biochemically closer to the 
5-HT2A antagonist M100907 than to haloperidol [71,173]. Interestingly, this pattern highly 
corresponded with behavioral outcome [71]. Indeed, many of the dopaminergic agents 
described in this review are non-selective. Pharmacological effects should be seen as a bal-
ance between multiple components of a network of affected biochemical pathways (Fig 4) 
[103]. CNS drug discovery should thus aim for rational development of non-selective drugs 
to attack the polygenic CNS disorders [16]. Proteomics and metabolomics will certainly 
provide additional and valuable tools for the investigation of the in vivo pharmacology 
[171].
2. Use longitudinal data and mathematical modeling
Mathematical modeling to understand CNS drug effects are further needed. A pharmaco-
logical interaction at one or more receptors will pass on to the neurotransmitter network, 
causing the net result on the individual neurotransmitters, as well as the balance between 
them, being not so intuitive. A mathematical evaluation is therefore needed to understand 
CNS drug effects [103,174,175]. In this regard, longitudinal data on biomarker levels is 
essential to calibrate these models. Indeed, the pattern of the response reveals informa-
tion that cannot be obtained from single time point measures [4,176]. For example, it was 
observed that not only basal levels of dopamine and norepinephrine were decreased after 
long-term treatment, but also the effect size after pharmacological stimulation [37,46]. 
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Moreover, it is also difficult to quantify the effect by a single time point in short-term 
treatments.
3. Evaluate CNS drug effects in combination with pharmacokinetics
This temporal pattern not only depends on the dynamic interactions within the biological 
system, but also on the exposure pattern of the drug and its possible active drug metabo-
lites at the site of action. It is therefore important to take into account the pharmaco-
kinetics when evaluating the pharmacodynamics. Only one study considered the steady 
state plasma concentrations of clozapine and its active metabolite N-desmethylclozapine 
in combination with a response measure [74]. The levels of the drug and the metabolite 
showed high variability between the animals. Moreover, the ratio between clozapine 
and its metabolite was dependent on the sex of the animal and the dose. Given the fact 
that the exposure of the drug and its metabolite drives the response, such variability can 
have a significant impact on the biomarker plasma levels. This is particularly true for CNS 
drugs, for which the exposure pattern in the brain is determined by a complex interaction 
of pharmacokinetics, BBB transport and distribution through the brain [175]. Moreover, 
the drug exposure is likely to be brain region-specific, which will lead to quantitative dif-
ferences in drug-receptor interactions, depending on the brain region [177]. Thus, when 
pharmacokinetics is taken into account, pharmacodynamics can be compared between 
drugs of the same pharmacological class, excluding the interference of pharmacokinetic 
differences.
4. Analyze brain, plasma and CSF biomarkers simultaneously
Plasma (or urine) samples are typically used for biomarker identification, while CSF 
samples are getting more and more interest in CNS-related diseases. Interestingly, our lit-
erature search did not reveal pharmacological biomarker evaluations in CSF, even though 
it has been used for other drug classes [41] and discovery of pathological biomarkers 
[88]. Although plasma and CSF have the advantage to be accessible in humans, biomarker 
responses in these biofluids may give a biased view with regard to the actual effects in 
the brain. Many biomarkers, for example dopamine, do not cross the BBB. Even in the 
case they do (e.g., HVA) or if the biomarker is measured in CSF, it is difficult to know how 
is quantitatively relates to the effects in the brain. The current overview shows hardly 
any studies that simultaneously studied biomarker responses in brainECF and plasma. One 
study measured plasma and brain cholesterol levels after long-term treatment with clo-
zapine or haloperidol, but no significant correlation was found [178]. Another study could 
positively associate serum progesterone levels with brain allopregnanolone as a reflection 
of GABAA potentiation and anxiolytic effect after short-term treatment with olanzapine 
and clozapine [150]. Systematic and simultaneous biomarker evaluations in plasma and 
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brain are recommended to provide a quantitative relation between the central effect and 
the accessible biomarker response.
5. Investigate the condition-dependency of pharmacological effects
Dopaminergic effects are highly condition dependent. As an illustration, dopamine recep-
tors are present on immune cells to reduce their activation level [179,180], but no effect of 
dopaminergic agents was found on immune markers such as C-reactive protein, interleu-
kin-6 or tumor-necrosis-factor alpha [144,181–183]. On the other hand, haloperidol was 
found to have immune-modulatory and anti-inflammatory effects in an animal disease 
model of rheumatoid arthritis [184]. Indeed, D2 receptor antagonists have been shown 
to normalize lipopolysaccharide-induced inflammation [185], indicating that only in an 
activated immune system, D2 receptor antagonists have an effect on immune markers. 
Thus, while some markers may not respond under healthy conditions, these observations 
cannot directly be extrapolated to a diseased condition. Patients or diseased animals need 
to be evaluated as a population on its own.
Conclusions
This review highlights that dopaminergic agents, even selective ones, have a wide array 
of biochemical effects. Indeed, dopaminergic drugs may interfere with at least 8 differ-
ent systems in the brain, including dopamine signaling, norepinephrine signaling, ACh 
signaling, GABA-glutamate circuits, serotonin signaling, kynurenine metabolism, nitric 
oxide pathway, endocannabinoid system, and 4 systems in the periphery, i.e., HPA axis, 
reproductive system, insulin signaling, and lipid metabolism. All these systems need to 
be taken into account during drug development. Moreover, in line with earlier reviews, 
many dopaminergic drugs are non-selective [16,20,21]. Therefore, although we refer to 
‘dopaminergic drugs’, the biochemical actions of these drugs may be elicited via non-
dopamine receptors. A systems pharmacology approach is expected to provide deeper 
insight into the actions of dopaminergic drugs. With such approach it will become possible 
to anticipate unwanted effects, such as weight gain or sexual disorders. It is stressed that 
CNS drug development lacks accessible biomarkers that represent central effect. Hardly 
any studies were found that relate the central effect to an accessible (i.e. CSF, plasma, 
urine) biomarker response. Moreover, plasma samples were mostly obtained at a single 
time-point, thereby missing the insight into the longitudinal pattern of the effect. Overall, 
given that other neurotransmitter systems are similarly interconnected as the dopamine 
system and also widely expressed, we highlight the need for longitudinal system-wide 
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Abstract
To reveal unknown and potentially important mechanisms of drug action, multi-biomarker 
discovery approaches are increasingly used. Time-course relationships between drug ac-
tion and multi-biomarker profiles, however, are typically missing, while such relationship 
will provide increased insight in the underlying body processes. The aim of this study was 
to investigate the effect of the dopamine D2 antagonist remoxipride on the neuroendo-
crine system.
Different doses of remoxipride (0, 0.7, 5.2 or 14 mg/kg) were administered to rats by 
intravenous infusion. Serial brain extracellular fluid (brainECF) and plasma samples were 
collected and analyzed for remoxipride PK. Plasma samples were analyzed for concentra-
tions of the eight pituitary related hormones as a function of time. A Mann-Whitney test 
was used to identify the responding hormones, which were further analysed by PK/PD 
modeling.
A three-compartment PK model adequately described remoxipride PK in plasma and 
brainECF. Not only plasma PRL, but also adrenocorticotrophic hormone (ACTH) concentra-
tions were increased, the latter especially at higher concentrations of remoxipride. Brain 
derived neurotropic factor (BDNF), follicle stimulating hormone (FSH), growth hormone 
(GH), luteinizing hormone (LH) and thyroid stimulating hormones (TSH) did not respond to 
remoxipride at the tested doses, while oxytocin (OXT) measurements were below limit of 
quantification. Precursor pool models were linked to brainECF remoxipride PK by Emax drug 
effect models, which could accurately describe the PRL and ACTH responses. To conclude, 
this study shows how a multi-biomarker identification approach combined with PK/PD 
modeling can reveal and quantify a neuroendocrine multi-biomarker response for single 
drug action.
Keywords: blood-brain barrier; central nervous system; dose-response; hormones; phar-
macokinetic/ pharmacodynamic models
Abbreviations
ACTH: adrenocorticotropic hormone; AL: anterior lobe; BBB: blood-brain barrier; BDNF: 
brain-derived neurotropic factor; ECF: extracellular fluid; FSH: follicle stimulating hormone; 
GH: growth hormone; IL: intermediate lobe; LH: luteinizing hormone; ODE: ordinary differ-
ential equation; OFV: objective function value; OXT: oxytocin; PACAP: pituitary adenylate 
cyclase-activating polypeptide; PHDA: periventricular hypothalamic dopaminergic; PK/
PD: pharmacokinetic/ pharmacodynamic; PL: posterior lobe; PRL: prolactin; RSE: relative 
standard error; THDA: tuberohypothalamic dopaminergic; TIDA: tuberoinfundibular dopa-
minergic; TSH: thyroid stimulating hormone; VPC: visual predictive check
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Introduction
To better understand pharmacological effects of central nervous system (CNS) drugs on the 
whole biological system, including the unknown mechanisms of action, a holistic approach 
is key [1,2]. Unfortunately, the focus of current in vivo pharmacology is often on the known 
mechanism of action only [3]. Therefore, to obtain insight in multiple system components, 
increasing efforts are made to show the utility of a multi-biomarker discovery approach, 
both in disease conditions and upon drug administration [3,4]. With that, the pathophysi-
ological and pharmacological influences are reflected by a multi-biomarker response.
Thereby it is not enough to investigate dose versus multi-biomarker response, because 
such relationships are not unique, i.e. condition dependent. It is therefore important to 
have insight into processes that govern drug distribution to target sites, target binding ki-
netics, signal transduction and homeostatic feedback mechanisms. Such insight is obtained 
by multilevel studies, i.e. measurement of different biomarker types in a time-dependent 
manner, and advanced pharmacokinetic/ pharmacodynamic (PK/PD) modeling [5–7].
PK/PD modeling was successfully applied for the selective dopamine D2 antagonist remo-
xipride, both in human [8] and rat [9], to predict the pharmacological response beyond 
the tested conditions. The pharmacological response was represented by prolactin (PRL), 
which is a well-known biomarker for D2 antagonism [10,11]. More specifically, dopamine 
binding to the D2 receptor inhibits the prolactin release from the pituitary into plasma, 
and therefore D2 antagonism induces its release [10]. Movin-Osswald & Hammarlund-
Udenaes (1995) developed a PK/PD model to describe the PK of remoxipride in plasma in 
conjunction to its effect on the PRL kinetics (synthesis, release and elimination) in human 
subjects, to successfully predict the PRL response after different and repeated doses [8]. 
Then, in our lab, Stevens et al. (2012) developed a translational PK/PD model for remoxi-
pride effects on PRL plasma concentrations in rats, using data on brain extracellular fluid 
(brainECF) concentrations that could be identified as target site concentrations [9]. With 
that, they successfully predicted the human PK/PD data of remoxipride and PRL of Movin-
Osswald & Hammarlund-Udenaes (1995). This indicated that plasma PRL is a translatable 
biomarker of D2 antagonism.
So far, D2 antagonism was only reflected by a single hormone, PRL. This hormone is part 
of the neuroendocrine system, which consists of the hypothalamus, the pituitary and 
peripheral hormone glands (e.g. adrenal gland), containing a variety of hormones. The 
neuroendocrine hormones are highly regulated through feedback mechanisms of single 
hormones on their own secretion or that of others, both in a direct or an indirect manner. 
PRL and oxytocin (OXT), for example, interact through a positive feedback loop in female 
rats [12]. Through the neuroendocrine system, the brain controls the plasma hormone 
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levels in response to neurological stimuli. Thus, from a pharmacological perspective, a 
change in plasma hormone concentration may reflect a central drug action. This provides 
the unique opportunity to study central pharmacology on plasma hormone concentra-
tions, overcoming the ethical and technical hurdles of taking samples from the human 
brain. Plasma hormones are released from the pituitary, which consists of the anterior 
lobe (AL), the intermediate lobe (IL) and the posterior lobe (PL). Dopaminergic neurons 
from the hypothalamus are involved in regulating all these parts of the pituitary [13]. 
Release of hormones (e.g. PRL) that are stored in the AL may be regulated by dopamine 
that is secreted from tuberoinfundibular dopaminergic (TIDA) neurons into the portal vein. 
Hormones from the IL and the PL (e.g. OXT) are directly released, possibly from tuberohy-
pothalamic dopaminergic (THDA) neurons that project into the pituitary. This tight con-
nection between the dopaminergic and the neuroendocrine system inspired us to use the 
neuroendocrine system as a source for multi-biomarker discovery of dopaminergic agents.
Indeed, next to the dopamine-PRL connection, other interactions between the dopami-
nergic system and neuroendocrine hormones have also been reported. For example, the 
dopamine agonist bromocriptine is used to treat hypersecretion of adrenocorticotrophic 
hormone (ACTH) in Nelson’s disease [14] as well as hypersecretion of growth hormone 
(GH) in acromegaly [15]. Moreover, dopamine was found to inhibit secretion of GH from 
human pituitary cells [16], and dopamine D2 receptors have been identified on thyroid 
stimulating hormone (TSH) adenoma’s [17]. Furthermore, stimulation of the D2 receptor 
leads to suppression of the luteinizing hormone (LH) by induction of the second mes-
senger pituitary adenylate cyclase-activating polypeptide (PACAP) in gonadotrophs [18]. 
Therefore, to understand whether these interactions between the dopaminergic and neu-
roendocrine system are relevant to dopamine D2 antagonists in vivo, it seems of interest 
to investigate their broader neuroendocrine responses in a well-controlled animal study.
In this study we applied a multi-biomarker discovery approach to investigate the neu-
roendocrine response to remoxipride in rats. Serial sampling of brainECF and blood was 
performed to determine the remoxipride PK in plasma and brain, following the procedures 
as earlier described [19]. Blood samples were also analyzed for ACTH, brain derived neu-
rotropic factor (BDNF), follicle-stimulating hormone (FSH), GH, LH, OXT, PRL and TSH to 
obtain a neuroendocrine multi-biomarker. We combined this approach with PK/PD model-
ing to gain a comprehensive understanding of the PK/PD relation between remoxipride 
and the neuroendocrine system.
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Methods
Animals
All animal experiments were performed in accordance with the Dutch Law of Animal Ex-
perimentation. The study protocols (DEC14051/DEC13186) were approved by the Animal 
Ethics Committee in Leiden. Male Wistar rats (n=106, 264 +/- 17 g), Charles River, The 
Netherlands) were housed in groups for 6-9 days until surgery (Animal Facilities Gorlaeus 
Laboratories, Leiden, The Netherlands), under standard environmental conditions with 
ad libitum access to food (Laboratory chow, Hope Farms, Woerden, The Netherlands) and 
acidified water. Artificial daylight was provided from 7:30AM to 7:30PM.
Surgery
Surgery was performed following the procedures as described earlier [19], with slight 
adaptations. In short, animals were kept under 2% isoflurane anesthesia while they 
underwent surgery. They received cannulas in the femoral artery for serial blood sam-
pling and femoral vein for drug administration. A microdialysis guide (CMA 12 Elite PAES, 
Schoonebeek, The Netherlands) was implanted in caudate-putamen (AP -1.0; L 3.0; V -3.4) 
for serial brainECF sampling. 24 hour before the experiment, the microdialysis guide was 
replaced by a probe (CMA 12 Elite PAES, 4 mm polycarbonate membrane, cut-off 20 kDA, 
Schoonebeek, The Netherlands). Between surgery and experiments, the animals were 
kept individually in Makrolon type 3 cages for 7 days to recover from surgery.
Experiments
Table I provides an overview of the groups and number of rats used (study numbers EW01 
and WB02). All experiments started between 8:00AM and 8:30AM, with rats randomly as-
signed to receive 0, 0.7, 5.2 or 14 mg/kg remoxipride by a 10-minute i.v. infusion at the start 
of experiment (t=0 min). Microdialysate perfusion buffer was prepared as described earlier 
[20], and 60 minutes before the experiment the perfusion was started using a flow rate of 1 
ul/min until the end of experiment (see table I for the sampling times). Samples with a devi-
ated flow rate of >10% were discarded. Microdialysate samples were stored at 4 degrees 
Celsius during the experiment and at -80 degrees Celsius after the experiment until analysis.
The extraction efficiency (in vivo recovery) of the microdialysis probe was determined 
following an in vivo loss experiment with 20, 100, 300 and 1000 ng/ml remoxipride. The 
microdialysate concentrations were corrected for an extraction efficiency of 11 +/- 0.5% 
(mean +/- SEM, n=208). Blood samples of 200 ul were taken at serial time points (Table 
I) through the arterial cannula and collected in heparin-coated eppendorf tubes. Animals 
received 200 ul saline after each sampling. The samples were centrifuged (1000 rpm, 10 
min) for separation of plasma and were subsequently stored at 4 degrees Celsius during 
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Analytical methods
Remoxipride in plasma and microdialysates – Remoxipride concentrations in plasma and 
microdialysates were determined following a previously published liquid chromatography 
tandem mass spectrometry method [21] with small modifications to improve the column 
lifetime. In short, formic acid instead of trifluoro acetic acid was added to the solvents 
of on-line solid phase extraction and liquid chromatography, while maintaining the same 
performance in peak shape and resolution.
Plasma hormones – The plasma hormone analysis was performed with Bio-Plex® MAG-
PIXTM technology (Biorad Laboratories, Veenendaal, The Netherlands). The hormones 
ACTH, BDNF, FSH, GH, LH, PRL and TSH were analyzed using the commercially available 
multiplex assay for analysis of pituitary hormones (RTPMAG-86K, Rat pituitary magnetic 
bead panel, Merck Millipore, Darmstadt, Germany). We followed the protocol provided 
by the manufacturer, analyzing 10 ul of each sample in duplo. OXT was analyzed using the 
commercially multiplex assay for analysis of neuropeptides (RMNPMAG-83K, Rat/mouse 
neuropeptide magnetic bead panel, Merck Millipore, Darmstadt, Germany). We followed 
the protocol provided by the manufacturer, analyzing 80 ul of each sample. Data were 
acquainted and concentrations were calculated using the Bio-Plex® Data ProTM software 
(Biorad Laboratories, Veenendaal, The Netherlands). Data below lower or above upper 
limit of quantifications were excluded, which was below 9% for all hormones, except for 
OXT for which most measurements were below limit of quantification (< 3.84 pg/ml).
Identification of responding hormones for further PK/PD analysis
To select responding hormones, the plasma hormone concentration-time data were first 
corrected for individual hormone baseline concentrations as obtained before administra-
tion of remoxipride (t=-15 min). These data were used to compare the experimental groups 
that received 5.2 or 14 mg/kg remoxipride with the placebo group (for baseline hormone 
values during the experimental period). A Mann-Whitney Wilcoxon non-parametric test 
was performed to compare the baseline corrected concentrations at each time-point for 
each hormone. Hormones that showed a significant difference (p<0.05) for at least one 
time-point were selected for further PK/PD analysis. All data analyses were performed 
using R version 3.1.1.
PK/PD modeling
NONMEM® version 7.3.0 with subroutine ADVAN13 was used to perform the PK/PD 
modeling on the remoxipride concentrations in plasma and brainECF, and the hormone 
concentrations in plasma. In addition to data from the studies described above, plasma 
and brainECF remoxipride concentrations were taken from a previously performed study 
in which 4, 8 and 16 mg/kg remoxipride was administered by a 30-minute i.v. infusion 
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(table I) [22]. Criteria to develop the best model were i) significant drop in objective func-
tion value (OFV) calculated as -2loglikelihood ratio (> 3.84, p < 0.05, df = 1); ii) parameter 
precision; iii) goodness-of-fit; iv) correlations; v) condition number; vi) shrinkage; vii) 
bootstrap and viii) visual predictive check (VPC). Furthermore, the PK/PD model for PRL 
was externally validated on available data from Stevens et al. 2012 [9].
A sequential PK/PD modeling approach was applied, in which the posthoc parameter 
estimates of the PK model were used as input for the PK/PD model. For the PK model 
data were log-transformed and an exponential error model was found to best describe 




A three-compartment model was identified to describe the free remoxipride concentra-
tions in plasma and brainECF (figure 1, middle part). Inclusion of saturable remoxipride 
Figure 1. Schematic overview of the final PK/PD model describing the pharmacokinetics of remoxipride in 
plasma and brain, as well as the pharmacodynamics for both PRL and ACTH. For explanation of the abbre-
viations the reader is referred to Table IV and Table V.
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clearance from plasma, described by Michaelis Menten kinetics, was found to improve the 
description of the data (dOFV -94, figure S1). This was particularly observed after low and 
high remoxipride doses (figure S1). Furthermore, in addition to passive blood-brain-barrier 
(BBB) transport, distribution from brainECF to plasma (dOFV -238) or elimination from 
brainECF (dOFV -239) was found to improve the model fit. However, the model with dis-
tribution from brainECF to plasma, showed imprecise parameter estimates (> 1000%) and 
therefore the model with elimination from brainECF was selected. Parameter estimates 
showed good precision (RSE < 30%), and bootstrap showed accurate estimates (table II).
Pharmacodynamics
Multi-biomarker discovery
As shown in figure 2A, not only plasma PRL but also ACTH was found to respond to re-
moxipride treatment (p < 0.05). The other hormones (BDNF, FSH, GH, LH and TSH) did 
not show a significant response, while for oxytocin most measurements were below limit 
of quantification. Plasma PRL showed a response after both 5.2 mg/kg and 14 mg/kg, 
whereas ACTH only showed a response after 14 mg/kg remoxipride. The response time 
profiles of plasma PRL were similar for 5.2 mg/kg and 14 mg/kg (figure 2B). Apparently the 
response maximum was already reached after 5.2 mg/kg. Therefore, an additional study 
was performed in which plasma PRL was measured after 0.7 mg/kg remoxipride (EW01 
study, table I). The plasma PRL concentrations after 0.7 mg/kg remoxipride were not only 
lower, but also exhibited a different longitudinal pattern. After 5.2 mg/kg and 14 mg/kg, 
but not after 0.7 mg/kg PRL showed a two-phasic decline (figure 2B). For plasma ACTH, a 
Table II. Remoxipride pharmacokinetics (PK). Parameter estimates and bootstrap results for the PK model 
following different doses of remoxipride. CL: clearance; CV: coefficient of variation; km: remoxipride con-
centration at half maximal clearance rate; Q: passive distribution between compartments; RSE: relative 
standard error of estimate; Vmax: maximal clearance rate; V: volume of distribution.
Parameter
Bootstrap (n=50)
Parameter estimate RSE (%) Bootstrap mean CV (%)
Vmax,centr (uM h-1) 5.9 25 5.9 32
km,centr (uM) 2.9 27 3.0 31
Vcentral (L) 0.14 8 0.13 10
QPL-periph (L h-1) 2.6 8 2.6 9
Vperiph (L) 0.52 15 0.52 14
QPL-ECF,passive (L h-1) 2.7 12 2.7 14
CLECF,el (L h-1) 3.1 14 3.1 18
VbrainECF (L) 3.5 10 3.5 12
Residual error
Plasma 0.26 13 0.26 14
ECF 0.51 16 0.52 18
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quick response was observed after 14 mg/kg, with ACTH levels back to baseline within one 
hour. No response was observed after 5.2 mg/kg (figure 2C). 
PK/PD model for PRL
For PRL, a pool model was identified linking brainECF remoxipride to the PRL 
release, including a positive feedback of PRL on its own synthesis (figure 1, up-
per part). First of all, although PRL in the placebo group initially decreased and 
subsequently increased (figure 2B), this trend was small relative to the pharma-
cological response (~3 ng/ml vs. ~45 ng/ml). Therefore, a steady baseline was 
assumed. Second, a turnover model outperformed a pool model as indicated by a signifi-
cant difference in the OFV (table III, models A&B vs. C&D, dOFV > 3.84, df = 1). However, 
inclusion of a positive feedback component of plasma PRL (figure 1) on its own synthesis 
led to a significant improvement in comparison with both a pool model and a turnover 
model (table III, models A and C vs. E dOFV > 7.81, df = 3). Moreover, this model explained 
the two-phasic decline (figure 3A), which was not possible without positive feedback (fig-
Figure 2. Biomarker responses upon remoxipride treatment. A) Heatmap showing the differential response 
of the different hormones after 5.2 mg/kg and 14 mg/kg remoxipride. Red squares indicate a significant 
difference compared to the control group that received saline (p < 0.05). B) Different response time curves 
for PRL and C) ACTH after 0 (solid), 0.7 mg/kg (dashed) 5.2 (dot-dashed) or 14 mg/kg (dotted). Data are 
geometric mean +/- geometric SD.
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ure 3B). The positive feedback parameters (Emax,pf, EC50,pf) were fixed to the values identified 
by Stevens et al. (2012), assuming that these system- specific parameters are not different 
between our earlier and more recent studies. Finally, remoxipride in brainECF could better 
explain the PRL response than remoxipride in plasma (table III, model E vs. F, dOFV > 3.84, 
df = 1). Parameter estimates were reasonably precise (RSE <30%), and bootstrap evalua-
tion showed good accuracy (table IV). The VPC showed a good agreement of the model 
with the data (figure 3A). The model was found to well-describe the data from Stevens et 
al. 2012 [9], although the upper variation was slightly overestimated (figure S2). 
PK/PD model for ACTH
Also for ACTH a pool model was identified, linking remoxipride in brainECF to the release 
of ACTH into plasma (figure 1, lower part). First of all, as indicated by a significant differ-
ence in the OFV, a pool model performed better than a turnover model (table II, model 
A&B vs. C&D, dOFV > 3.84, df = 1). Second, although it was not possible to discriminate 
between the model with brainECF remoxipride or plasma remoxipride explaining the 
ACTH response (table II, model C vs. D, dOFV < 3.84, df = 1), the brainECF model (model 
C) showed better parameter precision (28% vs. 89%). Moreover, the VPC showed better 
agreement, albeit a minor difference, with the data for this model (figure 3C) as compared 
to model D, with plasma remoxipride coupled to the response (figure 3D). Finally, because 
ACTH only showed a response after a high remoxipride dose, different drug effect models 
were compared. An Emax-model showed an equal model fit as a linear slope model (table 
III, model D vs. E, dOFV < 3.84, df = 1). However, to have a beginning of a clue about 
the potency of the ACTH response as compared to the PRL response, we sticked to the 
Emax-model.
Table III. Steps in PK/PD model development for the models describing the PRL and ACTH responses.
Model Description OFV
PRL
A Turnover model with drug effect from remoxipride in brainECF on PRL release 1861
B Turnover model with drug effect from remoxipride in plasma on PRL release 1897
C Pool model with drug effect from remoxipride in brainECF on PRL release 1909
D Pool model with drug effect from remoxipride in plasma on PRL release 1916
E Pool model with drug effect from remoxipride in brainECF on PRL release + positive feedback of 
PRL in its own synthesis [best model]
1848
ACTH
A Turnover model with drug effect (Emax model) from remoxipride in ECF on ACTH release 1957
B Turnover model with drug effect (Emax model) from remoxipride in plasma on ACTH release 1869
C Pool model with drug effect (Emax model) from remoxipride in ECF on ACTH release [best model] 1862
D Pool model with drug effect (Emax model) from remoxipride in plasma on ACTH release 1861
E Pool model with drug effect (linear slope model) from remoxipride in ECF on ACTH release 1860
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Since the degradation rate of ACTH (kdegr,acth) was not identifiable on basis of the current 
data, it was fixed to a value of 24.5 h-1, as obtained in rats during the ACTH decline after a 
stress response [23].
Also, the maximal drug effect parameter (Emax,rem,ACTH) was not identifiable. However, 
because this parameter is a composite of unknown underlying parameters, a literature 
value was not available. Therefore, Emax,rem,ACTH was chosen on basis of the sensitivity of 
the OFV to Emax,rem,ACTH values of 1, 7.5, 10, 15, 20 and 100. Up till a value of 10 the OFV 
dropped significantly, but from a value of 10 or higher, it showed no significant difference 
(dOFV < 3.84). Therefore, Emax,rem,acth was fixed to 10. Here it must be noted that, with 
changing Emax,rem,ACTH, the EC50 changed almost linearly with the change in Emax, while other 
parameters remained the same. Parameter estimates of the best model (table III, model 
C) showed good precision (RSE < 30%) and accuracy (table V), and the VPC showed good 
agreement between the model and the data (figure 3C).
Figure 3. Prediction corrected visual predictive checks (n=1000) for the remoxipride PK/PD model describ-
ing PRL after 0.7, 5.2 and 14 mg/kg (top) and ACTH after 0, 5.2 and 14 mg/kg (bottom). The pool models 
with (A) and without (B) positive feedback are shown for the PRL response. The models with ECF (C) and 
plasma (D) as target site of action are shown. Solid lines are the observed medians and the shaded area 
shows the 95% prediction interval around the simulated median. The extent to which this area captures the 
observed median is a measure of correct model specification. Ideally, at each point 50% of the prediction 
interval is above the observed median, and 50% below. The large prediction intervals in the third bin (see 
arrow) of figures (C) and (D) are explained by the fact that this bin contained only two observations.
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Table IV. Parameter estimates and bootstrap results for the remoxipride PK/PD model describing the PRL 
response. Bsl: baseline;Emax: maximal effect; CV: coefficient of variation; EC50: drug concentration at half 
maximal effect; IIV: interindividual variability; ksynth: PRL synthesis rate in the lactotroph; krel: PRL release 
rate from the lactotroph to plasma; kdegr: degradation rate of PRL in plasma; pf: positive feedback; prl: pro-
lactin; rem: remoxipride; RSE: relative standard error of estimate.
Parameter
Bootstrap (n=100c)
Parameter estimate RSE (%) Bootstrap mean CV (%)
Emax,rem,prl 13.3 12 13.8 16
EC50,rem,prl (uM) 0.064 28 0.074 63
Bslprl (ng ml-1) 7.3 7 7.2 6
ksynth,prl (ng ml-1 h-1) 41.7a 41.2
krel,prl (h-1) 0.35 12 0.36 18
kdegr,prl (h-1) 5.72b 5.72
Emax,pf,prl 3.47b 3.47
EC50,pf,prl (ng ml-1) 12.4b 12.4
IIV
Bslprl 0.075 19 0.071 43
Residual error
Proportional 0.13 8 0.13 13
a ksynth was calculated from bslprl*kdegr,prl. 
b values were obtained from literature. 
c 100 out of 100 bootstrap runs minimized successfully.
Table V. Parameter estimates and bootstrap results for the remoxipride PK/PD model describing the ACTH 
response. Bsl: baseline; Emax: maximal effect; CV: coefficient of variation; EC50: drug concentration at half 
maximal effect; IIV: interindividual variability; ksynth: ACTH synthesis rate in the lactotroph; krel: ACTH release 
rate from the lactotroph to plasma; kdegr: degradation rate of ACTH in plasma; pf: positive feedback; prl: 
ACTH; rem: remoxipride; RSE: relative standard error of estimate.
Parameter
Bootstrap (n=100d)
Parameter estimate RSE (%) Bootstrap mean CV (%)
Emax,rem,ACTH 10a 10
EC50,rem,ACTH (uM) 2.61 19 2.66 30
BslACTH (pg ml-1) 24.6 8 24.6 5
ksynth,ACTH (pg ml-1 h-1) 603b 603
krel,ACTH (h-1) 3.13 18 3.03 21
kdegr,ACTH (h-1) 24.5c 24.5
IIV
Bslprl 0.15 26 0.14 26
Residual error
Proportional 0.12 5 0.12 17
a Parameter was not identifiable and the value was chosen on basis of a sensitivity analysis. 
b ksynth was calculated from bslprl*kdegr,prl. 
c Values were obtained from literature. 
d 89 out of 100 bootstrap runs minimized successfully.
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Discussion
Our goal was to apply the multi-biomarker discovery approach in a quantitative manner, 
with remoxipride as a paradigm compound. To that end, hormones from the neuroendo-
crine system were analyzed as a source for a multi-biomarker to represent remoxipride 
effect. We showed that not only PRL, but also ACTH acts as biomarker for remoxipride 
pharmacology. Both these hormones are synthesized in the so-called ‘troph’ cells in the 
anterior pituitary, from which they are continuously released. In our study, we quantified 
the effect of remoxipride on the PRL and ACTH release, as described by pool models, 
thereby gaining a comprehensive understanding of remoxipride effect on the neuroendo-
crine system. With that, we revealed the in vivo concentration effect relation of brainECF 
remoxipride with the hormones PRL and ACTH enabling the prediction of a neuroendo-
crine response for other doses of remoxipride.
Pharmacokinetics
The brainECF concentrations were described by a three-compartment PK model, which 
was developed first to be subsequently linked to the PK/PD model. This model included 
drug elimination from the brain, confirming a previously developed PK model for remoxi-
pride in rats [22]. Whether this represented remoxipride active transport from brainECF 
to plasma, metabolism of remoxipride in the brain, or efflux of remoxipride from brainECF 
to cerebrospinal fluid (CSF) remains to be answered. No studies on remoxipride being a 
substrate for efflux transporters have been reported, to the knowledge of the authors. In-
terestingly, O-demethylase activity has been observed in the rat brain [24], suggesting that 
remoxipride metabolism in the brain may have occurred. Furthermore, whereas Stevens 
et al. (2011) found linear elimination from plasma, we identified saturable elimination, 
described by Michaelis Menten kinetics. They applied a 30-minute infusion time, but we 
used a 10-minute infusion time with similar doses. This led to a 1.5 times higher maximal 
plasma remoxipride concentrations in the current study, making it more likely to observe 
saturation of metabolic clearance. This is not surprising for remoxipride since in rats it 
is eliminated mainly through liver enzymatic processes of demethylation and aromatic 
hydroxylation [25]. However, in humans remoxipride is metabolized mainly via oxidation 
[25], which may not be saturated at these concentrations. Indeed, linear elimination was 
identified for remoxipride in humans [26].
Pharmacodynamics
Dopaminergic control over the neuroendocrine system is established via the tuberoinfun-
dibular system, which consists of TIDA, THDA and periventricular hypothalamic dopami-
nergic (PHDA) neurons that connect the hypothalamus to the pituitary [13]. Therefore, 
we were interested in plasma hormones that are released from the AL or the PL of the 
pituitary as a reflection of central pharmacology of dopaminergic agents. Whereas PRL 
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has been used as a biomarker for central dopaminergic activity, exerted via the tuberoin-
fundibular system, other neuroendocrine hormones have not been used for this purpose. 
Surprisingly, despite the potential to respond to dopaminergic perturbation as described 
in the introduction, FSH, LH, GH, TSH and BDNF did not show a response to a single dose 
of remoxipride. Thus, a D2 agonistic effect on these hormones, or presence of the D2 
receptor on the secretory cells does not necessarily imply a response to dopamine D2 
antagonism. Also, within four hours we could not identify feedback regulation on these 
five hormones by the two responding hormones. However, using the multi-biomarker 
discovery approach on eight hormones, we identified not only PRL, but also ACTH as a 
biomarker for the D2 antagonist remoxipride. Unfortunately, we were not able to measure 
OXT since its levels were lower than the limit of quantification, although it is likely that 
there is an interaction between PRL and OXT [12].
PK/PD model for PRL
To use prolactin as a biomarker for prediction of the response after a second remoxipride 
administration, it is important to take into account underlying tolerance mechanisms, 
either being the depletion of the lactotroph (pool model) [8,9] or the stimulation of 
dopamine production by PRL (agonist-antagonist interaction model) [27]. Although both 
models were able to account for the tolerance, only the pool model could explicitly sepa-
rate drug-specific and system-specific parameters, enabling a proper translational step 
from animal to human [9]. The models seem to have similar flexibility to fit the prolactin 
response after a D2 antagonist challenge [27–29], and we also found a similar goodness-
of-fit between the pool and the AAI models (AIC 1860 versus AIC 1844). In fact, to be 
able to discriminate between these models, a continuous infusion with a D2 antagonist 
should be applied. According to the pool model, the plasma PRL concentrations will drop 
to baseline after the pool is empty. Following the AAI model, the plasma PRL concen-
trations will reach a higher steady state during the continuous exposure. In this study, 
a pool model was found to describe the prolactin response with brainECF remoxipride 
related to the release of PRL. Furthermore, in agreement with Stevens et al. (2012), the 
inclusion of a positive feedback of PRL on its own synthesis significantly improved the 
model with particularly the two-phasic decline being better described (figure 3B). This 
feedback mechanism works by increasing the ‘refilling’ of the lactotrophs after release of 
PRL, possibly mediated through stimulation of the PRL receptor on the lactotrophs [9,10]. 
Although the inclusion of the positive feedback improved the data fitting, caution must 
be taken with this type of non-linear models. Bakshi et al. (2016) published a tutorial on 
mathematical analysis of ordinary differential equation (ODE) model behavior, showing 
that the pool model with positive feedback has two steady states and interesting stabil-
ity behavior. This means that the model may converge to one or the other steady state, 
depending on the specific simulated trajectory, which could be affected by small changes 
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in dose or parameter values. Such behavior is not physiological, and caution should be 
taken when extrapolating to other parameter regions or dosages. Still, the model proved 
powerful in translating the PRL response from animal to human, provided inclusion of an 
if-condition that forced the prolactin concentrations to remain above baseline prolactin 
concentrations [9,30]. Simulations with the current model including the if-condition up to 
ten hours, showed a convergence to the correct baseline (Suppl fig 1).
Furthermore, dopamine D2 receptors influence PRL release both at the level of the hypo-
thalamus (TIDA neurons) and the pituitary (lactotrophs) [10]. Stimulation of PRL release 
via D2 receptor antagonism at the TIDA neurons would be mediated through reduced 
dopamine release into the pituitary, whereas stimulation via the lactotrophs would be 
mediated through antagonism directly at the level of the pituitary. Reduced dopamine re-
lease via D2 antagonism at the TIDA neurons is driven by remoxipride in brainECF, whereas 
D2 antagonism at the lactotrophs is driven by remoxipride in plasma, since the pituitary 
is exposed to blood. With data on remoxipride both in plasma and brainECF, we could 
compare these hypotheses to find that PRL release was driven by remoxipride in brainECF 
(table III). However, domperidone, another D2 antagonist which hardly penetrates the 
brain, also stimulates prolactin release [31]. Indeed, drugs with limited brain penetra-
tion exhibit a low ED50 of D2 receptor occupancy in the pituitary as compared to that in 
the striatum, which correlated with the ED50 of prolactin release (peripheral effect) as 
compared to ED50 of apomorphine induced stereotype behavior (central effect) [32]. This 
suggests that direct antagonism of pituitary D2 receptors is responsible for the prolactin 
release. Unfortunately, no such data exists on D2 antagonists with high brain penetration 
(kp,uu > 1) to investigate whether the reduced dopamine release in the pituitary will be-
come dominant in stimulating the prolactin release. On basis of temporal PK/PD analysis 
we found brainECF remoxipride driving the PRL response. Therefore, because remoxipride 
highly penetrates the brain (kp,uu ~ 1), it is suggested that for D2 antagonists with high 
brain penetration, the reduced dopamine release into the pituitary becomes dominant in 
driving the PRL response.
Finally, the estimated EC50,rem,prl of 64 nM was 2-4 fold different from in vitro binding poten-
cies of 113 nM [33] and 240 nM [34] for remoxipride on striatal D2 receptors measured 
in rat brain homogenate, but comparable to the EC50 of 80 nM found for the previously 
developed pool model on basis of in vivo data [9]. The discrepancy between in vivo and 
in vitro estimates might be explained by a role of active metabolites [25]. Although their 
concentrations in plasma are 10-1000 times lower compared to remoxipride [25], four 
metabolites (FLA797, FLA908, NCQ436, NCQ469) showed 2-200 times higher in vitro af-
finity for the D2 receptor than the parent remoxipride [33]. Moreover, these metabolites 
showed in vivo activity on DOPA accumulation in rat striatum [35]. Interestingly, this 
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could be an alternative explanation of the two-phasic decline of prolactin (figure 2B). In 
that case, the PRL response would be the consequence of D2 receptor binding of both 
remoxipride and its active metabolites. Since the PK profile of the active metabolite lags 
behind that of remoxipride [25], the first part of the PRL response would be explained by 
remoxipride effect, whereas the second part would be driven by the active metabolites. 
Nevertheless, the contribution of active metabolites to the in vivo remoxipride potency is 
tentative and in further research remoxipride should be analyzed in conjunction with its 
active metabolites to obtain a complete picture of its PK/PD characteristics. 
ACTH as a biomarker of adrenergic receptor antagonism
To the knowledge of the authors, no studies have been performed for the ACTH response 
upon remoxipride, but other dopaminergic agents have been investigated. The relation 
between dopaminergic agents and ACTH is rather intriguing. Although the dopamine D2 
agonist bromocriptine is used to treat ACTH hypersecretion [14], suggesting an inhibiting 
effect, this appears to be specific for tumor cells [36]. On the contrary, ACTH release in 
rats was stimulated by the dopamine D2 agonists quinpirole and apomorphine, as well as 
by the dopamine reuptake inhibitor GBR12909. These effects were blocked by the dopa-
mine D2 antagonists haloperidol and sulpiride suggesting a D2 specific response [37,38]. 
However, counterintuitively, haloperidol could also stimulate ACTH release [39,40], which 
was also observed for the D2 antagonists thioproperazine [41] and eticlopride [42]. Yet, 
sulpiride did not stimulate ACTH release [37].
Since the stimulatory effect of D2 agonists on ACTH release has been confirmed to be D2 
specific, it is likely that the effect of the D2 antagonists is an off-target effect that these 
drugs have in common.
Although 5-HT1A agonists can induce ACTH release [43], remoxipride and haloperidol have 
no affinity for the 5-HT1 receptors [34]. Moreover, 5-HT1A agonists are known to stimulate 
GH release [43], which was not observed for remoxipride in the present study. On the 
other hand, the in vitro affinity to adrenergic receptors of both remoxipride (to α2 recep-
tor) and haloperidol (to α1 receptor) was only 10 - 50 times lower than to dopamine D2 
receptors [34,44]. Maximal ECF remoxipride concentrations that were observed in rats 
receiving 14.0 mg/kg (1.3 uM – 3.1 uM) exceed the EC50,prl (0.064 uM) by 20 – 50 times. In 
contrast, sulpiride has negligible affinity to adrenergic receptors (at least 100 times lower 
than its affinity to D2 receptor) [34,44]. In addition, haloperidol showed considerable in 
vivo receptor occupancy and functional activity at central adrenergic receptors [45,46]. 
The endogenous ligands for adrenergic receptors are epinephrine and norepinephrine, 
which are known to inhibit the release of corticotropin releasing hormone (CRH) from 
the hypothalamus to the pituitary [47]. In the pituitary, CRH stimulates the release of 
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ACTH from the corticotrophs, which was found to be the pathway for thioproperazine 
to stimulate ACTH release [41]. This is in line with our observation that ACTH release is 
likely to be linked to remoxipride in brainECF, suggesting a drug-receptor interaction at the 
hypothalamus level. Following these observations, it is thus well possible that the effect of 
remoxipride on ACTH is elicited via antagonism of the centrally located adrenergic recep-
tor, leading to an increased release of CRH and ACTH.
PK/PD model for ACTH
The mechanism of ACTH being released upon remoxipride administration thus seems simi-
lar to that of PRL, albeit via another pathway. Whereas PRL is released from lactotrophs, 
stimulated by reduction of dopamine, ACTH is secreted from corticotrophs, stimulated by 
induction of CRH. This provides further evidence for our observation that a pool model de-
scribed the ACTH response (table III). Furthermore, as discussed above, ACTH is suggested 
as a biomarker for an adrenergic response. Although it was not possible to determine 
the exact EC50,ACTH (2.61 uM), since it was dependent on the Emax,ACTH that was fixed to an 
arbitrary value of at least 10, we can conclude that it is at least 40 times higher than EC50,prl 
(0.064 uM). This confirms the earlier suggestion that ACTH represents an off-target effect 
of remoxipride, possibly via the adrenergic receptor. 
Thus, by simultaneous analysis of eight hormones in plasma for a multi-biomarker ap-
proach, we could identify ACTH as additional biomarker for remoxipride in rats. Together 
with PRL, this biomarker provides insights into the effects of remoxipride on the neuro-
endocrine system through different pathways. However, whereas animals in preclinical 
experiments are very similar, having the same genetic background and environmental 
conditions, humans are highly heterogeneous in terms of genetic background, lifestyle, 
disease, age, and other factors that may influence drug efficacy [48]. Such variation may 
impact the response of the neuroendocrine system to D2 antagonists. For example, cor-
ticotrophs in pituitary tumors have higher D2 receptor expression and become sensitive 
to dopamine D2 agents [36], which would impact the ACTH response, but not the PRL 
response. Thus taking into account a multi-biomarker would give more precise insights 
in the PK/PD processes on an individual level, providing opportunities for personalized 
medicine.
Furthermore, as discussed above, the D2 antagonists haloperidol [40], thioproperazine 
[41], eticlopride [42] and remoxipride all stimulate ACTH release, whereas sulpiride [37] 
does not show such response. With PRL only, it is shown that some D2 antagonists cause 
hyperprolactinemia, but others not, providing a sub-classification of D2 antagonists. A 
multi-biomarker provides further sub-classification, for example distinguishing sulpiride 
from haloperidol, thioproperazine, eticlopride and remoxipride. Thus, our approach en-
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ables detailed sub-classification and provides comprehensive insights in differential effects 
among drugs. As such, the approach should ultimately be applied to a series of dopamine 
D2 antagonists and agonists.
Finally, since now we could reveal the neuroendocrine response by combining a multi-
biomarker discovery approach with PK/PD modeling, we have provided a conceptual basis 
to use for example metabolism for a multi-biomarker paradigm. This is expected to provide 
a much more extensive multi-biomarker than the biomarkers used in the current study. 
With the metabolomics technique, more than one hundred endogenous metabolites can 
be measured, providing a promising next step with an untargeted biomarker discovery 
approach rather than the relatively targeted approach exploited in our study. These me-
tabolite responses are then analyzed by multivariate statistics [49], which would identify 
the underlying shared responses among the metabolites and provide a multi-biomarker. 
Metabolomics has been successfully applied for identification of new biomarkers of drug 
effects [2–4], although no studies have been performed that combined it with PK/PD 
modeling. Therefore, further studies should expand on the current study by using me-
tabolomics for untargeted biomarker discovery.
In conclusion, often multi-biomarker discovery and PK/PD modeling are separated fields, 
limiting the insights that can be obtained in in vivo pharmacological studies. In our study, 
we overcame this limitation by combining these fields, revealing remoxipride effects not 
only on PRL, but also ACTH. Moreover, using PK/PD modeling we revealed that both hor-
mone responses were i) likely to be driven by remoxipride in brainECF and ii) described 
by a pool model according to the underlying physiology of hormone release from ‘troph’ 
cells. With that, we quantified the dose response over a large dose range, enabling the 
prediction of neuroendocrine responses after different doses of remoxipride. More gen-
erally speaking, our study shows how multi-biomarker discovery can reveal and PK/PD 
modeling can quantify the multiple neuroendocrine responses for single drug action.
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Supplementary Materials
Figure S1A. Goodness-of-fit of remoxipride PK model in plasma and brainECF A) Observed versus individ-
ual predicted remoxipride plasma concentrations. B) Observed versus population predicted remoxipride 
plasma concentrations. C) Conditionally weighted residuals versus individual predictions. D) Conditionally 
weighted residuals versus time.
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Figure S1B. Goodness-of-fit of remoxipride PK model comparing linear plasma elimination and non-linear 
plasma elimination. A) Observed versus individual predicted remoxipride plasma concentrations. B) Con-
centration time graphs of observed and individual predicted remoxipride concentrations in plasma for a 
low dose (0.7 mg/kg) and a high dose (14 mg/kg) as examples. C) Conditionally weighted residuals versus 
time. D) Conditionally weighted residuals versus individual predictions.
Figure S1C. Individual remoxipride concentration profiles in plasma comparing observed concentrations 
with individual predicted concentrations with linear and non-linear elimination from plasma
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Figure S1D-J. Individual remoxipride concentration profiles in plasma comparing observed concentrations 
with individual predicted concentrations with linear and non-linear elimination from plasma
102 CHAPTER 4
Figure S2. External validation of the PRL PK/PD model on data from Stevens et al. 2012. 4, 8 and 16 mg/kg 
remoxipride was administered to rats by a 30 min. i.v. infusion. Observed data (black dots) are compared to 
simulated median (solid grey line) and 5% and 95% percentiles (dashed grey lines).
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Abstract
Because biological systems behave as networks multi-biomarker approaches increasingly 
replace single-biomarker approaches in drug development. To improve the mechanistic 
insights into CNS drug effects, a plasma neuroendocrine fingerprint was identified us-
ing multi-biomarker pharmacokinetic/pharmacodynamic (PK/PD) modeling. Short- and 
longer-term D2 receptor activation was evaluated using quinpirole as paradigm compound.
Rats (n=44) received 0, 0.17 or 0.86 mg/kg of the D2 agonist quinpirole intravenously. 
Quinpirole concentrations in plasma and brain extracellular fluid (brainECF), as well as 
plasma concentrations of 13 hormones and neuropeptides, were measured. Experiments 
were performed at day 1 and repeated after seven-day subcutaneous drug administration. 
PK/PD modeling was applied to identify the in vivo concentration-effect relations and 
neuroendocrine dynamics.
The quinpirole pharmacokinetics were adequately described by a two-compartment 
model with an unbound brainECF-to-plasma concentration ratio of 5. The release of ad-
enocorticotrophic hormone (ACTH), growth hormone (GH), prolactin (PRL), and thyroid 
stimulating hormone (TSH) from the pituitary was influenced. Except for ACTH, D2 receptor 
expression levels on the pituitary hormone-releasing cells predicted the concentration-
effect relationship differences. Baseline levels (ACTH, PRL, TSH), hormone release (ACTH), 
and potency (TSH) changed with treatment duration.
The integrated multi-biomarker PK/PD approach revealed a fingerprint reflecting D2 recep-
tor activation. This forms the conceptual basis for in vivo evaluation of on- and off-target 
CNS drug effects. The effect of treatment duration is highly relevant given the long-term 
use of D2 agonists in clinical practice. Further development towards quantitative systems 
pharmacology models will eventually facilitate mechanistic drug development.
Keywords: CNS drugs, neuroendocrine system, biomarkers, quantitative systems pharma-
cology, dopamine agonists, PK/PD modeling
Abbreviations
ACTH: adenocorticotropic hormone; BBB: blood-brain-barrier; BDNF: brain-derived neuro-
tropic factor; CNS: central nervous system; CRH: corticotropic releasing hormone; FSH: fol-
licle stimulating hormone; GH: growth hormone; LH: luteinizing hormone; OFV: objective 
function value; PK/PD: pharmacokinetic/pharmacodynamic; PRL: prolactin; RSE: relative 
standard error; TIDA: tuberoinfundibular dopaminergic; TSH: thyroid stimulating hormone
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1. Introduction
Besides insufficient information on drug distribution into and within the brain, a main 
cause of attrition in central nervous system (CNS) drug development is the lack of trans-
lational pharmacodynamic biomarkers, i.e. preclinical biomarkers that are predictive 
for clinical effect [1–3]. This enables the mechanistic extrapolation of drug effects from 
animals to humans [3,4]. 
It is important that these biomarkers are accessible in humans. This poses a challenge 
for CNS drug development, given that sampling from the human brain is highly limited. 
However, the pituitary hormones and peptides of the neuroendocrine system are released 
upon signals from the CNS, in particular the hypothalamus, providing an opportunity to 
study central drug effects in plasma. Dopamine, for example, is released from the tuberoin-
fundibular dopamine (TIDA) neurons into the median eminence of the pituitary to control 
the release of prolactin (PRL) from the lactotrophs into plasma [5]. It has been shown that 
dopamine D2 agonists stimulate the release of dopamine into the median eminence [6,7]. 
This principle has been used to evaluate the dopaminergic drug efficacy with PRL [8–13], 
including the translation of these effects from rats to humans [10,12].
Realizing that biological systems behave as networks, single biomarker approaches are 
increasingly replaced by multi-biomarker approaches [14,15]. Although PRL is a sensitive 
biomarker for dopamine D2 receptor activation, it is also sensitive to serotonin and thyroid 
releasing hormone [16]. A multi-biomarker approach is envisioned to provide a more 
specific reflection of D2 receptor activation. Indeed, the dopaminergic system has multiple 
connections to the neuroendocrine system, including the release of PRL, growth hormone 
(GH), and thyroid stimulating hormone (TSH) [17,18]. With that, it is important to iden-
tify the pharmacokinetic/pharmacodynamic (PK/PD) parameters that can be scaled from 
animals to humans [4]. Moreover, dopaminergic drug effects may change with increasing 
duration of treatment following sensitization and tolerance, as was shown for D2 agonists 
[19].
The aim of the current study was, therefore, to characterize both the short-term and 
longer-term interaction of the dopaminergic system with the neuroendocrine system, in 
order to obtain a fingerprint biomarker of D2 receptor activation. The selective D2/3 agonist 
quinpirole will be used as a paradigm compound. Here we present a PK/PD fingerprint of 




2.1. Animals, surgery, and experiment
Animals. Animal studies were performed in agreement with the Dutch Law of Animal Ex-
perimentation and approved by the Animal Ethics Committee in Leiden, the Netherlands 
(study protocol DEC12247). Male Wistar rats (n = 44) were housed in groups for 6-9 days 
until surgery (Animal Facilities Gorlaeus Laboratories, Leiden, The Netherlands). Animals 
were held under standard environmental conditions while artificial daylight was provided 
from 7:30 AM to 7:30 PM. They had ad libitum access to food (Laboratory chow, Special 
Diets Services, Tecnilab BMI, Someren, The Netherlands) and acidified water.
Surgery. The surgery was performed following previously reported procedures [20]. The 
rats received 2% isoflurane anesthesia while undergoing surgery. After induction of the 
isoflurane, 0.09 ml Buprecare® (AST Farma B.V., Oudewater, The Netherlands) was admin-
istered intramuscular. Cannulas were placed in the femoral artery for serial blood sam-
pling and the femoral vein for drug administration. Probe guides (CMA/12) with dummy 
probes were implanted in caudate putamen in both hemispheres (1.0 mm anterior, 3.0 
mm lateral, 3.4 mm ventral, relative to bregma) and replaced by the probes (CMA/12 
Elite – 4 mm) 24 hours before the experiment. After the surgery, the animals received 0.15 
ml Ampicillan® (Dechra Veterinary Products B.V., Bladel, The Netherlands) and 3 ml 0.9% 
NaCl subcutaneously. The rats were individually held in Makrolon type 3 cages for 7 days 
to recover and weighed on a daily basis to evaluate the recovery.
Experiments. The rats were randomly assigned to receive 0 (n=12), 0.17 mg/kg (n=16), 
or 0.86 mg/kg (n=16) intravenous quinpirole between 10:45 AM and 11:15 AM on the 
first experiment day. The smaller group size for the control group was chosen, because 
less variation was expected in the data; i.e. there is no inter-individual variation from PK 
and the resultant PD processes. The statistical non-linear mixed effect analysis (see sec-
tion 2.3. Data analysis) is able to handle unbalanced study designs. The microdialysate 
samples were collected from -200 to 180 minutes (20-minute interval, 1.5 ul/min, 120 min 
equilibration time) in polypropylene microvolume inserts (250 ul, Waters) containing an 
antioxidant mix of 10 ul 0.02M formic acid/0.04% ascorbic acid in water. Blood samples 
of 200 ul were collected in heparin-coated Eppendorf tubes at -5, 5, 7.5, 10, 15, 25, 45, 
90, 120 and 180 min and centrifuged (1000 x g, 10 min, 4°C) to separate the plasma. 
All samples were stored at -80°C until analysis. After the experiment, the cannulas were 
filled with a saline-heparin solution (venous) or a PVP-heparin solution (arterial), while a 
dummy replaced the probes. The rats received their quinpirole dose subcutaneously, until 
the second experiment on day 8, which was executed as on day 1. After the experiment, 
the rats were sacrificed following an overdose of Nembutal®.
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2.2. Chemical analysis of the samples
2.2.1. Quinpirole analysis in plasma and microdialysate
Quinpirole (Bio-Connect, Huissen, The Netherlands) was analyzed using liquid chroma-
tography-tandem mass spectrometry (LCMS/MS). Calibration standards were prepared in 
plasma with 0, 5, 10, 20, 50, 100, 200, 400 and 500 ng/ml and in buffered perfusion fluid 
(bPF) with 0, 0.5, 1, 2, 5, 10, 20, 50, 100, 200 ng/ml quinpirole. Quality controls (QC’s) 
were prepared in plasma with 5, 10, 50 and 500 ng/ml and in bPF with 1, 6, 30 and 150 
ng/ml quinpirole. Of the microdialysate samples, 20 µL was transferred to microvolume 
inserts (BGB Analytik, Harderwijk, the Netherlands and spiked with 20 µL of 40 ng/ml 
internal standard ropinirole-D4 (Bio-Connect, Huissen, the Netherlands). Of the plasma 
samples, 20 µL was spiked with 20 µL of the same internal standard and 20 µL water 
before deproteination with 1 mL acetonitrile (AcN). After centrifuging (20,000 x g, 10 min), 
the supernatant was transferred to an Eppendorf vial and dried by CentriVap vacuum cen-
trifugation (Labconco, Kansas City, Missouri). The residue was dissolved in 40 µL 5 % AcN. 
After centrifuging (20,000 x g, 10 min) the supernatant was transferred to microvolume 
inserts and inserted into 1.5 ml screw cap vials.
The vials were placed into the Nexera X2 UHPLC-MS/MS system (Shimadzu, ‘s Hertogen-
bosch, the Netherlands) at 10°C. 5 µl of the sample was injected into the system, operated 
by LCQuan software (version 2.7, Thermo Fisher Scientific, Breda, the Netherlands)) and 
the MS Finnigan TSQ quantum ultra-mass spectrometer (Thermo Fisher Scientific, Breda, 
The Netherlands), operated by XCalibur software (version 2.5, Thermo Fisher Scientific, 
Breda, The Netherlands). An Acquity UPLC BEH C18 column (130Å, 1.7 μm, 2.1 mm X 50 
mm; Waters, Etten-Leur, The Netherlands) was used with a flow rate of 0.4 ml/min and 
a column temperature of 40°C. The mobile phases were prepared in 10 mM ammonium 
acetate in water (adjusted to pH 7 with formic acid). The aqueous mobile phase (MPAQ) 
contained 5% and the organic mobile phase (MPORG) 95% AcN. A gradient was applied with 
10% MPORG (0 – 0.5 min) to 100% MPORG (0.5 – 2.0 min) and kept at 100% MPORG (2.0 – 2.8 
min), after which the column was re-equilibrated with 10% MPORG (2.8 – 3.0 min). The 
retention time of quinpirole and ropinirole-D4 was 1.8 and 2.24 minutes, respectively. The 
MS was used in positive electrospray ionization mode and all compounds were monitored 
by Selective Reaction Monitoring (SRM). The ionization voltage, capillary energy, capillary 
temperature and desolvation temperature were set to 3.50 kV, 3 V, 150°C, and 400°C, 
respectively. The transition ion pair was 220.18 m/z → 161.00 m/z, 16 V for quinpirole and 
265.22 m/z → 132.07 m/z, 32 V for ropinirole-D4. The quality of the method was assured 
following the guidelines for bioanalysis [21]. The unbound fraction of quinpirole in plasma 
was determined to be 71 ± 3% (concentration-independent) by filtrating plasma samples 
using high-speed filtration (Centrifree®, Merck Millipore, Amsterdam, The Netherlands, 
2000 x g, 10 min) and calculating the ratio of unbound to total plasma concentrations. 
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The measured total plasma concentrations of quinpirole were corrected accordingly, to 
obtain unbound plasma concentrations. The recovery of quinpirole over the microdialysis 
probe was determined to be 5.4 ± 1.7% (n = 191) using the retrodialysis method [22]. The 
measured microdialysate quinpirole concentrations were corrected for probe recovery to 
report the brainECF concentrations.
2.2.2. Pituitary hormones and neuropeptides in plasma
The pituitary hormones (ACTH, brain-derived neurotropic factor (BDNF), follicle stimu-
lating hormone (FSH), GH, luteinizing hormone (LH), PRL and TSH) and neuropeptides 
(α-melanocyte stimulating hormone, β-endorphin, neurotensin, Orexin A, oxytocin, Sub-
stance P) were analysed by multiplex assays (RTPMAG-86K and RMNPMAG-83k, Merck 
Millipore, Darmstadt, Germany) on a Bio-Plex® MAGPIXTM system (BioRad Laboratories, 
Veenendaal, The Netherlands). With the RTPMAG-86k, 10 uL and with the RMNPMAG-
83k, 50 uL plasma was used for analysis according to the protocol provided by the manu-
facturer.
2.3. Data analysis
2.3.1. PK/PD modeling software and criteria
The PK/PD models to describe the quinpirole and the hormone concentrations in brainECF 
and plasma were developed by a two-stage approach (the PK parameters were fixed 
before developing the PD models), using a non-linear mixed effect population approach in 
NONMEM® version 7.3.0 with subroutine ADVAN13. The inter-individual variability around 
the parameters and the residual error were described by an exponential distribution 
(suppl. Equation 1, 2). Model selection was based on successful convergence, objective 
function value (OFV), parameter precision and visual evaluation of the model predictions 
as compared to the observations.
2.3.2. Pharmacokinetic model development
Two- and three-compartment models were compared, both with linear or non-linear 
clearance from plasma for their description of unbound quinpirole concentrations in 
plasma and brainECF. Here it should be noted that a two-compartment model refers to one 
compartment describing plasma and another compartment describing brainECF quinpirole 
concentrations. The transport into and out of the brain across the blood-brain-barrier 
(BBB) in these models was estimated with two separate distribution clearances. The 
experiment day was evaluated as covariate on one of the model parameters. The selected 
model was evaluated on additional data to guarantee external validity, and the details of 
which are described in the supplementary information.
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2.3.3. Pharmacodynamic model development
For each hormone, baseline, PK/PD and covariate models were developed in a step-wise 
manner. Baseline patterns were evaluated on placebo data following supplementary equa-
tions Part I, 4 – 7. The selected baseline models were, together with the pharmacokinetic 
model, integrated into the PK/PD models. The PK/PD models were defined as a combina-
tion of the following characteristics: i) baseline model for each hormone; ii) plasma or 
brainECF as target site; iii) the slope, the EMAX, the alternative EMAX [23], the on-off, or no 
drug effect model; iv) and the direct response, the turnover or the pool model as link 
model (suppl. Equations Part I, 9-16). The best model was automatically selected on basis 
of model convergence and OFV. Finally, the selected PK/PD models were evaluated for an 
effect of experiment day using step-wise covariate model building [24] (suppl. Equations 
Part I, 17-19).
2.3.4 Estimation of signal transduction efficiency
The quantitative relation between receptor binding and pharmacological effect depends 
on the signal transduction efficiency [25,26], which is made explicit in the operational 
model of agonism [27]. Therefore, the selected PK/PD models were simulated and fitted 




In which Em is the systems maximum, τ is the transduction efficiency, and kA is the affinity 
for the D2 receptor. It was assumed that the target site of action is in the brainECF. Further-
more, the assumption was made that quinpirole is selective for the dopamine D2 receptor, 
and the GH, PRL and TSH responses were modulated via the TIDA neurons (Figure 2). 
Therefore, the affinity of quinpirole to the D2 receptor was estimated equal among all 
hormones, while the signal transduction efficiency of GH, PRL and TSH was assumed de-
pendent on pituitary D2 receptor expression obtained from literature [28]. The D2 receptor 
expression for somatotrophs, lactotrophs and thyrotrophs was calculated as the number 
of ‘troph’ cells expression the D2 receptor relative to the total number of ‘troph’ cells. This 
relation to the signal transduction efficiency was made explicit following equation 2:
τ = τ0 * eslp * receptor expression (2)
Where τ is estimated for GH, PRL and TSH on basis of the pituitary D2 receptor expression.
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3. Results
3.1. Pharmacokinetics of quinpirole in plasma and brainECF
A two-compartment model best described the pharmacokinetics of quinpirole in plasma 
and brainECF with linear first-order elimination from plasma and a net active influx from 
plasma to brainECF (Suppl. Equation 3). The parameter estimates were precise and accurate 
(Table I), and the model could well describe the quinpirole concentrations in plasma and 
brainECF over a large dose range (Figure 1A). Although there is a slight over-prediction of 
quinpirole concentrations in brainECF, external validation showed good extrapolative ability 
of the model (Figure 1B).
Figure 1. Visual predictive check (A) and external validation (B) for the quinpirole pharmacokinetic model 
in plasma and brainECF. The colored dots represent the observed data, with the solid colored lines show-
ing the mean of the observations. The solid grey line shows the mean, and the dashed grey lines the 90% 
confidence interval of 500 simulations. *The experiments in which the animals received 0.43 mg/kg and 
2.14 mg/kg represented experimental protocol deviations (higher dose), and were included in PK model 
development only.
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Table I. Parameter estimates of the quinpirole pharmacokinetic model
Parameter
Model evaluation Bootstrap (nbtstr = 168)
Estimate (RSE)[shr] Estimate (CV)
CLPL,o (L h-1) 0.71 (9%) 0.70 (9%)
IIV CLPL,o 0.12 (32%) [7%] 0.12 (35%)
CLPL,ECF (L h-1) 2.5 (20%) 2.5 (19%)
CLECF,PLASMA (L h-1) 0.52 (24%) 0.55 (24%)
kp,uu (CLPL,ECF/CLECF,PL) 5
VCENTRAL (L) 1.0 (6%) 1.0 (7%)
VECF (L) 0.12 (13%) 0.013 (17%)
RUV CQP,PL 0.08 (24%) [3%] 0.08 (24%)
RUV CQP,ECF 0.12 (28%) [2%] 0.12 (30%)
C: concentration; CL: clearance; CV: coefficient of variation; ECF: brain extracellular fluid; h: hour; IIV: inter-
individual variability; kp,uu: ratio of unbound brainECF and plasma drug concentration; L: liter; nbtstr: number 
of successful bootstrap model runs out of a total of 200 runs; PL: plasma; RSE: relative standard error; RUV: 
residual unexplained variability; shr: shrinkage; V: volume of distribution
3.2.1. Responding pituitary hormones and neuropeptides in plasma
On basis of automated model selection, the hormones luteinizing hormone, PRL and TSH 
showed a placebo response described by circadian rhythm with a period of 120 minutes, 
the Bateman equation, or exponential decay, respectively (Suppl. Figure 1A). A model 
with no baseline pattern best described the other hormone baselines. ACTH, GH, PRL and 
TSH responded to quinpirole treatment with diverse PK/PD relations, while no effect was 
observed on the neuropeptides, BDNF, FSH and LH, following automated model selection 
(Suppl. Figure 1B, Table II). Except for kdeg,ACTH (relative standard error (RSE) = 282%) and 
EC50,Prl (RSE = 99%), the parameters were identified with reasonable precision (Table III) 
and the models could describe the data well (suppl Equations Part II, suppl. Figure 2).
Table II. The PK/PD effects of quinpirole on ACTH, GH, PRL and TSH, including the PK/PD model type and 
target site of drug action that was identified
Hormone Effect PK/PD model Target site
ACTH + Slope model &
Pool model with stimulation of kREL
Plasma
GH - EMAX model &
Turnover model with inhibition of kREL
BrainECF
PRL - EMAX model &
Turnover model with inhibition of kREL
BrainECF
TSH - EMAX model &
Turnover model with inhibition of kREL
BrainECF
ACTH: adenocorticotropic hormone; ECF: extracellular fluid; Effect: + increased release, - reduced release; 
GH: growth hormone; kREL: hormone release rate; PRL: prolactin; TSH: thyroid stimulating hormone
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3.2.2. Target site of effect
No statistically significant difference was identified comparing the best models for ACTH, 
GH, PRL and TSH with either plasma or brainECF as target site (Table III).
Table III. Parameter estimates of the PK/PD models for quinpirole effect on ACTH, GH, PRL and TSH with 
plasma and brainECF as target site. In bold the parameters of the selected models.
Plasma BrainECF
ACTH Estimate (RSE) Estimate (RSE)
OFV -31.3 -32.9
Baseline (pg/ml) 3.74 (17%) 3.71 (17%)
IIVBaseline 0.68 (71%) [0%] 0.68 (72%) [0%]
Slope ([ng/ml]-1) 0.873 (43%) -
EMAX - 2.35 (11%)
EC50 (ng/ml) - 54.1 (40%)
KDEG (min-1) 0.0146 (24%) 308 (282%)
KREL (min-1) 0.00760 (29%) 0.00421 (31%)
RUV 0.27 (21%) [3%] 0.27 (21%) [3%]
GH
OFV 667.6 664.1
Baseline (pg/ml) 1002 (n.a.) 992 (25%)
EMAX -1 (n.a.) -1 (39%)
S0 ([ng/ml]-1) 0.0545 (n.a.) 0.00985 (53%)
EC50 (ng/ml) 18.4 (calc.) 101 (calc.)
KDEG (min-1) 0.0228 (n.a.) 0.0282 (22%)
RUV 2.48 (13%) 2.45 (13%)
PRL
OFV 377.0 373.5
Baseline (pg/ml) 284 (25%) 262 (25%)
IIVBaseline 0.70 (28%) [4%] 0.67 (28%) [4%]
DPlac (pg/ml) 8.72 (fix) 8.72 (fix)
KIN, Plac (min-1) 1.65 (fix) 1.65 (fix)
KDEC, Plac (min-1) 1.55 (fix) 1.55 (fix)
EMAX -0.961 (21%) -0.959 (13%)
EC50 (ng/ml) 0.0983 (275%) 0.933 (99%)
KDEG (min-1) 0.584 (22%) 0.0652 (22%)
RUV 0.79 (18%) [3%] 0.79 (18%) [3%]
TSH
OFV -272.2 -270.0
Baseline (pg/ml) 305 (5.3%) 293 (4.7%)
IIVBaseline 0.047 (30%) [8%] 0.045 (30%) [9%]
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Table III. Parameter estimates of the PK/PD models for quinpirole effect on ACTH, GH, PRL and TSH with 
plasma and brainECF as target site. In bold the parameters of the selected models. (continued)
Plasma BrainECF
ACTH Estimate (RSE) Estimate (RSE)
KDEC, Plac (min-1) 0.00489 (fix) 0.00489 (fix)
EMAX -0.819 (36%) -0.794 (32%)
EC50 (ng/ml) 31.2 (30%) 178 (34%)
KDEG (min-1) 0.0781 (13%) 0.126 (20%)
RUV 0.17 (19%) [2%] 0.18 (19%) [2%]
ACTH: adenocorticotropic hormone; DPlac: the extent of the placebo effect; ECF: extracellular fluid; EC50: 
concentration at half maximal drug effect; EMAX: maximal drug effect; GH: growth hormone; kDEC: dose-
independent hormone decay; kDEG: hormone elimination rate; kREL: hormone release reate; OFV: objective 
function value; PRL: prolactin; RSE: relative standard error; RUV: residual unexplained variability; S0: EMAX/
EC50; TSH: thyroid stimulating hormone
3.2.3. Mechanistic evaluation of quinpirole effect on ACTH, GH, PRL, and TSH
The concentration-effect relations between quinpirole and every single hormone are de-
picted in Figure 3, assuming brainECF as target site (table III). Prolactin was most sensitive 
to quinpirole with a potency of 0.93 ng/ml, while ACTH, GH and TSH responded with a 
potency of 54 ng/ml, 101 ng/ml and 178 ng/ml, respectively (Table III). The operational 
model could fit the simulated concentration-effect relationships well (Figure 3, Table IV). 
Within this model, the signal transduction efficiency values (τ) of GH, PRL and TSH could 
be related to the pituitary receptor expression on the somatotrophs, lactotrophs and the 
thyrotrophs, respectively. In contrast, the ACTH concentration-response relationship could 
not be fitted under the assumption of signal transduction efficiency being dependent on 
pituitary D2 receptor expression (suppl. Figure 3).
3.2.4. One-day versus eight-day treatment responses
The pharmacokinetics of quinpirole were not significantly influenced by eight-day drug 
treatment. In contrast, the pharmacodynamics showed a significant change for ACTH, PRL 
and TSH (suppl. Table I). The differences between the responses after short- and long-term 
treatment are graphically presented in Figure 4. The basal levels of ACTH were increased 
independent of dose, while the hormone release rate was increased in a dose-dependent 
manner. This resulted in a lower maximal ACTH response after 8-day treatment with a high 
dose as compared to a low dose of quinpirole. The basal PRL concentrations after eight 
days were increased with dose, while the extent of the placebo effect was decreased, 
independent of dose. The basal levels of TSH have decreased with eight-day treatment 
regardless the dose, while the sensitivity to quinpirole (EC50) was decreased in a dose-
dependent manner.
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Figure 2. The interacti on between quinpirole and the neuroendocrine system with the pharmacokineti cs as 
white compartments and the pharmacodynamics as grey compartments. Quinpirole sti mulates TIDA neu-
rons in the hypothalamus to increase the release of dopamine into the pituitary. Dopamine inhibits the 
release of GH, PRL and TSH into plasma. ACTH was sti mulated by quinpirole, suggesti ng a pathway other 
than TIDA neuron sti mulati on. The main eff ect site is assumed to be the brain, given the high quinpirole in 
brainECF as compared to plasma. QP: quinpirole; DA: dopamine; CRH: corti cotropic releasing hormone; ACTH: 
adenocorti cotropic hormone; GH: growth hormone; PRL: prolacti n; TSH: thyroid sti mulati ng hormone.
Figure 3. A) Simulated concentrati on-eff ect relati ons for ACTH (black), TSH (green), GH (red) and PRL (blue) 
on basis of the parameter esti mates in table III. The dark segments represent the quinpirole concentrati on 
range measured in brainECF. The dott ed lines represent the fi t with the operati onal model, in which the signal 
transducti on effi  ciency τ for GH, PRL and TSH is dependent on D2 receptor expression following equati on 2.
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Table IV. Relative D2 receptor expression on the troph cells in the rat anterior pituitary, the signal transduc-
tion efficiency τ, and the systems maximal effect Em estimated from the operational model in equation 1. 





Corticotrophs (ACTH) 20% 13.8 2.51
Somatotrophs (GH) 34% 8.7 -1.11
Lactotrophs (PRL) 76% 743 -0.96
Thyrotrophs (TSH) 13% 0.94 -1.76
ACTH: adenocorticotropic hormone; GH: growth hormone; PRL: prolactin; TSH: thyroid stimulating hor-
mone
Figure 4. Simulated hormone actual (A) and baseline normalized (B) concentration-time profiles of ACTH, 
PRL and TSH after one administration (solid black line) and 8 administrations (dashed grey line).
4. Discussion and conclusion
This study systematically evaluated the effects of quinpirole on the neuroendocrine 
system following a PK/PD based multi-biomarker approach. Quinpirole showed a high 
rate of transport over the blood-brain-barrier with an unbound partition coefficient 
(kp,uu) of 5. ACTH, GH, PRL, and TSH responded to quinpirole, each with a unique target 
site concentration-effect relationship, providing a fingerprint of D2 receptor activation. 
Additionally, while no changes were found in PK, the pharmacodynamics changed with 
eight-day administration both dependent and independent of the quinpirole dose. This 
study underlines the need for integrative multi-biomarker evaluations of drug effects to 
comprehend the system-wide pharmacological profile. 
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4.1. Can the target site of effect be determined?
Since the ultimate purpose is to identify peripheral biomarkers of the central drug ef-
fect, an important question is whether we can consider brainECF concentrations as the 
target site concentrations of the effect of quinpirole. We have shown that, on basis of 
statistical significance, it was not possible to discriminate between brainECF or plasma as 
target site of effect. Given that the D2 receptors on the ‘troph’ cells are accessible from 
plasma, and the release of these hormones have been modified by systemic dopamine 
infusion [29,30], it is suggested that these hormones are released upon peripheral drug 
action. On the other hand, the release of these hormones is tightly controlled by signals 
from the hypothalamus that are highly connected to dopamine and other neurotransmit-
ter systems. Considering this, the rate and extent of drug distribution into the brain may 
determine the dominant target site of effect. For the D2 antagonist remoxipride (kp,uu = 
1) [11]) , brainECF could be considered as target site to release PRL into plasma, while for 
the D2 antagonist risperidone (kp,uu = 0.45 [31]), plasma could be considered as target site 
[10,11,32]. Quinpirole is found to be subjected to active influx: although no information 
on the transporter is available in literature, it is observed that, under steady state condi-
tions, the free drug concentration in brainECF is as much as five times higher than in plasma 
(kp,uu = 5, Table I). Therefore, although we could not provide a statistical determination, it 
is presumed that the main effect of quinpirole on the neuroendocrine system is mediated 
via the brain rather than via the periphery. 
4.2. Interpretation of the unique concentration-effect relationships
Dopamine activity in the brain is reflected in the tuberoinfundibular dopamine pathway 
that consists of three types of neurons that project from the hypothalamus to the pitu-
itary: 1) the TIDA neurons; 2) the periventricular hypophyseal dopamine neurons, and 3) 
the tuberohypophyseal dopamine neurons [5]. TIDA neurons release dopamine into the 
long portal veins of the pituitary to which the ‘troph’ cells are exposed. While quinpirole 
has affinity for both the D2 and the D3 receptor [33], the effects on the neuroendocrine 
system are putatively mediated via the D2 receptor because of the following findings. First, 
, the enhancing effect of quinpirole on ACTH release was reversed with administration 
of the D2 receptor antagonist sulpiride [34,35]. Second, the effect of quinelorane, which 
is similarly specific for the D2/3 receptor, on the neuroendocrine TIDA neurons was an-
tagonized by the selective D2 receptor antagonist raclopride [6]. Third, while the selective 
D2 agonist PNU-95,666 activated the TIDA neurons and inhibited PRL release, this was 
not the case for the selective D3 agonist PD128907 [7]. In contrast, studies with selective 
D2 and D3 agonists in ovariectomized estrogen-primed female rats showed a decrease of 
TIDA neuron activity and an increase of subsequent PRL release [36,37]. However, the 
estrogen-priming in these studies prevents a direct comparison between these results and 
our results, since estrogen interferes with TIDA neuron activity as well as the sensitivity of 
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the pituitary to dopamine [38,39]. Indeed, our study design is more similar to that of the 
studies observing activation of TIDA neuron activity and suppression of PRL release, i.e. 
they studied male rats, or diestrous female rats with low estrogen levels [6,7]. Therefore, 
we assume that the stimulation of TIDA neuron activity by of quinpirole in our study is D2 
specific. Dopamine D2 receptors were identified not only on lactotrophs (PRL), but also 
on corticotrophs (ACTH), somatotrophs (GH), gonadotrophs (FSH, LH), and thyrotrophs 
(TSH) [17,28]. Also, dopamine agonists inhibited the release of ACTH, GH, PRL and TSH in 
vitro, likely mediated via the D2 receptors [40–42]. Overall, it is thus expected that ACTH, 
GH, PRL, and TSH concentrations decrease with quinpirole treatment upon the stimula-
tion of TIDA neuron activity that enhances dopamine release into the pituitary to bind to 
the pituitary dopamine receptors on the ‘troph’ cells. Interestingly, the secretion of ACTH 
was increased, indicating a different mechanism of action not via the TIDA neurons. The 
hypothalamic mediator of ACTH release is corticotrophin-releasing hormone (CRH). CRH 
is under control of several neurotransmitters, for example, norepinephrine and gamma-
aminobutyric acid. Since the effect of quinpirole on ACTH was found to be D2 receptor 
specific [34], it is likely that CRH or the controlling neurotransmitters are influenced in a 
D2 specific manner (Figure 2).
According to these mechanisms the assumptions of D2 receptor selectivity for all hormones 
and the pituitary D2 receptor expression dependent signal transduction for GH, PRL and 
TSH were made (Figure 2, Table IV). Conceptually, the differences in signal transduction 
efficiency may also be explained by differences in fractional receptor occupancy needed to 
elicit a certain level of pituitary hormone release, i.e. the release of some hormones may 
be more sensitive dopamine receptor activation than that of other hormones. However, 
our assumptions are confirmed by a good fit of the operational model on the simulated 
concentration effect relationships as depicted in Figure 3. Physiologically, this suggests a 
receptor expression dependent sensitivity of the hormones to the increase of pituitary 
dopamine following the central quinpirole effect. In fact, it indicates that τ indeed is a 
system-specific parameter. The opposed direction of the ACTH response, and the deviation 
of τACTH from the relation between receptor expression and τ indicates a different mecha-
nism of action of D2 receptor activation on ACTH release (Figure 3, Table IV, suppl. Figure 
3). Altogether, the systems response expressed in terms of signal transduction efficiency 
provides a fingerprint that is specific for D2 receptor stimulation in the brain.
4.3. Habituation, tolerance and homeostatic feedback mechanisms
There are three mechanisms through which the differences between day 1 and day 8 are 
explained (Figure 4). First of all, the dose-independent changes are likely the consequence 
of habituation; the animals’ response to the daily injection procedure returns to basal 
levels with longer-term administration. Indeed, the ACTH and TSH basal levels and the 
118 CHAPTER 5
PRL placebo response changed over the period of quinpirole administration (Figure 4). 
Second of all, pharmacodynamic tolerance may occur as a consequence of long-term drug 
administration [43]. Tolerance is the mechanism of physiological adaptation to continu-
ous external stimuli, for example, the change in receptor expression. Pharmacodynamic 
tolerance was identified for the TSH response, as indicated by the dose-dependent change 
of EC50 (Figure 4, suppl. Table I). Assuming a D2 dependent mechanism, this cannot be 
explained by reduced hypothalamic D2 receptor expression, since this was not observed 
for the other hormones. Moreover, D2 receptor expression was found not to change with 
long-term D2 agonist exposure [44]. Possibly, the balance between other mediators of TSH 
release and dopamine has changed, thereby influencing the transduction efficiency. Third 
of all, the differences between the experiment days can be explained by homeostatic feed-
back mechanisms. The release rates of ACTH and PRL were increased in a dose-dependent 
manner, suggesting a positive and negative feedback, respectively (Figure 4, Suppl. Table 
I). These hormones are components of highly complex networks that include multiple 
negative and positive feedback mechanisms that are affected by eight-day administra-
tion of quinpirole. The net effect is reflected in the current analysis, showing that these 
networks have changed to another equilibrium.
4.5. Strengths, limitations and future research
Our integrated PK/PD approach included multiple hormones and neuropeptides that pro-
vide comprehensive insight into the interaction between quinpirole and the neuroendo-
crine system to reveal a fingerprint reflecting D2 receptor activation. Nevertheless, it has a 
few limitations that will be discussed in this section. First of all, the 3-hour duration of the 
experiments limited the evaluation of the full pharmacodynamic response. While ACTH 
levels were back to baseline at the end of the experiment, GH, PRL and TSH levels were still 
decreased. This may have limited the precise identification of the PK/PD model, although, 
in general, the parameter estimates showed good precision. Second, a wider dose range 
may have enabled better identification of the EC50 parameter in case of, for example, ACTH 
that was best described by a slope model. However, since a relatively untargeted approach 
was applied, it was not possible to anticipate the dose range beforehand. Moreover, the 
current choice of doses was based on an experimental regimen, reflecting the therapeutic 
range [45,46], in order to gain pharmacologically relevant insights. Third, the choice of 
hormones and neuropeptides, although guided by pharmacological knowledge, was based 
on the available platforms rather than based on the physiology. While this provides a non-
biased evaluation of neuroendocrine effects of quinpirole, there is a series of hormones 
that will be of interest for further research, for example, the downstream signals of the 
pituitary hormones, such as will be discussed below.
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Suggestions for further investigation include the validation of the D2 receptor activation 
fingerprint with other selective D2 agonists, for example, quinelorane and ropinirole [33]. 
Furthermore, we suggest efforts towards unraveling the mechanisms underlying the 
quinpirole-hormone relationships that were identified in the current study. Such investiga-
tion should include: i) the measurement of quinpirole and dopamine in the hypothalamus 
using microdialysis [47]; ii) the measurement of quinpirole and CRH, GHRH, dopamine, 
and TRH in the pituitary using microdialysis [48]; iii) the measurement of ACTH, GH, PRL, 
and TSH in plasma; iv) the measurement of corticosterone, IGF-1, triiodithyronine, thy-
roxine as downstream signals of ACTH, GH and TSH, respectively; v) a study duration of at 
least 6 hours of experiment. This takes into account the duration of quinpirole exposure 
(~4 hours) as well as the delay of the hormone responses.
Such data will form the basis of a quantitative systems pharmacology model describing 
the interaction between quinpirole and the neuroendocrine system in terms of purely 
drug- and system-specific parameters. This will also allow the separation of central and 
peripheral quinpirole effect since the drug concentration will be evaluated in both the 
hypothalamus and the pituitary. Moreover, the upstream hormones that are released 
from the hypothalamus will exclusively reflect the hypothalamic interaction with the drug. 
Eventually, such model can be evaluated with different lengths of chronic administration 
periods to mechanistically understand the tolerance and homeostatic feedback mecha-
nisms.
4.6. Conclusion
The current study has made the case for an integrated and system-wide approach to un-
derstand the interaction between dopaminergic pharmacology and the neuroendocrine 
system. It was shown that, under standard experimental conditions, quinpirole interferes 
with the hypothalamus-pituitary-adrenal axis (ACTH), the growth hormone system (GH), 
parts of the reproductive system (PRL), and the thyroid function (TSH). With this multi-
biomarker approach, a fingerprint of transduction efficiency values was obtained that is 
specific for D2 receptor activation. In contrast to PRL alone, as classical biomarker, this 
multi-biomarker fingerprint provides a specific reflection of D2 receptor activation. Our 
study also indicated a clear change of the PK/PD relationship with comparing short-term 
and longer-term administration. This is highly relevant, considering the long-term use of 
D2 receptor agonists in clinical practice. Further understanding of the underlying tolerance 
and homeostatic feedback mechanisms will increase the proper application of these drugs 
in clinical practice. 
In conclusion, this study provided further insights into the interaction between dopami-
nergic pharmacology and the neuroendocrine system. Using a multi-biomarker approach, 
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a fingerprint of D2 receptor activation was obtained. This forms the conceptual basis for 
the in vivo evaluation of the on- and off-target effects of drug effects in the CNS. Further 
efforts towards quantitative systems pharmacology model development will eventually 
lead to mechanistic translational dopaminergic drug development.
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Supplementary Table I. Parameter estimates for ACTH, PRL and TSH with and without covariate effect
Without covariate effect With covariate effect
ACTH
OFV -31.3 -117.3
BaselineDAY1 (pg/ml) 3.74 (17%) 2.80 (19%)
BaselineDAY8 (pg/ml) 3.74 (17%) 2.80 (19%) * 1.85 (37%)
IIVBaseline 0.68 (71%) [0%] 0.71 (67%) [0%]
Slope ([ng/ml]-1) 0.87 (43%) 0.79 (45%)
KDEG (min-1) 0.0146 (24%) 0.0150 (22%)
KREL,DAY1 (min-1) 0.00760 (29%) 0.0055 (30%)
KREL,DAY8 (min-1) 0.00760 (29%) 0.0055 (30%) * (1 + 2.1 (41%) * dose)a
RUV 0.27 (21%) [3%] 0.22 (16%) [3%]
PRL
OFV 373.5 290.9
BaselineDAY1 (pg/ml) 262 (25%) 296 (38%)
BaselineDAY8 (pg/ml) 262 (25%) 296 (38%) * (1 + 0.34 * dose)a
IIVBaseline 0.67 (28%) [4%] 0.69 (28%) [2%]
ExtentPlac,DAY1 (pg/ml) 8.72 (fix) 8.72 (fix)
ExtentPlac,DAY8 (pg/ml) 8.72 (fix) 8.72 (fix) * 0.34 (11%)
KIN, Plac (min-1) 1.65 (fix) 1.65 (fix)
KDEC, Plac (min-1) 1.55 (fix) 1.55 (fix)
EMAX -0.959 (13%) -0.963 (11%)
EC50 (ng/ml) 0.933 (99%) 0.556 (174%)
KDEG (min-1) 0.0652 (22%) 0.068 (5.9%)
RUV 0.79 (18%) [3%] 0.63 (18%) [3%]
TSH
OFV -270.0 -362.1
BaselineDAY1 (pg/ml) 293 (4.7%) 384 (7.0%)
BaselineDAY8 (pg/ml) 293 (4.7%) 384 (7.0%) * 0.61 (21%)
IIVBaseline 0.045 (30%) [9%] 0.071 (27%) [4%]
KDEC, Plac (min-1) 0.00489 (fix) 0.00489 (fix)
EMAX -0.794 (32%) -0.948 (149%)
EC50,DAY1 (ng/ml) 178 (34%) 27.1 (26%)
EC50,DAY8 (ng/ml) 178 (34%) 27.1 (26%) * (1 + 2.84 (48%) * dose)a
KDEG (min-1) 0.126 (20%) 0.070 (13.2%)
RUV 0.18 (19%) [2%] 0.14 (17%) [3%]
a dose in mg/kg
ACTH: adenocorticotropic hormone; ECF: extracellular fluid; EC50: concentration at half maximal drug effect; 
EMAX: maximal drug effect; GH: growth hormone; kDEC: dose-independent hormone decay; kDEG: hormone 
elimination rate; kREL: hormone release reate; OFV: objective function value; PRL: prolactin; RSE: relative 
standard error; RUV: residual unexplained variability; S0: EMAX/EC50; TSH: thyroid stimulating hormone
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Supplementary Figure 1. Visualizati on of the automated model selecti ons for the baseline model (A) and 
the PK/PD model (B) on basis of adjusted objecti ve functi on value (suppl. Equati ons part I, 8). Grey dots 
represent the adjusted objecti ve functi on value for each evaluated model, while blue dots represent the 
selected models.
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Supplementary Figure 2. Visual predictive check of the quinpirole PK/PD models for ACTH, GH, PRL and 
TSH at experiment day 1 and 8. The colored dots represent the observed data, with the solid colored lines 
showing the mean of the observations. The solid grey line shows the mean, and the dashed grey lines the 
90% confidence interval of 500 simulations.
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Supplementary Figure 3. A) Simulated concentrati on-eff ect relati ons for ACTH (black), TSH (green), GH (red) 
and PRL (blue) on basis of the parameter esti mates in table III as compared to the fi ts by the operati onal 
model (equati on 1). Each fi gure represents a diff erent scenario with regard to the hormones included in 
the relati on between tau and D2 receptor expression (equati on 2). The signal transducti on effi  ciency τ is 
assumed dependent on pituitary D2 receptor expression for the hormones indicated above each fi gure. For 
the hormone not included, the signal transducti on effi  ciency τ is esti mated separately.
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Supplementary Equations
Inter-individual and residual variability
θi = θpop * eηi (Eq. 1)
Log(Cobs , i , j) = Log(Cpred , i , j) + εi , j (Eq. 2)
θi is the estimated parameter for individual i; θpop is the estimated parameter for the 
population; ηi follows a normal distribution with mean 0 and variance ω2; Cobs,i,j is the 
observed concentration data point for individual i at timepoint j; Cpred,i,j is the predicted 
concentration for data point for individual i at timepoint j; εi,j follows a normal distribution 





CLECF , PL * AQP , ECF  (Eq. 3a)dt VPL VPL VECF
dAQP , ECF =
CLPL , ECF * AQP , PL - 
CLECF , PL * AQP , ECF  (Eq. 3b)dt VPL VECF
With     AQP , PL , 0 = Dose ,      AQP , ECF , 0 = 0
Where     CQP , PL =
AQP , PL ,      CQP , ECF =
AQP , ECF
VPL VECF
AQP,PL is the amount of quinpirole in plasma; AQP,ECF is the amount of quinpirole in brainECF; 
CLPL,o is the elimination clearance of quinpirole from plasma; VPL is the volume of distribu-
tion of quinpirole in plasma; CLPL,ECF is the clearance of quinpirole from plasma to brainECF; 
CLECF,PL is the clearance of quinpirole from brainECF to plasma; VECF is the volume of distribu-
tion of quinpirole in brainECF; CQP,PL is the concentration of quinpirole in plasma; CQP,ECF is the 











D * ke *( e- kINtime - e- kDECtime )  (Eq. 6)
kDEC - kIN
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Placebo exponential decay function
CHORM , BSL = BSLHORM * e- kDECtime (Eq. 7)
CHORM,BSL is the hormone concentration given no drug effect; BSLHORM is the hormone con-
centration at baseline at time = 0; A is the amplitude; p is the period; φ is the phase shift; D 
determines the extent of the placebo response; ka the rate at which the placebo response 
occurs; ke the rate at which the placebo response disappears.
Objective function value
adjOFV = OFVtest - OFVref + inv.χ2 ( 1 - p.value , df ) (Eq. 8)
adjOFV is the adjusted objective function value to compare two models. An adjOFV below 
0 indicates a significant improvement of the test model over the reference model. The inv.
χ2 is a statistical test to compare two models. For example, a significant improvement with 
a p-value of 0.05 and 1 degree of freedom is equivalent to a decrease of 3.84 points in OFV 


















0 ,    & CQP = 0  (Eq. 12)EMAX ,    & CQP > 0
E is the magnitude of drug effect; Slope is the parameter that determines the strength of 
the drug effect; CQP is the drug concentration at the target site, either plasma or brainECF; 








Turnover model (effect on hormone release)
dCHORM , PL = kDEG * CHORM , BSL * E - kDEG * CHORM , PL  (Eq. 15)dt
Pool model (effect on hormone release)
dCHORM , Pool = kDEG * CHORM , BSL - kREL * E * CHORM , Pool  (Eq. 16a)dt
dCHORM , PL = kREL * E * CHORM , Pool - kDEG * CHORM , PL  (Eq. 16b)dt
CHORM,PL is the hormone concentration in plasma; kDEG is the hormone turnover rate; kDEG * 
CHORM,BSL is equivalent to kIN, the hormone production rate within the pool compartment; 
CHORM,POOL is the hormone concentration in the pool; kREL is the hormone release rate from 
the pool into plasma.
Covariate models
θDAY =  θpop *( 1 + COV ) (Eq. 17)
θDAY =  θpop *( 1 + COVSLP * Dose ) (Eq. 18)
θDAY =  θpop *( 1 + 
COVMAX * Dose ) (Eq. 19)
COV50 + Dose
θDAY is the estimated parameter for the specific day; θpop the population parameter; 
COV the dose independent covariate parameter; COVSLP the dose dependent covariate 
parameter following a linear relation; COVMAX and COV50 the dose dependent covariate 
parameters following a non-linear relation. The covariate effect is set to zero for day 1.
Supplementary Methods
Additional PK experiment as external validation of the quinpirole PK model
The experimental procedures applied in this additional experiment have been previously 
described (Wong et al. Eur J Pharm Sci. 2018:111;514-525), which involved similar proce-
dures as those in the current manuscript with some modifications. In brief, 15 male Wistar 
rats were used, and 7 of which received microdialysis surgery in addition to the femoral 
artery and vein cannulations. Two microdialysis guides (CMA 12 Guide Cannula, Aurora 
Borealis Control BV, Schoonebeek, the Netherlands) were embedded in the brain striatum 
(AP − 1.0; L 3.2; V − 3.5 mm relative to bregma) and cerebellum (AP − 2.51; L 2.04; V 
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− 3.34 mm, at an angle of 25° from the dorsoventral axis (toward anterior) and 11° lateral 
from the anteroposterior axis relative to lambda). The rats were given 7 days to recover 
from surgery. One day before the experiment, the microdialysis guides were substituted 
by the microdialysis probes (CMA 12 Elite Polyarylethersulfone, 4 mm membrane, cut-off 
20 kDA, Aurora Borealis Control BV, Schoonebeek, the Netherlands).
On the day of experiment, rats received an IV infusion of quinpirole 1 mg/kg at the start 
of experiment (t = 0 min). The duration of the infusion was either 10 min (for 12 rats) or 
0.5 min (for 3 rats). Plasma and brain microdialysate were collected and analyzed in the 
same manner as in the current manuscript. The plasma and striatum ECF data were used 




PHARMACODYNAMIC (PKPD) ANALYSIS WITH 
METABOLOMICS SHOWS MULTIPLE EFFECTS OF 
REMOXIPRIDE IN RATS
WJ van den Brink, J Elassaiss-Schaap, B Gonzalez-Amoros, AC Harms, 
PH van der Graaf, T. Hankemeier, ECM de Lange




The study of central nervous system (CNS) pharmacology is limited by a lack of drug effect 
biomarkers. Pharmacometabolomics is a promising new tool to identify multiple molecular 
responses upon drug treatment. However, the pharmacodynamics are typically not evalu-
ated in metabolomics studies, although being important properties of biomarkers.
In this study we integrated pharmacometabolomics with pharmacokinetic/pharmaco-
dynamic (PKPD) modeling to identify and quantify the multiple endogenous metabolite 
dose-response relations for the dopamine D2 antagonist remoxipride.
Remoxipride (vehicle, 0.7 or 3.5 mg/kg) was administered to rats. Endogenous metabo-
lites were analyzed in plasma using a biogenic amine platform and PKPD models were 
derived for each single metabolite. These models were clustered on basis of proximity 
between their PKPD parameter estimates, and PKPD models were subsequently fitted 
for the individual clusters. Finally, the metabolites were evaluated for being significantly 
affected by remoxipride. 
In total 44 metabolites were detected in plasma, many of them showing a dose dependent 
decrease from baseline. We identified 6 different clusters with different time and dose de-
pendent responses and 18 metabolites were revealed as potential biomarker. The glycine, 
serine and threonine pathway was associated with remoxipride pharmacology, as well as 
the brain uptake of the dopamine and serotonin precursors.
This is the first time that pharmacometabolomics and PKPD modeling were integrated. 
The resulting PKPD cluster model described diverse pharmacometabolomics responses 
and provided a further understanding of remoxipride pharmacodynamics. Future research 
should focus on the simultaneous pharmacometabolomics analysis in brain and plasma to 
increase the interpretability of these responses.
Keywords: Systems pharmacology; PK/PD modeling; pharmacometabolomics; biomark-
ers; CNS drugs; D2R antagonists
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Introduction
Central nervous system (CNS) drug development is difficult and attrition rates are high [1]. 
While important progress has been made in the insight into human brain pharmacokinet-
ics (PK) in response to plasma PK, insights into the relation to the time dependent CNS 
drug effects are limited [2–4]. It is therefore essential to utilize biomarkers that provide 
proof of pharmacology and dosing guidance for early clinical drug development [2,4–9]. 
Preferably, these biomarkers are measured in the blood, since blood can be easily ob-
tained from humans.
Biomarker discovery is increasingly driven by (pharmaco)metabolomics [10–15]. It mea-
sures the end-products of cellular biochemical reactions under a drug-perturbed, disease 
or control condition, and is as such a phenotypic measure, sometimes referred to as the 
“metabotype” [16]. As an example, a pharmacometabolomics approach has been success-
fully applied in CNS drug research for identification of serum biomarkers of antipsychotic 
drug efficacy [17] or toxicity [18].
An important limitation so far has been that pharmacometabolomic studies are often per-
formed at single time points while many biological processes change with time. A single 
time point evaluation thus limits the ability to accurately quantify the extent and duration 
of drug effects. Whereas for single time point studies multivariate data analysis mostly is 
performed using principal component analysis (PCA) and partial least squares discriminant 
analysis (PLS-DA) [19], more advanced methods are needed, and have been developed, 
to evaluate time-dependent effects in metabolomics data. For example, an extension of 
PCA was developed called ANOVA Simultaneous Component Analysis (ASCA), allowing for 
multivariate evaluation in multiple dimensions (e.g. dose, time and response) [20]. Still, a 
remaining limitation with this method is that the variables are treated as categorical data, 
while factors as dose and time typically are continuous variables. Furthermore, longitu-
dinal clustering approaches are promising for the evaluation of multivariate longitudinal 
data, although its application until now has been mainly on gene expression data [21–24].
Not only the time course of the effect biomarker is important for the understanding of 
drug effects, but also the causal relation between drug dose and biomarker response 
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(Danhof et al. 2005). This relation is governed by processes of drug distribution to the 
target site [2,25], receptor binding [26] and activation [27], signal transduction [23,27] 
and homeostatic feedback [28]. These processes are typically non-linear, which increases 
the complexity from a data analysis perspective. Quantitative insights in drug effects are 
obtained by a combination of studies that measure biomarkers at different causal levels 
in a time-dependent manner and pharmacokinetic/pharmacodynamic (PKPD) modeling 
[2,5,29–31].
In this study we integrated pharmacometabolomics with PKPD modeling to identify and 
quantify multiple endogenous metabolite dose-response relations for the paradigm com-
pound remoxipride. Rats received remoxipride in different dose levels and we obtained 
serial plasma samples for analysis of multiple endogenous metabolites. PKPD models 
were subsequently developed to fit the longitudinal dose-response data of each single 
metabolite. Biomarker clusters were identified on basis of the PKPD parameters to derive 
a PKPD model that fitted the cluster responses. Potential biomarkers and putative pharma-
cological pathways of remoxipride effect were identified using this approach; we obtained 
comprehensive insight in its differential effects on the endogenous metabolism. 
Methods
Animal studies
Animal studies were performed in agreement with the Dutch Law of Animal Experimen-
tation and approved by the Animal Ethics Committee in Leiden, the Netherlands (study 
protocol DEC13186). Male Wistar rats (n= 28, 278 +/- 15 g, Charles River, The Netherlands) 
were housed in groups for 6-9 days until surgery (Animal Facilities Gorlaeus Laboratories, 
Leiden, The Netherlands). Animals were held under standard environmental conditions 
while artificial daylight was provided from 7:30AM to 7:30PM. They had ad libitum ac-
cess to food (Laboratory chow, Hope Farms, Woerden, The Netherlands) and acidified (to 
prevent infection) water.
Surgery and experiment
Surgery was done according to previously reported procedures [25]. In brief, animals 
received 2% isoflurane anesthesia while undergoing surgery. Cannulas were placed in the 
femoral artery for serial blood sampling and the femoral vein for drug administration. 
Microdialysis guides (CMA 12 Elite PAES, Schoonebeek, The Netherlands) were placed in 
caudate putamen (AP −1.0; L 3.0; V −3.4, relative to bregma) and replaced by microdialysis 
probes (CMA 12 Elite PAES, 4 mm polycarbonate membrane, cut-off 20 kDA, Schoonebeek, 
The Netherlands) before the experiment. For 7 days, animals were individually held in 
Makrolon type 3 cages to recover from surgery. The start of the experiments was between 
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8:00AM and 8:30AM and rats were randomly assigned receiving 0 mg/kg (n=5), 0.7 mg/kg 
(n=8), or 3.5 mg/kg (n=9) remoxipride by i.v. bolus (2 min infusion) at the start of experi-
ment (t=0 min). Microdialysis was performed using buffered perfusion fluid and a flow rate 
of 1μl/min. Blood samples of 200 μl were collected in heparin-coated eppendorf tubes at 
-15, 2, 10, 22, 30, 40, 60, 100, 180 and 240 min, after which animals received 200 ul saline 
to compensate for the lost blood volume. Plasma was separated by centrifuging (1000 g, 
10 min) and was stored at 4°C during the experiment and at -20°C after the experiment 
until analysis.
Metabolomics analysis
Metabolomics analysis in the plasma samples was performed using an amine platform, 
according to a previously described method [32]. The amine platform covers amino acids 
and biogenic amines employing an Accq-tag derivatization strategy adapted from the 
protocol supplied by Waters (Etten-Leur, The Netherlands). 5 µL plasma was spiked with 
an internal standard solution and reduced with TCEP (tris(2-carboxyethyl)phosphine) fol-
lowed by deproteination by addition of MeOH. After centrifuging (9400xg, 10 min, 10°C), 
the supernatant was transferred to a deactivated autosampler vial (Waters) and dried 
under N2. The residue was reconstituted in borate buffer (pH 8.5) with 6-aminoquinolyl-
N-hydroxysuccinimidyl carbamate (AQC) derivatisation reagent (Waters). Microdialysate 
samples underwent the same procedure, but without deproteination. After reaction, the 
vials were transferred to an autosampler tray and cooled to 10°C until the injection (1.0 µL) 
of the reaction mixture into the UPLC-MS/MS system. This consisted of an ACQUITY UPLC 
system with autosampler (Waters) coupled online with a Xevo Tandem Quadrupole mass 
spectrometer (Waters), and operated using Masslynx data acquisition software (version 
4.1; Waters). The samples were analyzed by UPLC-MS/MS using an Accq-Tag Ultra column 
(Waters). The Xevo TQ was used in the positive-ion electrospray mode and all metabolites 
were monitored in Selective Reaction Monitoring (SRM) using nominal mass resolution. 
Acquired data were evaluated using Quanlynx software (Waters), by integration of assigned 
SRM peaks and normalization using proper internal standards. For analysis of amino acids 
their 13C15N-labeled analogs were used. For other amines, the closest-eluting internal 
standard was employed. Blank samples were used to correct for background, and in-house 
developed algorithms were applied using the pooled QC samples to compensate for drift 
in the sensitivity of the mass spectrometer with and over different batches [33]. Quality 
assurance of metabolite measurements was performed only reporting compounds with a 
QC relative standard deviation (RSDQC) under 15%.
Data exploration, PKPD modeling and clustering
Outliers were detected for each metabolite using Tukeys’ Test (equation 1) [34], by com-
paring concentrations to the range:
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[Q1 - 3 * (Q3 - Q1) , Q3 + 3 * (Q3 - Q1)] , (Equation 1)
in which Q1 and Q3 are the lower and upper quartiles per metabolite, respectively.
1.3% of the data points were designated as outlier, and replaced by the median of the 
metabolite concentration of the dose group in which the data point existed. Most of the 
outliers came from one specific sample in the vehicle group (see figure S1). Sequential 
PKPD modeling approach was applied on the non-scaled metabolite concentrations, using 
NONMEM® version 7.3.0 with subroutine ADVAN13. Posthoc parameter estimates of a 
previously developed PK model were used as input for the PKPD model [35]. This model 
provided remoxipride concentrations both in plasma and brain extracellular fluid (brainECF).
A proportional error model was used in which the residual variability (RV, εijk) follows a 
normal distribution with zero mean and an estimated variance (equation 2).
Robs , ij = Rpred , ij * (1 + εijk)  (Equation 2)
Criteria for model evaluation were the drop in objective function value (OFV) calculated 
as -2loglikelihood ratio (> 3.84, p < 0.05, df = 1), the precision of the parameter estimates 
(relative standard error (RSE) < 30%) and the visual evaluation of the goodness-of-fit. 44 
models were developed linking the remoxipride brainECF concentrations to the metabolite 
responses. The drug effect was described by an EMAX equation (equation 3), which was 
coupled to the metabolite production rate (kIN) in a turnover model (equation 4) as follows:
Drug effect(DE) = 
EMAX * [CREM] , (Equation 3)
EC50 + [CREM]
∂R
= kIN * (1 - DE) - kOUT * R , (Equation 4)∂t
in which CREM is the remoxipride concentration in brainECF, EMAX is the maximal inhibition, 
EC50 is the concentration at half maximal effect, kIN is the metabolite production rate 
(which is derived from the metabolite baseline * kOUT), kOUT is the metabolite elimination 
rate, and R is the metabolite concentration in plasma.
We identified clusters in the scaled parameters EMAX, EC50 and kOUT using the k-means 
method, with scaling performed according to equation 5. K-means clustering aims to 
minimize the within-cluster sum of squares (WCSS), which may reach a local minimum, 
depending on the chosen initial cluster means. Therefore, the algorithm was repeated 
5000 times, and the model with the lowest WCSS was selected.
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� ̃ij =
log (Pij) - log (Pi) , (Equation 5)
sdlog (Pi )
in which Pij is parameter value i for metabolite j.
A range of 4 – 10 clusters of metabolites was obtained on basis of an elbow plot (figure 
S2). For each candidate clustering, a PKPD model was developed estimating a single EMAX, 
EC50 and kOUT per cluster and a separate baseline and RV per metabolite. The best model 
was selected on basis of ΔOFV < 16.27 (p < 0.001, df = 3), as compared with the next 
candidate cluster model.
Parameter estimates for EMAX, EC50 and kOUT appeared similar between some clusters and 
allowed model simplification by sharing parameters among different clusters. The initial 
sharing was based on similarity of parameter estimates. The reduction was performed in a 
stepwise approach. The first step consisted of reducing three separate models each shar-
ing only EMAX, EC50 or kOUT. In a second step, dual combinations of these models were evalu-
ated. The third and last step consisted of testing a shared value for all three parameters. In 
all three steps, the reduced models were rejected if they were significantly different from 
the non-reduced model (p < 0.05).
Finally, the best model was compared to a baseline model that did not include a drug ef-
fect component (i.e. DE = 0 in equation 5). A ΔOFV significance threshold was calculated to 
be 16.00 for each single metabolite, taking into account the family wise error rate (FWER) 
using Bonferroni correction. The results were compared to a partial least squares discrimi-
nant analysis (PLS-DA) on the data pooled per dose group, using the R-package mixOmics 
[36] after log-transformation and autoscaling of the data (excluding t=0). A Variable 
Importance in Projection (VIP) on the first principal component was calculated for each 
metabolite. Metabolites with a VIP score > 1 were reported as contributing significantly to 
a dose response relation for remoxipride and compared to those selected from the PKPD 
clustering approach. The methods were compared by a weighted Cohen’s kappa-analysis.
Results
PKPD models of remoxipride effect on individual metabolites
The biogenic amine analysis detected 44 metabolites in plasma with good reproducibility 
(RSDQC ≤ 15%). Unfortunately, due to metabolite degradation and detection limits, the 
biogenic amines could not reliably be measured in microdialysate samples. The plasma 
metabolites showed a general dose dependent decrease from baseline (t = 0h) in the 
treatment groups (figure 1) with different longitudinal patterns, some of them showing 
a slow and others a more rapid return to baseline (figure 1). The placebo group showed 
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an increase from baseline for many metabolites, which we initially attempted to describe 
by the mathematical bateman function that previously has been used to describe such 
placebo response [37]. This, however, did not result in an improved description of the data 
as compared to a model without a placebo effect included (Bonferroni corrected p > 0.05).
Figure 1 Heatmap showing the longitudinal response for each metabolite in the different remoxipride dose 
groups. Data are log-transformed and autoscaled, and mean responses are shown.
Since the metabolite responses were decreasing after treatment, the effect of remoxi-
pride was mathematically described as an inhibition of the metabolite production rates 
(equations 4 & 5) for each individual metabolite, in a turnover model. The EMAX for the 
metabolite kynurenine approached zero, indicating that remoxipride had no effect on 
this metabolite (figure 2). Furthermore, some metabolites showed a similar parameter 
pattern (e.g. glycine versus lysine), whereas others exhibited different characteristics (e.g. 
threonine versus tryptophan) (figure 2, indicated in pink). Particularly, the EC50 and kout 
estimates were different for some metabolites (figure 2, figure S3)).
Metabolomics and multi variate PK/PD of remoxipride 141
Figure 2. Parameter esti mates of the 44 PKPD models describing the individual metabolite responses. The 
red colors are indicati ng examples of metabolite with similar (glycine and lysine) or disti nct (threonine and 














Figure 3. K-means clustering results for 3 – 8 candidate clusters. Black dott ed lines indicate the cluster sepa-
rati on. OFV values are shown for each candidate PKPD cluster model.
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PKPD models of remoxipride effect on clusters of endogenous metabolites
Metabolite clusters were identified on basis of the parameter estimates for EMAX, EC50 and 
KOUT. Using the multi-model k-means clustering approach and subsequent cluster-based 
turnover model development (see methods section), the model with 6 clusters was found 
to best fit the data (figure 3). This model was significantly different from the 5-cluster 
model (ΔOFV > 16.27, p < 0.001, df = 3), but not from the 7-cluster model (ΔOFV < 16.27, 
p > 0.001, df = 3).
Figure 4. The effect of parameter reduction on the parameter estimates of EMAX, EC50 and kOUT were evalu-
ated for each cluster, comparing the estimates before (black bars) and after (grey bars) reduction.
Parameter sharing led to a further simplification of the model with 6 less parameters. 
The more complex model was not significantly different from the simplified model (ΔOFV 
< 12.59, p > 0.05, df = 6) and the parameter estimates were highly similar (figure 4). We 
identified four different EMAX, four different EC50, and four different kOUT parameters (figure 
4, Table 1). The parameter estimates in cluster 1 and 5 were imprecise (Table 1) and did 
not show a significant effect when compared with the model not including drug effect 
(figure 6). Moreover, the EC50 approached 0 for these clusters and was therefore fixed at 
a value close to 0. It is concluded that a remoxipride effect could not be reliably identi-
fied. Although the kynurenine response (cluster 0) showed a possible trend in the placebo 
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group (0 mg/kg), this was not consistent in the other dose groups (figure 5). Parameter 
estimates in cluster 2, 3, 4 and 6 could be precisely determined (RSE < 30%), except for the 
EC50 in cluster 3 (RSE > 50%). The predicted centroids (i.e. the time and dose dependent 
average cluster response) showed good agreement with the observed centroids (figure 
5). Ornithine (cluster 2) was excluded from this graph, since the effect on ornithine was 
in the positive direction. The single metabolite responses for ornithine and the other 
metabolites were reasonably to well predicted (figure S5).
Identification of potential plasma biomarkers for remoxipride effect
As indicated in figure 6 and table SI, the model including the drug effect significantly 
outperformed the model without drug effect for 18 metabolites (ΔOFV > 16.00, adjusted 
p < 0.05, df = 3).
3 metabolites (cluster 3) showed a high impact of remoxipride (EMAX/EC50 = 122), 13 me-
tabolites (cluster 2 and 6) a medium impact (EMAX/EC50 = 5 – 8), whereas 2 metabolites 
Table 1. Parameter estimates for the PKPD cluster model describing the multiple metabolite responses in 
6 different response clusters. 
Parameter Estimate (RSE%)
Cluster 1 EMAX 0.093 (7)
(4 metabolites) EC50 (uM) ~ 0 (fix)
kout (h-1) 39 (182)
Cluster 2 EMAX 0.093 (7)
(6 metabolites) EC50 (uM) 0.019 (19)
kout (h-1) 9.9 (15)
Cluster 3 EMAX 0.33 (19)
(4 metabolites) EC50 (uM) 0.0027 (72)
kout (h-1) 0.96 (23)
Cluster 4 EMAX 0.22 (23)
(7 metabolites) EC50 (uM) 0.12 (43)
kout (h-1) 9.9 (15)
Cluster 5 EMAX 0.093 (7)
(3 metabolites) EC50 (uM) ~ 0 (fix)
kout (h-1) 1.3 (51)
Cluster 6 EMAX 0.16 (6)
(19 metabolites) EC50 (uM) 0.019 (19)
kout (h-1) 9.9 (15)
Note: cluster 0 is not included since it represented the metabolite (kynurenine) that was not affected by 
remoxipride.
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(cluster 4) showed a low impact (EMAX/EC50 = 2). The turnover rate was high (9.9 /h) for 
cluster 2, 4 and 6, and low (0.96 /h) for cluster 3.
The PLS-DA revealed 18 metabolites with a VIP score > 1 with 13 metabolites overlapping 
and a Cohen’s kappa of 0.38, suggesting a fair agreement between the two methods (Table 
2).
Discussion
This study showed how the integration of pharmacometabolomics and PKPD modeling led 
to identification and significant description of 4 clusters of pharmacodynamic patterns. 
The model predicts the diverse longitudinal effects of remoxipride on endogenous me-
tabolites in plasma using a clustering approach. We propose 18 metabolites as potential 
biomarkers of remoxipride pharmacology.
Figure 5. Goodness of fit on basis of the cluster centroids (or means) for each cluster and remoxipride dose. 
Predicted response is indicated by the black solid line, whereas the observed data is indicated by the grey 
dots (mean) and error bars (+/- standard deviation).
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Earlier clustering approaches have been dedicated to cluster time dependent multivariate 
responses. As a next step, the current method deals with the complex non-linear (concen-
tration-effect relations are typically sigmoidal), time dependent (biological processes differ 
in their rates of change upon pharmacological treatment) and multivariate dose response 
data by step-wise integration of PKPD modeling and clustering. The model is therefore 
suited for predicting the multivariate dose-response relation for remoxipride with time 
and dose. Moreover, the model provides pharmacological meaning with the parameters 
that determine the concentration-effect relation (EMAX, EC50) and the longitudinal behavior 
of the response (kOUT).
Many metabolites identified by the PKPD clustering method were also obtained by PLS-DA 
(Table 2), although PLS-DA assumes linear dose-response relations, and does not account 
Figure 6. ΔOFV for each metabolite between the baseline model with no drug effect component and the 
best model with drug effect component. The light grey line indicates the significance threshold with no bon-
ferroni correction (α = 0.05), whereas the dark grey line indicates the significance threshold with bonferroni 
correction (α = 0.05/44). Clusters are indicated by the different symbols.
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for the time dependent response behavior. Other metabolites were only identified by one 
of the methods. This raises the question under which conditions the methods are in agree-
ment and when they contradict each other. As an illustrative example, homoserine shows 
a longitudinal dose-dependent response, which was captured by the PKPD clustering, de-
spite the high variability. The dose-dependency was not visible if the serial data is pooled 
per dose group for PLS-DA analysis (figure S4, A1 vs. A2). On the other hand, glycylproline 
was only identified by PLS-DA. This is explained by a decrease with 3.5 mg/kg remoxipride 
relative to the other dose levels when pooling the data per dose group, which does not ap-
pear as a dose dependent decrease from baseline (figure S4, B1 vs. B2). Random variation 
in the data interfered thus both for homoserine and glycylproline with the pooled dose 
Table 6. Metabolites identified to show a significant dose response with PLS-DA and PKPD based clustering



























a Metabolites with a VIP score > 1; b Metabolites with a ΔOFV > 15.99; Cohen’s kappa = 0.38
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response analysis (figure S4 - A2, B2, C2), and thus with PLS-DA. This suggests that the 
PKPD clustering method outperforms PLS-DA if random variation dominates the response. 
In contrast to homoserine and glycylproline, tyrosine showed a clear dose response, also 
as a longitudinal decrease from baseline, and was only identified by PLS-DA (figure S4, 
C1 vs. C2). Whereas the PKPD clustering method failed to identify tyrosine, it showed a 
significant response in the single metabolite model (ΔOFV = 31.19). The clustering thus 
negatively affected the fitting of the tyrosine response, while overall the 6-cluster model 
was identified as the best model. It is concluded that the clustering could not identify the 
cluster for the unique tyrosine response pattern. Further investigation did not show other 
cases in which the single metabolite model outperformed the cluster model.
There are clusters associated with metabolic pathways, providing a biological context of 
the clustering results. The branched chain amino acids (BCAA) are clustered into cluster 
1, although this cluster showed no significant effect of remoxipride (figure 6). Cluster 6 
is associated with the glycine, serine and threonine metabolism. Others have also found 
an association of D2R antagonism with this pathway, for example a decrease of glycine in 
plasma [17], a decrease of glycine and serine [38] as well as an increase of homoserine 
in brain tissue [39]. Serine is actively transported into the brain, where it is converted to 
glycine and phosphatidylcholine, both implicated in memory function [40]. Serine and gly-
cine both modulate NMDA receptors, which play a main role in the glutamate pathway in 
the brain. Although plasma glutamate itself was not changed by remoxipride, such interac-
tion may exist in the brain. This would not be surprising, since dopamine and glutamate 
systems in the brain are highly interrelated [41]. Furthermore, cluster 3 included tyrosine 
and tryptophan, the precursors of dopamine and serotonin, respectively. Dopamine levels 
are increased in different brain regions after treatment with D2R antagonists [42]. Fur-
thermore, both tyrosine and tryptophan are converted to their neurotransmitters by the 
aromatic amino acid decarboxylase (AAAD) enzyme, of which the activity was increased 
after remoxipride and other D2R antagonists treatment [43]. The decreased tyrosine and 
tryptophan levels in plasma may therefore be explained by the increased uptake into the 
brain to refill their brain stores after increased conversion to dopamine and serotonin. 
These connections to pathways show how remoxipride has a potential interaction with 
multiple biological pathways. Further studies to these interactions should confirm the 
hypotheses that are generated by this study.
The different time and concentration dependent patterns in our data suggest a multilevel 
interaction between remoxipride and the metabolic system. It is not deducible what the 
exact origin of these differences is, but there are possible explanations. It might be partly 
caused by on-target versus off-target effects, considering the large differences in EMAX/EC50 
ratio between the clusters (table SI). Although remoxipride is very selective compared to 
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other dopamine D2R antagonists, it also has affinity for other receptors, for example the 
σ-receptors [44]. The differential patterns might also be explained by remoxipride having 
a potential effect in multiple tissues. The dopamine D2 receptor is not only expressed in 
the brain, but also in many other tissues [45]. Different tissues may have different receptor 
concentrations affecting EMAX and EC50, and different drug distribution characteristics influ-
encing kOUT. Indeed, it is likely that the kOUT is determined by distribution rather than by 
enzymatic conversion. Typically, enzymatic conversion rates of biogenic amines are >1000 
/h (BRENDA Enzyme Database, 2017), while their BBB transport rates are in the range of 
0.1 – 10 /h [47], similar to the kOUT values that we identified. Finally, even when bound to 
the same receptor in the same tissue, multiple downstream pathways might have been 
affected with differential time and concentration dependent patterns. This idea is clearly 
illustrated by the differential gene expression patterns in the liver after antagonism of the 
glucocorticoid receptor [23].
We are aware of limitations that are to be addressed in future studies. Unfortunately, the 
information on the dopaminergic pathway was limited because the analytical reproduc-
ibility was not sufficient for dopamine and its metabolite 3-methoxytyrosine. Moreover, 
dopamine metabolites 3,4-dihydroxyphenylacetic acid (DOPAC) and homovanillic acid 
(HVA), as well as the dopamine precursor L-3,4-dihydroxyphenylalanine (L-DOPA) were 
not measurable by the current analytical platform. Activity of the dopamine pathway in 
the current experiment is nevertheless illustrated by significant response of tyrosine in the 
single metabolite model.
Furthermore, data that we obtained on metabolite concentrations in brainECF could not 
be used because of assay limitations. The relation between metabolite concentrations in 
plasma and the brain (or CSF) is not straightforward; they do not always correlate [48–51]. 
Good insight into this relation is crucial for the application of blood-based biomarkers in 
CNS pharmacology. Simultaneous analysis of biomarker-data in brain and blood would be 
highly valuable in translational CNS drug development because the brain provides infor-
mation on drug effects at the site of action, while blood is better accessible in humans. 
Moreover, such analysis would enable the separation of effects in the brain from those in 
the periphery. Further work should improve the application of metabolomics on micro-
dialysate samples to enable the identification of the longitudinal biomarker response in 
brain and plasma simultaneously.
Taking into consideration these discussions, our analysis framework that we developed on 
preclinical data is also promising in a clinical context. Pharmacometabolomics is increas-
ingly used to provide insights into between-subject variability in drug response [14]. It is 
similarly important, or perhaps even more so, to identify the particular causes of variable 
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drug responses when analyzing larger and typically more variable clinical datasets. Ap-
plication of PKPD based multivariate data analysis is envisioned to increase understanding 
of inter-individual variability of pharmacometabolomics responses. Additionally, the cur-
rent framework provides the basis for interspecies translation of pharmacometabolomics 
responses. Applying the principles of allometric scaling can be used to scale the clearances 
and rate constants, while physiological information with regard to receptor functionality 
can be implemented to scale the EMAX and the EC50 parameters [52,53]. Interestingly, the 
metabotype is highly conserved among mammalian species [11]. It is therefore anticipated 
that the combination of PKPD based multivariate data analysis and interspecies scaling will 
improve the dose selection in early clinical development.
In conclusion, we have laid out the basis for the integration of pharmacometabolomics 
and PKPD modeling. The developed PKPD cluster model predicts the different biochemi-
cal responses in plasma for a range of remoxipride doses and provided comprehensive 
insights in its drug effects. The study design with multiple dose levels and time serial sam-
pling, together with an analytical method that measured a large number of metabolites 
enabled this model-based approach that mathematically linked the PK and the multiple 
PD responses. Remoxipride showed 6 differential response patterns, indicating a multi-
level interaction between the drug and the biochemical system. In particular, the glycine, 
serine and threonine pathway, as well as the precursors of dopamine and serotonin, were 
influenced by remoxipride. It is envisioned that PKPD clustering could serve as an initial 
framework for the development of mechanistic systems pharmacology models.
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SUPPLEMENTARY MATERIALS
Figure S1. Investigation of the main source of outliers. The red dot represents sample R26_T15, obtained 
from animal 26 at 15 minutes after administration of placebo. The response is deviated from the other 
responses in the placebo group (black dots), indicating that this is a sample specific, and not a treatment 
or time point specific outlier.
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Figure S2. Elbow plot visualizing the total within cluster sum of squares (WCSS) against the number of can-
didate clusters for the k-means clustering. The red dots show the ‘elbow’ of the WCSS, indicating the range 
comprising the optimal number of clusters.
Figure S3. Correlations between EMAX, EC50 and kout (dots). Linear regression was applied to the log-trans-
formed parameter estimates as indicated by the dashed line. Kynurenine (EMAX < 0.001) was excluded from 
the linear regression analysis since it highly skewed the regression.















































































































































































































Figure S4. Dose responses for homoserine (A), glycylproline (B), and tyrosine (C), with the longitudinal re-
sponses per dose (left, 1) and the dose response (right, 2). Homoserine (A) is identified by PKPD clustering, 
but not by PLS-DA. No dose response is visible if the data is pooled per dose group (A2), but a longitudinal 
decrease from baseline is observed (A1). Glycylproline (B) is identified by PLS-DA, but not by PKPD cluster-
ing. A lower response is observed in the highest dose group (B2), but this does not appear as a longitudinal 
response (B2). Tyrosine (C) is identified by PLS-DA, but not by PKPD clustering. A dose response is observed 







































































































































































































































































































































































































































Figure S5. Goodness-of-fit for each single metabolite. Predicted response is indicated by the black solid line, 
whereas the observed data is indicated by the dots (mean) and error bars (+/- standard deviation).








































































































































































































































































































































































































































































































Figure S5. Goodness-of-fit for each single metabolite. Predicted response is indicated by the black solid line, 























































































































































































































































































































































































































































































Figure S5. Goodness-of-fit for each single metabolite. Predicted response is indicated by the black solid line, 
whereas the observed data is indicated by the dots (mean) and error bars (+/- standard deviation).





























































































































































































































































































































































































































































































Figure S5. Goodness-of-fit for each single metabolite. Predicted response is indicated by the black solid line, 
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Figure S5. Goodness-of-fit for each single metabolite. Predicted response is indicated by the black solid line, 
whereas the observed data is indicated by the dots (mean) and error bars (+/- standard deviation).
CHAPTER 7
BLOOD-BASED BIOMARKERS OF QUINPIROLE 
PHARMACOLOGY: MULTIVARIATE PK/PD AND 
METABOLOMICS TO UNRAVEL THE UNDERLYING 
DYNAMICS IN PLASMA AND BRAIN
W.J. van den Brink, R. Hartman, D.J. van den Berg, G. Flik, B. Amoros-
Gonzalez, N. Koopman, J. Elassais-Schaap, P.H. van der Graaf, T. 




A key challenge in the development of CNS drugs is the availability of drug target specific 
blood-based biomarkers. As a new approach, we applied multivariate pharmacokinetic/
pharmacodynamic (PK/PD) analysis in brainECF and plasma simultaneously after 0, 0.17 and 
0.86 mg/kg of the dopamine D2/3 agonist quinpirole (QP) in rats. We measured 76 biogenic 
amines in plasma and brainECF after single and 8-day administration, to be analyzed by 
multivariate PK/PD analysis. Multiple concentration-effect relations were observed with 
potencies ranging from 0.001 – 383 nM. Many biomarker responses propagated over 
the blood-brain-barrier. Effects were observed for dopamine and glutamate signaling in 
brainECF, and branched-chain amino acid metabolism and immune signaling in plasma. 
Altogether, we showed for the first time how multivariate PK/PD could describe a systems-
response across plasma and brain, thereby identifying potential blood-based biomarkers. 
This concept is envisioned to provide an important connection between drug discovery 
and early drug development.
Keywords: Metabolomics, systems pharmacology, PK/PD, CNS drug development, dopa-
mine agonists
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Introduction
One of the key challenges in central nervous system (CNS) drug development is the dis-
covery of blood-based biomarkers that reflect the central response (1,2). Such biomarkers 
enhance the evaluation of the proof of pharmacology of CNS drugs, which is crucial for 
successful drug development (3). It is particularly important to dynamically evaluate the 
biomarker responses in relation to the systems pharmacokinetics (PK) of the drug, given 
that the interaction between PK and pharmacodynamics (PD) typically is non-linear and 
time-dependent (4,5).
While currently biomarker discovery is nowadays typically driven by the known phar-
macological mechanisms, metabolomics fingerprinting is not limited to these pathways. 
Metabolomics analysis has revealed multiple new biochemical pathways in relation to 
drug responses (6–11).
One of the techniques being useful in CNS biomarker discovery is intracerebral microdi-
alysis. It is a well-established technique that has been successfully applied to study drug 
concentrations as well as drug response biomarkers in brain extracellular fluid (brainECF) 
to evaluate CNS PK and PD (12–14). Therefore, microdialysis is the method of choice to 
dynamically evaluate a metabolomics fingerprint in brain extracellular fluid (brainECF) 
simultaneously upon CNS drug treatment. Such dynamical evaluation would improve the 
quantitative insights into systems-wide responses (i.e. changes in biomarker concentra-
tions), thereby shifting CNS drug development from an empirical towards a mechanistic 
discipline (15,16).
In an earlier study we have already shown that a multivariate (PK/PD) evaluation of a 
metabolomics response in plasma reveals multiple dynamics underlying a systems re-
sponse upon treatment with remoxipride (17). In the current study we set out to extend 
this methodology with a simultaneous evaluation of a metabolomics response in both 
plasma and brainECF, using the dopamine D2/3 receptor agonist quinpirole (QP) as paradigm 
compound. Overall, the purpose is to provide insight into the systems-wide biochemical 
responses of CNS drugs, combined with PKPD modeling as a new approach to discover 
blood-based biomarkers of central responses.
Methods
Animals, surgery and experiment
Animals – Animal studies were performed in agreement with the Dutch Law of Animal 
Experimentation and approved by the Animal Ethics Committee in Leiden, the Netherlands 
(study protocol DEC12247). For details on animals, surgery and experiment, we refer to (18).
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Surgery – In short, male Wistar rats (n=44) underwent surgery while anesthetized, to 
receive cannulas in the femoral artery and vein for blood sampling and drug administra-
tion, respectively. The microdialysis probe guides (CMA/12) and their dummy probes were 
implanted in the caudate putamen in both hemispheres. The probes (CMA/12 – Elite 4 
mm) were placed 24 hours before experiment.
Experiment – The animals were subjected to an experiment on two days with 7 days in 
between. On the days of experiment, the rats were randomly assigned to receive 0 mg/
kg (n=12), 0.17 mg/kg (n=16) or 0.86 mg/kg (n=16) QP. Microdialysate samples were col-
lected from -200 to 180 minutes (20-minute interval, 1.5 μl/min, 120 min. equilibration 
time). Blood samples were taken at -5, 5, 7.5, 10, 15, 25, 45, 90, 120 and 180 minutes 
and centrifuged to separate the plasma (1000 x g, 10 min, 4°C). Samples were stored at 
-80°C until analysis. Between the experiment days, the same doses were administered 
subcutaneously.
Chemical analysis of the samples
Targeted monoamine + metabolite analysis – A selection of plasma and microdialysate 
samples collected on experiment day 1 were analyzed by BrainsOnline (Groningen, The 
Netherlands). The samples were delivered on dry ice and stored at -80°C until analysis. 
Monoamines and their metabolites (serotonin, 5-hydroxy indoleacetic acid, dopamine, 
3,4-hydroxyphenylacetic acid, homovanillic acid, glutamate and glycine) were analyzed 
employing SymDAQ derivitization (19,20). Data were calibrated and quantified using the 
Analyst™ data system (Applied Biosystems, Bleiswijk, The Netherlands) to report concen-
trations of the analytes.
Untargeted biogenic amine analysis – The biogenic amines were analyzed in microdialy-
sate and plasma samples of experiment day 1 and 8 according to a previously described 
method (21). Amino acids and amines were derivatized by an Accq-tag derivatization 
strategy. Plasma samples (5 µL) were reduced with TCEP (tris(2-carboxyethyl)phosphine) 
and deproteinated by MeOH. Microdialysate samples (30 µL) were only reduced with 
TCEP. The samples were dried under vacuum while centrifuged (9400xg, 10 min, Room 
Temperature), and reconstituted in borate buffer (pH 8.8) with with AQC (6-aminoquinolyl-
N-hydroxysuccinimidyl carbamate) derivatization reagent. The reaction mixtures were 
injected (1 µL) into an UPLC-MS/MS system, consisting of an Agilent 1290 Infinity II LC 
system, an Accq-Tag Ultra column, and a Sciex Qtrap 6500 mass spectrometer. The peaks 
were assigned using Sciex MultiQuant software, integrated, normalized for their internal 
standards, and corrected for background signal. Only compounds with a QC relative stan-
dard deviation (RSDQC) under 30% were reported to assure quality of the data.
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Data analysis
Pharmacokinetic model – The PK model has been published previously and described the free 
QP concentrations in plasma and brainECF with QP doses ranging from 0.17 to 2.14 mg/kg (18).
Pharmacodynamic models – A PD model was developed for each single metabolite (here-
after called biomarkers) using a population approach in NONMEM® version 7.3.0 with sub-
routine ADVAN13. The inter-individual variability around the parameters and the residual 
error were described by an exponential distribution (suppl. Equation 1, 2). A combination 
of submodels was evaluated for each single biomarker consisting of i) a straight baseline, 
an exponential decay, or a linear slope model; ii) a linear or a sigmoid EMAX concentration 
response model; iii) a transit or no transit compartment model; and iv) a turnover or a 
pool model (Suppl. equations 4 - 7). In addition, a model with no drug response function 
was evaluated (Suppl. equation 8) The models were selected on basis of the objective 
function value (χ2-test, p < 0.05), the condition number, successful convergence and visual 
evaluation of goodness-of-fit plots.
Exploration of target site – For biomarkers showing a response in either plasma or brainECF, 
the site with the response was identified as effect target site. In case a biomarker showed 
a response both in plasma and brainECF, two PD models were developed with either the 
plasma biomarker response driving the brainECF biomarker response or vice versa. The link 
between the response in plasma and brainECF was described by a linear or a non-linear 
brain transport model following Michaelis Menten kinetics (Suppl. Equation 9). The Aikaike 
Information Criterium (AIC) of the ‘brainECF target site model’ was subtracted from that of 
the ‘plasma target site model’ to calculate the ΔAIC for selection of the target site model. 
A negative ΔAIC indicated plasma as target site of effect, while a positive ΔAIC suggested 
brainECF as target site of effect.
Clustering – The longitudinal biomarker responses were simulated for their determined 
target site and subsequently clusters of the dynamical pharmacological responses were 
identified in plasma and brainECF using k-means clustering. The number of clusters was 
selected in two steps. First an elbow plot, depicting number of clusters against within clus-
ter sum of squares, was used to identify a range of potential number of clusters. Second, 
for each potential number of clusters a PK/PD cluster model was developed describing 
the cluster responses. The AIC was used to select the model with the optimal number of 
clusters. Subsequently, a step-wise parameter sharing procedure was applied as previ-
ously described (17). In short, a single parameter (e.g. EC50) was estimated for multiple 
clusters and evaluated by the change in OFV (χ2-test, p < 0.05) to determine whether this 
was statistically different from a model with separate parameters. If no difference was 
found, the shared parameter was kept in the model.
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Significance score calculation - The cluster-based model was compared to a model with 
no drug effect model included, i.e. assuming no effect of QP. A significance score was 
calculated by the change in OFV corrected for the degrees of freedom with a Bonferroni-
corrected significance threshold of α = 0.01 (Suppl. equation 10). A significance score > 0 
reflects a significant effect of QP on a biomarker response.
Effect of eight-day QP administration
Basal biomarker levels (t = 0) in both brainECF and plasma at experiment day 1 and experi-
ment day 8 were compared using two-way ANOVA with interaction between dose and ex-
periment day. Tukey honest significant different test was used for posthoc analysis. BrainECF 
basal biomarker levels were averaged per animal, given that there were 4-6 baseline 
samples for each animal. For the biomarkers that revealed a significant change with experi-
ment day, a covariate analysis was performed in the single biomarker models by estimating 
a separate baseline parameter per combination of treatment group and experiment day. 
Only if the covariate analysis revealed a difference, the effect was considered significant.
Results
Exploration of target site of effect
The metabolomics data revealed 23 biomarkers primarily responding to QP in plasma, and 
15 biomarkers primarily affected by QP in the brain (Table I, Figure 1). DL-3-aminobutyric 
acid and serotonin could only be measured in plasma, while L-glutamine could only be 
measured in brainECF. From all the biomarkers that reflected an effect of plasma QP, 19 
showed a net transport to the brainECF. Inversely, 5 biomarkers exhibited a net transport 
from brainECF into plasma, potentially leading to secondary responses in plasma. The inter-
compartmental transport rates between plasma and brainECF of many biomarkers were 
described by non-linear Michaelis-Menten kinetics (Table I).
Table I. Overview of biogenic amines and their target site that showed a response upon QP treatment. The 
Delta Akaike Information Criterium (ΔAIC) indicates the target site (see methods). Also, the type of brain 
transport is indicated (yes, no or not available (N.A.)). PàB and BàP stand for plasma-to-brain and brain-to-
plasma, respectively. Only biomarkers presented in black showed a significant response in the cluster models.
Biomarker Target site ΔAIC Brain transport
Targeted approach (BrainsOnline)
Dopamine BrainECF - No
DOPAC BrainECF - No
HVA BrainECF - No
Glycine Plasma -56.216 Yes – NonLinPàB
5-HIAA Plasma - No
L-Glutamic acid Plasma - No
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Table I. (continued)
Biomarker Target site ΔAIC Brain transport
Untargeted approach (BMFL)
L-Phenylalanine Plasma -75.811 Yes – NonLinBàP
L-Valine Plasma -73.682 Yes – NonLinBàP
L-Methionine sulfoxide Plasma -55.917 Yes – NonLinPàB
Taurine Plasma -48.638 Yes – NonLinBàP
S-Methylcysteine Plasma -46.564 Yes – Linear
L-Alpha-aminobutyric acid Plasma -40.634 Yes – NonLinPàB
L-Asparagine Plasma -37.597 Yes – NonLinBàP
L-Alanine Plasma -35.086 Yes – NonLinPàB
Gamma-L-glutamyl-L-alanine Plasma -33.872 Yes – NonLinPàB
L-Threonine Plasma -31.734 Yes – Linear
L-Methionine Plasma -24.946 Yes – Linear
L-Histidine Plasma -24.715 Yes – Linear
L-Arginine Plasma -24.469 Yes – NonLinPàB
L-Isoleucine Plasma -13.582 Yes – NonLinBàP
Glycine Plasma -12.572 Yes – Linear
Homocysteine Plasma -10.954 Yes – Linear
L-Serine Plasma -8.129 Yes – Linear
Citrulline Plasma -5.407 Yes – NonLinBàP
L-Leucine Plasma -2.462 Yes – NonLinBàP
DL-3-aminoisobutyric acid Plasma - N.A.
Histamine Plasma - No
L-Glutamic acid Plasma - No
L-Homoserine Plasma - No
Methionine sulfone Plasma - No
Serotonin Plasma - N.A.
L-Proline BrainECF 41.574 Yes – NonLinBàP
N6,N6,N6-Trimethyl-L-lysine BrainECF 27.282 Yes – NonLinBàP
Hydroxylysine BrainECF 8.103 Yes – Linear
L-Lysine BrainECF 4.747 Yes – NonLinBàP
L-4-hydroxy-proline BrainECF 1.111 Yes – NonLinBàP
Homocitrulline BrainECF 0.261 Yes – NonLinBàP
3-Methoxytyramine BrainECF - No
5-Hydroxy-L-tryptophan BrainECF - No
Cystathionine BrainECF - No
Gamma-aminobutyric acid BrainECF - No
L-2-aminoadipic acid BrainECF - No
L-Glutamine BrainECF - N.A.
L-Tryptophan BrainECF - No
L-Tyrosine BrainECF - No
Ornithine BrainECF - No
Putrescine BrainECF - No
Sarcosine BrainECF - No
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Figure 1. Significance score of responding metabolites in brainECF (left) and plasma (right) indicating their 
potential as a biomarker of the QP systems effect. The grey line marks the significance threshold; metabo-
lites right of the line were significantly affected by QP. The red circles indicate the metabolites that distrib-
ute from brainECF to plasma and vice versa. *Cluster 1 was excluded for brainECF since no effect was observed. 
[BO] refers to the amines analyzed by BrainsOnline.
Clustered response patterns in brainECF and plasma
A total of 7 clusters of dynamical biomarker responses in brainECF was selected (Table II). 
Using parameter sharing, it was observed that the biomarkers responded with either a 
high or a low potency (EC50 = 0.01 nM or EC50 = 122 nM, Table III, Figure 2). The turnover 
of these biomarkers was low (0.031 min-1 – 0.056 min-1) or high (0.13 min-1 – 0.44 min-1). 
The responses in plasma were also separated into 7 clusters (Table II) described by models 
with transit compartment models (cluster 1 & 4), pool models (cluster 5 & 6) and turnover 
models (cluster 2, 3 & 7) (Table III). A wider variety of potency parameter estimates were 
identified in plasma as compared to brainECF: 0.01 nM, 17.2 nM, and 113 - 383 nM (Table 
III, Figure 2). Moreover, the direction of response was both up (cluster 1 & 4) and down 
(cluster 2, 3 & 5-7). The responses in brainECF and plasma were well described by the 
cluster-PKPD models (Figure 3, suppl. Figure 2).
Effect of QP on the dopamine pathway
Dopamine (DA), 3,4-dihydroxyphenylacetic acid (DOPAC), and homovanillic acid (HVA), the 
key constituents of the dopamine pathway, were decreased in brainECF upon QP treatment. 
Whereas the in vivo potency was found to be similar for these biomarkers (122 nM), the 
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maximal inhibition values (DA: 67%, DOPAC: 41%, HVA: 60%) and the turnover rates (DA: 
0.44 min-1, DOPAC: 0.13 min-1, HVA: 0.031 min-1) were different (Table III, Figure 2). No 
responses of QP treatment were observed for DA and HVA in plasma, while DOPAC could 
not be measured in plasma due to assay lower limit of detection of 50 nM.
Table III. Parameter estimates of the cluster models. RSE: relative standard error.
Plasma BrainECF
Parameter Estimate (RSE) Parameter Estimate (RSE)
Cluster 1*
EMAX (%) 4650 (41.1%)
EC50 (nM) 383 (54.3%)
kout (min-1) 0.035 (42.3%)
ktransit (min-1) 0.044 (33.1%)
Table II. Determination of optimal number of clusters in plasma and brainECF using the Akaike Information 
Criterium (AIC). In bold the selected number of clusters.
Plasma BrainECF
# clusters AIC # clusters AIC
4 65500.76 6 78140.64
5 64991.03 7 76518.12
6 64966.79 8 76523.49
7 64876.42 9 78319.55
8 66314.62 10 76535.81
Figure 2. An overview of the concentration-effect relations that underlie the systems responses in brainECF 
(left) and plasma (right). Thick line parts represent the range of observed biomarker concentrations *Clus-




IMAX (%) -20 (30.1%) IMAX (%) -20 (6.1%)
IC50 (nM) 113 (98.5%) IC50 (nM) 0.001 (fix)
kout (min-1) 0.057(38.3%) kout (min-1) 0.056 (27.9%)
Cluster 3
IMAX (%) -20 (30.1%) IMAX (%) -29 (7.1%)
IC50 (nM) 17.2 (50.6%) IC50 (nM) 0.001 (fix)
kout (min-1) 0.11 (12.2%) kout (min-1) 0.13 (13.3%)
Cluster 4
EMAX (%) 363 (67.5%) IMAX (%) -15 (13.5%)
EC50 (nM) 113 (98.5%) IC50 (nM) 0.001 (fix))
kout (min-1) 9.58 (104%) kout (min-1) 0.14 (32.7%)
ktransit (min-1) 0.0052 (46.8%)
ntransit 1.79 (17.9%)
Cluster 5
IMAX (%) -41 (14.6%) IMAX (%) -41 (9.0%)
IC50 (nM) 339 (32.8%) IC50 (nM) 122 (51.4%)
kout (min-1) 0.11 (12.5%) kout (min-1) 0.13 (13.3%)
krel (min-1) 0.018 (27.5%)
Cluster 6
IMAX (%) -90 (0.3%) IMAX (%) -67 (4.9%)
IC50 (nM) 0.001 (fix) IC50 (nM) 122 (51.4%)
kout (min-1) 0.10 (18.4%) kout (min-1) 0.44 (47.9%)
krel (min-1) 0.35 (19.6%)
Cluster 7
IMAX (%) -41 (6.4%) IMAX (%) -60 (9.3%)
IC50 (nM) 17.2 (50.6%) IC50 (nM) 122 (51.4%)
kout (min-1) 0.060 (13.5%) kout (min-1) 0.031 (28.9%)
* Cluster 1 was excluded for brainECF since no dose-response was observed.
Consequently, parameter estimates were not informative.
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Figure 3. Goodness-of-fit of the cluster responses as change from baseline in brainECF (top) and plasma (bot-
tom). Dots and error bars mark the geometric mean +/- standard deviation of the observed cluster respons-
es, light lines represent the geometric mean of the single metabolite responses and dark lines show the 
predicted cluster responses. The facet labels show the number of metabolites between the parentheses. 
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Effect of QP on other pathways in brainECF
In brainECF QP was found to interact with the polyamine metabolism (ornithine, putres-
cine), the proline metabolism (proline, L-4-hydroxyproline), neurotransmitter precursors 
(tryptophan, tyrosine), and lysine metabolism (lysine, hydroxylysine) (Table I, Figure 1).
Effect of QP on metabolic pathways in plasma
The systemic response on amino acid metabolism in plasma indicated interactions be-
tween QP and the branched chain amino acid (BCAA) metabolism (leucine, isoleucine, 
valine), neurotransmitter synthesis (phenylalanine), serine-glycine-threonine metabolism 
(serine, glycine, threonine), and histamine metabolism (histidine, histamine) (Table I, 
Figure 1). Furthermore, alpha-aminobutyric acid and DL-3-aminoisobutyric acid strongly 
responded to QP treatment (Table I, Figure 1).
Effect of eigth-day QP administration on basal biomarker levels
Eight-day QP administration did not result in significant changes in basal brainECF biomarker 
levels, but showed a significant change in plasma levels of alpha-aminobutyric acid and 
DL-3-aminoisobutyric acid after 0.17 mg/kg (p < 0.05), but not after 0.86 mg/kg QP (p 
> 0.05) (Figure 4). However, including the interaction between treatment and day as a 
covariate in the PK/PD models for these biomarkers did not result in a significant improve-
ment of the model (p > 0.05), potentially related to the lack of a dose-response relation.
Figure 4. Relative change of L-Alpha-aminobutyric acid levels in plasma after 8-day administration as com-
pared to a single administration. * denotes a significant effect with p < 0.05.
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Discussion
In this study we aimed for combining metabolomics in brainECF and plasma with multivari-
ate PK/PD modeling to obtain insight into the systems response, as well as to explore the 
target site of effect upon CNS drug administration. By integrating time-resolved metabo-
lomics analysis with multivariate PK/PD, we revealed the diverse dynamical responses of 
biogenic amines and amino acids in brainECF and plasma upon administration of the D2/3 
agonist QP. Indeed, the quantitative characterization of the system-wide biomarker re-
sponses showed a variety of in vivo potency and maximal response values in both brainECF 
and plasma. Additionally, the unique evaluation of time-resolved metabolomics in both 
brainECF and plasma revealed a few potential blood-based biomarkers reflecting effects in 
brainECF. Interestingly, it was also observed that many biochemical responses of QP have 
their main origin in the periphery rather than in the brainECF. Finally, our study showed no 
response of eight-day administration on biogenic amine and amino acid levels.
Exploration of target site and identification of blood-based biomarkers
It is a great challenge to identify blood-based biomarkers that reflect neurochemical re-
sponses in the brain. Often, these measurements are done at one time-point. In such case, 
however, correlations between plasma and brainECF responses cannot reveal the causal 
relation. In the current study we were able to use the temporal delay between the brainECF 
and plasma biomarker responses to identify the potential causal relation between them 
(i.e. the slowest response is likely a consequence of the quickest response via transport 
over the blood-brain barrier (BBB)). The BBB has multiple transport systems that transport 
biogenic amines and amino acids, for example, the large neutral amino acid transporter 1 
(LAT1; for transport of e.g. glutamine, tyrosine, tryptophan), the cationic amino acid trans-
porter 1 (CAT1; for transport of arginine and lysine), or the serotonin transporter (SERT; 
for transport of serotonin) (22,23). These transport systems exist at both the luminal and 
abluminal site of the BBB, whereby biogenic amines and amino acids can be transported 
from plasma to brain and vice versa. It is therefore likely that the parallel responses in 
plasma are, at least partially, explained by BBB transport. Interestingly, the number of 
biogenic amines transported from brainECF to plasma was lower than those transported 
from plasma to brain (Table I). This observation it suggests first of all that, even if a drug 
does not cause a direct response in the brain (e.g. because of no exposure), biochemical 
responses may propagate from plasma to brainECF and cause secondary responses. Second, 
the observed assymetry underlines the difficulty of finding blood-based markers reflective 
of drug responses in brainECF. 6 Potential blood-based biomarkers nevertheless reflected 
a response in brainECF (Table I, Figure 1). Importantly, 5 of them showed non-linear trans-
port over the BBB. It is advisable to take this non-linearity into account when evaluating 
blood-based biomarkers as a surrogate for an effect in brainECF. The blood-based biomarker 
response may be restricted by the maximal transport rate over the BBB and hence it 
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may affect the estimation of the maximal effect (EMAX) parameter. Therefore, in order to 
understand the dynamics of the blood-based biomarker response in a clinical context, it 
is recommended to determine the relation between the plasma and brainECF biomarker 
response preclinically similar to the current study.
The effects of eight-day QP administration
Interestingly, while there was a significant response upon eight-day administration of QP 
in PK/PD parameters describing the neuroendocrine response (18), no significant impact 
on basal biomarker levels was identified in the current study, although dopamine, DOPAC 
and HVA were only analyzed for experiment day 1. A possible explanation could be that 
the biological systems that underlie the amino acid and biogenic amine responses have 
greater flexibility than the neuroendocrine system in adapting to perturbations such as QP 
administration.
The effects of QP on multiple pathways
QP appeared to have an overall inhibiting response on multiple biogenic amine pathways. 
First of all, the dopamine metabolism in the brainECF was inhibited, which could be ex-
plained by the response of QP on the D2 autoreceptors located on the presynaptic neuron 
(24). Moreover, QP reduced peripheral phenylalanine concentrations, thereby lowering 
the brain levels of phenylalanine and tyrosine that constitute the basis of the dopamine 
metabolism. Second, although QP did not significantly affect cerebral glutamate levels, 
glutamate signaling may be inhibited by QP, given that glycine, serine, proline and pu-
trescine levels in brainECF were decreased, all acting as co-activator of the NMDA receptor 
(25,26).
Furthermore the reduction of the BCAA levels and the increase of DL-3-aminoisobutyric 
acid in plasma may both be associated with increased activity of the animals. BCAA levels 
were found negatively correlated with activity (27), while DL-3-aminoisobutyric acid was 
observed positively associated with activity (28). Indeed, QP does induce locomotion as 
measure of increased activity and movement (29), and the modified levels of BCAA and 
DL-3-aminoisobutyric acid in our study may be a reflection of that.
Finally, the reduction of histidine and histamine in plasma may reflect an inhibitory ef-
fect of QP on the immune system. Histamine is directly released from dendritic cells, 
macrophages and neutrophils upon production from histidine by the enzyme histidine 
decarboxylase (30). Interestingly, dopamine receptors are expressed in various immune 
cells such as dendritic cells, neutrophils and natural killer cells (31), indicating a potential 
mechanism through which QP may have influenced the histamine metabolism.
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Some limitations of the current study
Of course we are aware of some limitations of this study. First of all, while the results 
in our study strongly indicate a systems wide response for the D2/3 receptor agonist QP, 
it should be confirmed by using other D2 agonists whether the observed responses are 
related to dopaminergic activity, and to which receptor subtype they are related. Such 
analysis would give insights into drug-class specific system-wide responses. For example, 
a multivariate analysis of several antipsychotic D2 receptor agonists showed large neuro-
chemical and behavioral overlap of clozapine with 5-HT2a antagonists, but not haloperidol 
(32). Ultimately, the multivariate PK/PD approach may link in vitro and in vivo characteriza-
tions of drug-class related pharmacology by connecting the pattern of in vivo potencies to 
in vitro affinities.
Second, although the analytical platforms that have been used in the current study are 
well-developed with proven robustness (19,21), glycine measured by the targeted platform 
was described by cluster 3 dynamics, while the glycine response as analyzed by untargeted 
analysis was closer to the cluster 2 pattern (Figure 1). Inter-laboratory reproducibility is 
currently a topic of investigation, although early research suggests good robustness of 
metabolomics platforms towards this type of variation (33). An explanation could be non-
linearity of the apparatus response given the fact that the untargeted analysis provided 
response ratios (analyte peak area/internal standard peak area), whereas the targeted 
analysis presented concentrations. 
Third, although not only biogenic amines and amino acids are expected to respond to QP, 
we were limited by sample volume of the microdialysates. It would be valuable to extend 
the current approach with multiple platforms integrated to obtain a comprehensive insight 
into the system-wide effects of CNS drugs. Fortunately, the microdialysis-metabolomics 
technology is rapidly evolving, requiring lower sample volumes for metabolomics analysis 
(34,35). Furthermore, to counteract the high attrition rates in CNS drug development, it 
will be important to accurately monitor the pharmacology in early clinical drug develop-
ment (3). Such monitoring needs accessible biomarkers that can be obtained from the 
blood, for example. The combined microdialysis-metabolomics technology is envisioned 
valuable and relatively low-cost to develop specific biomarker panels for CNS drugs (or 
drug classes).
Finally, all brainECF measurements were made in the striatum. To gain insight into the 
higher hierarchy of the brain, the brain circuitry, it is essential to do measurements in 
multiple brain regions that are relevant to the drugs’ mechanism of action. Indeed, CNS 
diseases and treatment responses are determined by the balance among signaling of 
multiple neurotransmitters in multiple regions (36–38). Addition of multiple brain regions 
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to a multivariate PK/PD model is therefore envisioned to further elucidate the systems 
pharmacodynamics of CNS drugs.
Conclusion
CNS drug development is challenged by low success rates and high development costs. 
Biomarker-driven drug development is seen as a logical step to improve these success 
rates, and metabolomics holds great promise in this regard. It provides a relatively low-
cost method to comprehensively screen for drug response biomarkers. In this study we 
showed for the first time how time-resolved metabolomics analysis in combination with 
multivariate PK/PD describes the diverse dynamical patterns in brainECF and plasma in a 
pharmacologically meaningful manner to evaluate systems-wide CNS drug effects. More-
over, our approach also enables to explore the target site of effect, as well as to identify 
blood-based biomarkers that are reflective of drug responses in brainECF. Further applica-
tion and development of this method is envisioned to provide an important connection 
between drug discovery and early drug development.
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Supplement 1 – Equations
Inter-individual and residual variability
θi = θpop * eηi (Eq. 1)
Log(Cobs , i , j) = Log(Cpred , i , j) + εi , j  (Eq. 2)
θi is the estimated parameter for individual i; θpop is the estimated parameter for the 
population; ηi follows a normal distribution with mean 0 and variance ω2; Cobs,i,j is the 
observed concentration data point for individual i at timepoint j; Cpred,i,j is the predicted 
concentration for data point for individual i at timepoint j; εi,j follows a normal distribution 







CMET , BSL =( BSLMET - BSLmin )* e- kdec * time + BSLmin  (Eq. 3c)
CMET,BSL is the biomarker concentration given no drug response; BSLMET is the biomarker 
concentration at baseline at time = 0; s is the slope of the change in baseline with time; 
BSLmin is the minimum level of the basal biomarker levels; kdec is the rate of baseline bio-
marker decay with time.
Drug response models
Linear model
E = slope * CQP  (Eq. 4a)
EMAX model
E = 
EMAX * CQP  (Eq. 4b)
EC50 + CQP
E is the magnitude of drug response; Slope is the parameter that determines the strength 
of the drug response; CQP is the drug concentration at the target site, either plasma or 








(ktr * time )Ntr  (Eq. 5b)
e- Ntr * √2π* NtrNtr + 0.5)
Turnover model (effect on biomarker release)
dCMET = kOUT * CMET , BSL *( 1 + E * Tr )- kOUT * CMET  (Eq. 6)dt
Pool model (effect on biomarker release)
dCMET , pool = kOUT * CMET , BSL - kREL *( 1 + E * Tr )* CMET , pool  (Eq. 7a)dt
dCMET = kREL *( 1 + E * Tr )* CMET , pool - kOUT * CMET , PL  (Eq. 7b)dt
No response
CMET = CMET , BSL  (Eq. 8)
Tr describes the time delay of response using a transit compartment model (1 = no delay); 
ktr is the rate at which the response goes through the transit compartments; Ntr is the 
number of transit compartments; CMET is the biomarker concentration in plasma or brainECF 
; kOUT is the hormone turnover rate; CMET,POOL is the biomarker concentration in the pool; 
kREL is the biomarker release rate from the pool into plasma or brainECF.
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Brain transport models
ktransp = ktransp  (Eq. 9a)
ktransp =
Vmax + CMET , target  (Eq. 9b)km
kOUT , notTS = kOUT , notTS  (Eq. 9c)
kOUT , notTS = 
Vmax + CMET , notTS  (Eq. 9d)km
dCMET , notTS = ktransp * CMET , target - kOUT , notTS * CMET , notTS  (Eq. 9e)dt
ktransp is the transport rate over the blood-brain-barrier from the target site to the other 
compartment; Vmax the maximal rate with km being the concentration at 50% of the maxi-







OFVref is a model with no drug effect included and OFVtest is a model with the drug effect 
included. The inv.χ2 calculates a penalty for additional parameters (df) in the drug effect 
model on basis of the significance threshold (α) divided by the total number of biomarkers 
(nbiomarker), i.e. bonferroni-correction.
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Supplement 2 – Elbow plots
Figure S1. Elbow plots for the clustering of brainECF (left) or plasma (right) responses. The elbow plot shows 
the balance between the number of clusters and the total variation that is explained by the clusters. The 
‘elbow’ in this figure marks the point where adding another cluster does not further decrease the total un-
explained variation, and is used to define the optimal number of clusters. While this is not always very clear 
from an elbow plot, a series of cluster numbers were selected, marked by the red dots, to subsequently be 
evaluated in a PK/PD cluster model.
Supplement 3 – Goodness-of-fit single biomarkers
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Figure S2. Goodness-of-fit of the cluster models on the baseline corrected single metabolite levels in 
brainECF (top) and plasma (bottom). Dots are the geometric means per time point and dose, while the er-
rorbars mark the geometric standard deviation. The lines represent the model-based predictions for 0 mg/
kg (red), 0.17 mg/kg (green) and 0.86 mg/kg (blue).
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Diseases of the Central Nervous System (CNS) decrease the quality of life of millions of 
people worldwide (1–3). A lot of time, effort and resources are therefore put into the 
development of CNS drugs, while the success rates are low. For example, in the period 
from 2003 – 2011, almost 400 CNS drugs entered phase I clinical development, while less 
than 10% of them received market approval (4). The main reasons for these low success 
rates are the lack of understanding of the complexity of the brain, the presence of the 
blood-brain-barrier limiting drug penetration, CNS mediated side effects, and the lack 
of good biomarkers that represent the interaction of the drug with neurophysiological 
systems (5–7).
Systems pharmacology aims to integrate multiple biological systems for the evaluation 
pharmacological effects to improve the understanding and the prediction of drug effects 
(8–12). While several examples show the merits of systems pharmacology (13,14), they 
are driven by a priori insights into detailed pharmacological knowledge. This is not always 
available during early drug development. As an alternative, the pharmacometabolomics 
approach in combination with multivariate statistical methods provides an unbiased and 
data-driven way to evaluate the system-wide drug effects at the level of biochemical path-
ways (15–17). However, in order to understand and extrapolate the typically non-linear 
drug effects, one needs to quantify the relation between drug dose and response using 
pharmacokinetic/pharmacodynamic (PK/PD) modeling (18–20). In other words, it will 
be important to divert from a fully empirical approach towards a mechanistic approach, 
without loosing the unbiased and data-driven properties of pharmacometabolomics. Ad-
ditionally, given the limited access to the brain in terms of sampling, it is important to 
discover blood-based biomarkers that represent drug effects in the brain. In this thesis, 
we therefore asked two questions:
1. How can we quantify the relation between drug dose and the dynamic systems re-
sponse in vivo?
2. How can we obtain blood-based markers that represent central drug effect?
Section I – General introduction
As an initial step, in Chapter 2, these questions were placed in the context of translational 
pharmacology of CNS drugs with particular focus on interspecies scaling. On one hand, me-
tabolomics enables comprehensive evaluation of interspecies differences at the biochemi-
cal level (21–23). On the other hand, mechanistic PK/PD modeling in combination with allo-
metric and physiology-based scaling is used to extrapolate drug responses from one species 
to another (18,19). Moreover, mechanistic PK/PD modeling can potentially be applied to 
describe the relation between neurological drug effects and blood-based biomarkers, as 
will be discussed below. PK/PD-metabolomics modeling was proposed as an integration 
of PK/PD and pharmacometabolomics with the potential to increase understanding and 
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extrapolati ve ability during translati onal drug development (Figure 1). In Chapter 3, a 
systemati c search was performed in PubMed to investi gate the pathways involved in dopa-
minergic drug eff ects, as well as the availability of blood-based biomarkers related to these 
pathways. A multi tude of pathways appeared to be associated with dopaminergic drug 
eff ects. This included the neurotransmitt er, the nitric oxide and the kynurenine pathway 
in the brain, as well as neuroendocrine and energy pathway responses in the periphery. 
Although this may parti ally be att ributed to the lack of selecti vity of dopaminergic drugs 
(24,25), also selecti ve drugs appeared to perturb multi ple pathways (26–28). Additi onally, 
we found no studies describing the relati on between drug eff ects in the brain and blood-
based biomarkers, except for prolacti n. Moreover, pharmacological eff ects were typically 
evaluated in a stati c manner, with no quanti fi cati on of the dynamics underlying the dose 
response relati on. On basis of these two chapters, we identi fi ed three goals an integrati ve 
PK/PD-metabolomics method needs to fulfi ll in order to answer our questi ons:
- Longitudinal measurement of a systems biomarker response with multi ple dose levels 
included
- Simultaneous evaluati on of drug concentrati ons and drug response biomarkers in 
plasma and the brain
- Integrati on of PK/PD principles into pharmacometabolomics data analysis
Figure 1. Proposed workfl ow of PK/PD metabolomics in interspecies scaling Modifi ed from (56) with per-
mission of Taylor and Francis.
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Secti on II – The dynamical neuroendocrine systems response to study 
dopamine D2 drug eff ects
One way to discover blood-based biomarkers is to evaluate the neuroendocrine systems 
response to CNS drug administrati on (Figure 2). The neuroendocrine system is a connec-
ti on between the neural system and the endocrine system, composed of the hypothala-
mus, the pituitary and the distant endocrine organs. Neural projecti ons from the hypo-
thalamus to the pituitary, for example the tuberoinfundibular dopamine (TIDA) neurons, 
are controlled by neurochemicals, such as dopamine, serotonin or acetylcholine. These 
neurons then release signal (e.g. dopamine) into the pituitary to regulate the release of 
hormones (e.g. prolacti n) from the anterior pituitary into the circulati on (29). Additi onal 
to this mechanism, hypothalamic neurons can also release neuropepti des (e.g. oxytocin) 
directly into the circulati on from their end-feet located in the posterior pituitary. As one 
of the blood-based biomarker strategies depicted in Figure 2, this principle has been used 
to evaluate dopaminergic drug eff ects with prolacti n as blood-based biomarker (30–33).
Although widely applied with proven applicability in biomarker-driven drug development, 
a single-biomarker approach has limitati ons. As we have seen, dopaminergic drugs exhibit 
multi ple eff ects on the neuroendocrine system. To anti cipate a broader in vivo pharmaco-
logical profi le, we set out for a multi -biomarker approach that can refl ect the dynamic en-
docrine systems response to dopamine drug administrati on. In Chapter 4 we investi gated 
the feasibility of a dynamical neuroendocrine systems response upon administrati on of 
the dopamine D2 antagonist remoxipride. Interesti ngly, only adenocorti cotropic hormone 
(ACTH) and prolacti n showed a response, while brain-derived neurotropic factor (BDNF), 
follicle-sti mulati ng hormone (FSH), growth hormone (GH), luteinizing hormone (LH), thy-
roid sti mulati ng hormone (TSH) and oxytocin remained unaff ected by remoxipride (Table 
I). The number of neuroendocrine biomarkers responding to the dopamine D2 agonist 
quinpirole was also low as we showed in Chapter 5, although now also GH and TSH re-
sponded in additi on to ACTH and PRL (Table I). Considering that the dopaminergic system 
is biologically connected to more pituitary hormones and neuropepti des than those iden-
ti fi ed in our studies, for example FSH and LH (34), it is likely that the underlying biological 
networks are resilient to dopaminergic perturbati on by remoxipride and quinpirole. Also, 
the absence of remoxipride eff ect on GH and TSH release suggests no basal D2 receptor 
acti vati on by endogenous dopamine. Considering the higher affi  nity of quinpirole to the 
D2 receptor relati ve to endogenous dopamine, it is indicated that only high levels of D2 
receptor acti vati on infl uence the release. Further studies with multi ple dopamine agonists 
and antagonists are required to validate this series of neuroendocrine markers that can 
evaluate pharmacological perturbati on of the dopaminergic system.
General discussion and conclusion 189
Table I. Overview of neuroendocrine responses aft er remoxipride and quinpirole administrati on
Remoxipride Quinpirole
Alpha MSH NA 0
Beta Endorphin NA 0
Neurotensin NA 0
Orexin A NA 0
Oxytocin 0 0









Figure 2. Diff erent physiological mechanisms through which blood-based biomarkers may be related to 
pharmacological eff ects in the brain. Modifi ed from (57) with permission of Springer.
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An important question is how the hormone-specific potencies are to be interpreted. Two 
factors influence the potency: receptor affinity and signal transduction efficiency (35). 
For remoxipride, prolactin was assumed to be the ‘gold standard’ as biomarker for D2 
receptor activation. While ACTH was found controlled by dopamine in a D2 specific man-
ner, remoxipride would inhibit its release following this mechanism (36). Interestingly, an 
increase of ACTH release was observed in Chapter 4. Therefore, ACTH likely represents an 
off-target effect. Concretely, it was concluded that the effect was possibly mediated via the 
adrenergic receptor, given the ratio of potencies EC50,ACTH/EC50,PRL being similar to the ratio of 
receptor affinities ki,α2/ki,D2 (37) (Chapter 4). While this is an example of the affinity driving 
the differences in potency estimates, Chapter 5 shows how signal transduction efficiency 
determined the differences in potency estimates with quinpirole. Indeed, we could well de-
scribe the ACTH, GH, prolactin and TSH responses assuming equal affinity (kA), but different 
maximal effect (EM) and signal transduction efficiency (τ) (Equation 1, Figure 3, Chapter 5). 
Interestingly, τ could be assumed being related to D2 receptor expression on the hormone 
releasing ‘troph’ cells in the pituitary (Equation 2), showing that the signal transduction 
efficiency can be driven by the characteristics of a specific biological subsystem.
Figure 3. Simulated concentration-effect relation profiles between quinpirole and ACTH, PRL, GH and TSH 




τ = τ0 * eslp * receptor expression  (2)
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Additional to single-administration biomarker responses, Chapter 5 also presented the 
effects of longer-term quinpirole administration. This is potentially important for drugs 
with intended chronic use, amongst which antiparkinson D2 agonists. Indeed, the effect 
of D2 agonists may be subject to sensitization or tolerance as was shown in rats (38). The 
basal levels of ACTH and prolactin were changed after 8-day administration relative to 
a single administration. Moreover, not only the basal levels were changed, but also the 
potency of quinpirole affecting the TSH release. Thus, homeostatic feedback mechanisms 
may cause changes in basal biomarker levels, as well as the responsiveness of biomarkers 
to the drug. Interestingly, the biogenic amine and amino acid responses were not changed 
with longer-term quinpirole administration (Chapter 7). This suggests that the systems 
related to biogenic amines and amino acids are more resilient than the neuroendocrine 
system to longer-term quinpirole treatment.
As a final remark on using the neuroendocrine system to identify blood-based biomarkers 
of pharmacological action in the brain, we would like to discuss the topic of target site 
of drug action. The pituitary is not protected by the blood-brain-barrier, and hence, it is 
exposed to plasma drug concentrations. While we could statistically identify brain extracel-
lular fluid (brainECF) as target site for the effect of remoxipride on prolactin, also confirmed 
by others (31), this was not possible for ACTH. Neither could we draw such conclusion 
for the effect of quinpirole on ACTH, GH, prolactin and TSH. In case of quinpirole, we 
assumed that with 5 times higher concentrations around the D2 receptor in the brain as in 
plasma (i.e. Kp,uu = 5), the brain influence would be dominant. However, we acknowledge 
that the hormone release likely is influenced both at the level of the hypothalamus and 
the pituitary. The current lack of simultaneous drug and dopamine concentration data in 
both tissues hampers the development of a model describing a two-level influence of the 
drug. However, the collection of this type of data appears possible; others have performed 
microdialysis sampling in the hypothalamus (39) and the pituitary (40), enabling the quan-
titation of dopamine and drug levels in both tissues.
Altogether, these chapters included longitudinal measurement of a neuroendocrine sys-
tems biomarker, after multiple doses of a D2 antagonist and a D2 agonist. By applying a 
PK/PD evaluation to these data, we gained quantitative insights into the neuroendocrine 
response to dopaminergic drugs and relate those to drug-specific and system-specific 
pharmacological characteristics.
Section III – The dynamical biochemical systems response to study dopamine D2 
drug effects
In section III the multi-biomarker approach was extended from a neuroendocrine platform 
with up to 15 hormones and neuropeptides to a metabolomics platform containing 76 
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amino acids and biogenic amines (41). Several statistical methodologies had been devel-
oped dealing with time-resolved high-dimensional (e.g. metabolomics) data. Clustering, 
for example, is a useful method to identify the main longitudinal patterns in a multivariate 
dataset (42,43). However, in our experiments we intended not only to include the dimen-
sion of time, but also the dimension of dose and sampling site (i.e. plasma and brainECF), in 
a parallel study design. A multivariate method that can include multiple dimensions, such 
as time, dose and sampling site, ANOVA-simultaneous component analysis (ASCA) was de-
veloped (44). It has been applied to study the effects of dose and time on a metabolomics 
response in osteoporosis arthritis guinea pigs receiving different dose levels of vitamin C. 
While this method filled the gap of taking into account underlying study design factors in 
multivariate statistics, it did not apply very well to our data. In contrast to the guinea pig 
data, our sampling times are very close and unevenly spaced. Therefore, the successive 
data points are correlated in a non-linear manner. Treating these time points as factor 
would limit the identification of the underlying dynamics. More importantly, none of the 
existing methods dealing with multivariate dynamical patterns integrates pharmacological 
principles into the data analysis. Therefore, we set out to integrate PK/PD principles into 
multivariate data analysis. In Chapter 6, we measured time-resolved biogenic amine and 
amino acid patterns upon administration of several remoxipride dose levels. Then, using a 
three-step approach of i) fitting a turnover model to each single biomarker; ii) clustering 
the metabolites on basis of the pharmacological parameter estimates; and iii) fitting a 
turnover model to each cluster of biomarkers, we identified 6 different PK/PD patterns in 
the data. The in vivo potency values related to the clusters were estimated to be 0.0027, 
0.019 or 0.12 μM, indicating multiple pathways involved in remoxipride pharmacology. 
Although we cannot indicate whether these differences were related to off-target effects 
or differences in signal transduction efficiency, either way this PK/PD-metabolomics model 
provided a way to define a therapeutic range on basis of a systems response. Furthermore, 
from the 44 analytes that could be robustly analyzed, 18 were identified as potential 
biomarker for further validation. While this was a step forward shifting the fully empirical 
multivariate statistical methods towards a mechanistic modeling approach, the PK/PD-
metabolomics method lacked one important feature. No information was included on the 
biomarker responses in the brain. Unfortunately, at the time, the measurement of biogenic 
amine and amino acid response in brainECF by means of intracerebral microdialysis ap-
peared not robust enough. In Chapter 7, however, after optimization of the microdialysis 
method for biogenic amine and amino acid analysis, simultaneous biomarker measure-
ments in brainECF and plasma were included. Using model comparison metrics, the target 
site of action related to the individual biomarkers was identified. The clustering step, now 
both on the brainECF and the plasma response, was different from that applied in Chapter 
6. While the remoxipride responses could all be described by turnover models, a larger 
variety of models, including pool models, turnover models and transit compartment mod-
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els, was needed for the quinpirole responses. Therefore, parameter-based clustering not 
being possible, the clustering was based on simulated biomarker patterns. This clustering 
approach was proven successful by a good fit of the cluster patterns, as well as the single 
metabolite patterns by the cluster-based PK/PD model. From this chapter, there are three 
important conclusions to draw. First of all, even considering that the plasma quinpirole 
concentrations are 5 times lower than those in brainECF, there are multiple effects observed 
with plasma as target site. Second, while these biomarker responses originate in other tis-
sues than the brain, most of them are propagated to the brain via transport over the BBB 
by various transporters. Thus even a drug that does not penetrate the brain, might cause 
secondary responses in the brain (Figure 4). Third, although multiple biomarker responses 
were observed in brainECF, only a few of them were transported over the BBB into plasma 
as a potential blood-based biomarker (Figure 4).
Figure 4. Potential biomarkers of quinpirole effect in brainECF (left) or plasma (right), positioned right from 
the vertical grey line. Red circles indicate the biomarkers that distribute over the blood-brain-barrier.
Counter-intuitively, many of the amino acids and biogenic amines that decreased upon 
remoxipride treatment, were also inhibited by quinpirole. Since in both studies a control 
group receiving saline was included, the responses must be attributed to drug action. A 
possible explanation could be that the responses of either remoxipride or quinpirole are 
caused via another target than the D2 receptor. Quinpirole has high affinity for the D2 and 
the D3 receptor. There is, however, no reason to believe that D3 receptor opposes D2 
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receptor, such that D3 receptor agonism leads to similar actions as D2 receptor antago-
nism. Alternatively, remoxipride possibly interacts with the adrenergic receptor at high 
concentrations (Chapter 3); however, in Chapter 6 the highest dose was reduced by 50%. 
Interestingly, remoxipride has higher affinity as an antagonist for the sigma receptor than 
for the D2 receptor (37,45,46). Sigma receptor ligands have been investigated in clinical 
trials for several indications, including diarrhea (agonists) and schizophrenia (antagonists) 
(47,48). Activation of the sigma receptor reduced the motility of the ileum (49). Antago-
nism of the sigma receptor, possibly leading to increased motility of the ileum, may lead 
to shorter intestinal transit time and the concordant reduction of amino acid uptake. 
Furthermore, the sigma receptor inhibits NMDA receptor sensitization by phosphoryla-
tion of the NR1 subunit (50). As an antagonist, remoxipride may thus have disinhibited 
NMDA receptor sensitization, with the reduction of the NMDA co-activators glycine and 
serine as a consequence of negative feedback. The reduction of biogenic amine and amino 
acid levels caused by remoxipride may thus be mediated via the sigma receptor. Although 
a definitive answer to this matter remains elusive, it underlines the need for extension 
of our work with other dopamine ligands to identify the responses that are specifically 
related to D2 receptor interaction.
Altogether, in Chapter 6 and Chapter 7, we have developed a methodology that accounts 
for the pharmacological principles underlying the relation between the drug dose and the 
systems biomarker response. Concretely, we could identify unique in vivo concentration-
effect relations, target site of drug action, and potential blood-based biomarkers repre-
senting the systems response.
We have shown how the PK/PD-metabolomics method, in combination with serial blood 
and brainECF sampling and multiple dose levels included, enables the identification of 
multiple concentration-effect relations and the concordant target site of drug action, 
and potential blood-based biomarkers that represent these pharmacological properties. 
Furthermore, as a step towards further mechanistic insight, in a targeted analysis on the 
neuroendocrine system, we could reveal the relation between drug response, signal trans-
duction efficiency and D2 receptor expression on the pituitary hormone secreting cells. 
This positions the PK/PD-metabolomics method in between the unbiased, yet empirical 
multivariate statistical methods and the mechanism-based quantitative systems pharma-
cology (QSP) approaches (Figure 5).
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Figure 5. Positi oning of PK/PD-metabolomics models between quanti tati ve systems pharmacology (QSP) 
models and multi variate stati sti cal models
Perspecti ves of the PK/PD-metabolomics method in CNS drug development
CNS drug development is hampered by poor understanding of pharmacological mecha-
nisms underlying the drug eff ects on one hand, and lack of (blood-based) biomarkers 
representi ng these mechanisms on the other hand. Given that insight into pharmacologi-
cal mechanisms are strongly associated with the success in clinical drug development (20), 
there is a need for methodologies that enable early investi gati on of these mechanisms. 
The PK/PD-metabolomics method has the potenti al to increase early insights into phar-
macological mechanisms in an unbiased and integrated manner. Metabolomics analysis 
can easily be added to the standard batt ery of analysis performed in (pre-)clinical studies. 
Currently, the metabolomics analysis of one sample costs between the 25 and 400 euros, 
depending on the sensiti vity and the number of analytes. A hypotheti cal study with 50 
subjects and 20 samples per subject will thus cost between 25,000 and 400,000 euros. In 
the context of the costs of late att riti on, this is negligible (4).
PK/PD-metabolomics could have an advantage from early drug discovery to late drug 
development. During early drug discovery, drugs are typically selected on basis of their 
affi  nity to the target of interest. However, it is argued that the effi  cacy of many CNS drugs 
is related to multi -target affi  nity, rather than the selecti vity for a single-target (24). Multi -
variate analysis of in vitro receptor affi  nity profi les of anti -Parkinson drugs revealed sub-
clusters of the D2 agonists, and it was suggested that other receptors were also involved in 
the effi  cacy of these drugs. PK/PD-metabolomics could provide the basis of the correlati on 
between these in vitro receptor affi  nity profi les and the in vivo potency profi les to further 
investi gate the relati on between the in vitro binding fi ngerprint and the in vivo systems 
eff ects.
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During early drug development, PK/PD-metabolomics will be of value for the discovery 
of biomarkers, as well as their characterization in terms of pharmacological parameters. 
Moreover, we have shown how blood-based biomarkers can be discovered with metabolo-
mics analysis performed both in brainECF and plasma. These biomarkers will be of great value 
for CNS drug development, given the limitations of human brain sampling. Ultimately, PK/
PD-metabolomics could provide the basis of interspecies scaling of a systems-biomarker 
response as tool in the guidance of the first-in-human dosing regimen. The subsequent 
validation of the PK/PD-metabolomics model on human metabolomics data could create 
insights into interspecies differences relevant for drug development.
Finally, in this thesis inter-individual variation was mostly assumed not present given the 
standardized experimental design. However, inter-individual variation is a key element 
in precision medicine during clinical development (51). PK/PD-metabolomics is easily 
extended to describe personal drug responses in order to optimize dosing regimen in an 
individualized manner. For example, the reduction of TSH by D2 agonists is known to ex-
acerbate the clinical condition of hypothyroidism patients (52). Knowing the quantitative 
relation between D2 agonist dose and the TSH response will enable personalized dosing 
guidance preventing an unacceptable reduction of TSH levels.
Further development of the PK/PD-metabolomics method
While we have shown the potential of the PK/PD-metabolomics method, we would like to 
make a few recommendations for further research.
Application of the PK/PD-metabolomics method to other D2 ligands and clinical 
validation for proof-of-concept
This thesis has shown the development and feasibility of the PK/PD-metabolomics ap-
proach, which now is ready for further validation to generate a proof-of-concept. As we 
discussed earlier, the comparative results of the D2 agonist quinpirole and the D2 antagonist 
remoxipride appeared non-intuitive, possibly because non-dopaminergic responses are 
involved. Therefore, to ensure the discovery of dopamine system specific biomarkers, we 
recommend applying the PK/PD-metabolomics method to multiple D2 ligands to reveal the 
overlapping systems biomarker responses. Furthermore, as we argued in Chapter 2 the 
PK/PD-metabolomics method has potential to bridge the lack of mechanistic biomarkers 
that can be used across preclinical and clinical drug development. In Chapter 7 we showed 
how a combination of microdialysis and PK/PD-metabolomics enables the identification 
of blood-based biomarkers. As visualized in Figure 1, an important future step will be the 
clinical validation of these biomarkers.
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Microdialysis in multiple brain locations to study regional responses in the brain
In our experiments, microdialysate samples were collected from the caudate putamen to 
evaluate biomarker responses representing the function of striatal neurons. A higher level 
of complexity is presented in the form of brain circuitry that would allow for a regional 
evaluation of CNS pharmacology (7,14). An interesting next step will be to connect those 
circuits to the underlying biochemical processes. We recommend the simultaneous evalu-
ation of biochemical responses in multiple brain regions, such as the caudate putamen, 
the prefrontal cortex or the nucleus accumbens, in order to evaluate the biochemistry 
related to the circuit functionality. Simultaneous microdialysis sampling in multiple brain 
regions has proven feasible for CNS PK studies (53).
Additionally, cerebrospinal fluid (CSF) sampling should be included in future PK/PD-metab-
olomics studies. CSF-based biomarkers have the advantage over blood-based biomarkers 
that they are not blocked by the BBB. Indeed, in our study with quinpirole, we found many 
brainECF biomarkers not reflected in plasma. CSF might provide a good alternative.
Application of PK/PD-metabolomics to measurements from multiple analytical platforms
The PK/PD-metabolomics methodology was developed on basis of the biogenic amine 
and amino acid metabolomics platform. The choice of this platform was based on our ex-
pectation that many of these biomarkers would respond to dopamine ligands. Indeed, we 
identified many of them responding to remoxipride and quinpirole. However, many other 
biomarkers, for example, lipids and acylcarnitines, may also be included in the future to 
study the effects of CNS drugs on multiple biochemical pathways. Our analyses were lim-
ited to biogenic amines and amino acids because of limited microdialysate sample volume. 
Indeed, with microdialysis, there is a compromise between sample volume, time resolu-
tion and recovery of the biomarker into the microdialysate. Fortunately, developments 
at the microdialysis-metabolomics interface are continuously increasing, also focusing on 
improving the sensitivity of analytical methodology (54,55).
Inclusion of sex differences in the study design
While in our studies only male animals were included for purposes of standardization, 
there is clear evidence for the impact of sex on biological pathway functionality in disease 
and drug effect (56,57). Indeed, sex difference was one of the factors that limited the 
comparison of studies in Chapter 3 and Chapter 5. As an example, the interaction between 
dopamine or dopamine agonists and the pituitary D2 receptor is influenced by estrogen, 
that is expressed in much higher levels in females than in males (58,59). Given the impor-
tance of sex differences in disease and drug effect, it will be important to include sex as a 
variable in clinical and preclinical studies. 
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General conclusion
We set out to quantify the relation between drug dose and the dynamic systems biomarker 
response, as well as to discover blood-based biomarkers that represent drug effects in the 
brain. To that end, we developed the PK/PD-metabolomics method for identification of the 
main PK/PD patterns in the data. These PK/PD patterns were described in terms of phar-
macologically relevant parameters, such as EMAX and EC50, enabling inter- and extrapolation 
of the systems biomarker response. For the neuroendocrine system, with more knowledge 
available on the physiological processes involved, we could obtain further mechanistic 
insights, relating signal transduction efficiency to D2 receptor expression in the pituitary. 
Furthermore, with time-resolved metabolomics data available in both brainECF and plasma, 
PK/PD-metabolomics enabled the identification of the target site of drug effect for the 
different biomarkers, as well as the discovery of blood-based biomarkers of drug effects 
in the brain. Being positioned between the general multivariate statistical methods and 
QSP models, PK/PD-metabolomics will be useful to provide quantitative pharmacological 
insights into the systems response of CNS drugs in a data-driven manner. 
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Ziekten van het centraal zenuwstelsel (Central Nervous System; CNS) verlagen de kwaliteit 
van leven van miljoenen mensen over de hele wereld. Er is veel tijd, moeite en energie 
gestoken in het ontwikkelen van CNS medicijnen, terwijl de successen beperkt zijn. Een 
belangrijke reden hiervoor zijn het beperkte begrip van de complexiteit van de hersenen, 
de aanwezigheid van de bloed-hersen-barrière die de penetratie van medicijnen in de 
hersenen tegenhoudt, bijwerkingen in het centraal zenuwstelsel, en de afwezigheid van 
goede biomarkers die de interactie tussen medicijnen en neurofysiologische systemen 
representeren. 
Systeemfarmacologie heeft als doel om meerdere biologische systemen te integreren bij 
het evalueren van farmacologische effecten, om zo het begrip en de voorspelbaarheid van 
medicijneffecten te verbeteren. Veel systeem-farmacologische benaderingen zijn veelbe-
lovend, echter, deze zijn veelal gebaseerd op gedetailleerde farmacologische voorkennis 
van het betreffende medicijn en biologische systeem. Dit is niet altijd het geval tijdens 
de vroege fase van medicijn-ontwikkeling. Met de zogenaamde metabolomics-benadering 
kunnen de farmacologische effecten gescreend worden op een data-gedreven manier om 
de systeem-effecten van medicijnen te evalueren op het niveau van biochemische mecha-
nismen. Echter, om de typisch niet-lineaire relaties tussen medicijn dosering en effect te 
begrijpen en te extrapoleren, moeten deze relaties gekwantificeerd worden met behulp 
van farmacokinetisch/farmacodynamisch (PK/PD) modelleren. Het is daarom belangrijk 
om van een volledige empirische benadering te bewegen naar een mechanistische bena-
dering zonder daarbij de data-gedreven eigenschappen van de metabolomics-benadering 
te verliezen. Bovendien, omdat de mogelijkheden het bemonsteren van het brein beperkt 
zijn, is het belangrijk om biomarkers te vinden die, aanwezig in het bloed, de medicijn-
effecten in het brein representeren. Dit proefschrift gaat daarom in op twee vragen: 
1. Hoe kunnen we de relatie tussen medicijn dosering en de systeem-respons in vivo 
kwantificeren? 
2. Hoe kunnen we biomarkers in het bloed identificeren die effecten in het brein repre-
senteren? 
Sectie I – Algemene introductie
Als eerste stap zijn deze vragen in hoofdstuk 2 in de context geplaats van de vroege fase 
van CNS medicijnontwikkeling, namelijk die van de translationele  farmacologie; de stap 
van dier naar mens. Hierbij ligt een speciale focus op de farmacologische schaling tus-
sen diersoorten. Aan de ene kant maakt metabolomics het mogelijk om de biochemische 
verschillen tussen dieren grondig te onderzoeken. Aan de andere kant geeft mechanistisch 
PK/PD modelleren, in combinatie met technieken als allometrische en fysiologie-geba-
seerde schaling, de mogelijkheid om medicijn-effecten te extrapoleren van de ene naar 
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de andere soort. Bovendien kan mechanistisch PK/PD modelleren gebruikt worden om 
de relatie tussen neurologische effecten en biomarkers in het bloed te beschrijven. Het 
zogenaamde PK/PD-metabolomics modelleren is voorgesteld als een integratie tussen PK/
PD en metabolomics die de potentie heeft om het begrip en het voorspelbaar vermogen 
gedurende translationeel medicijnonderzoek te verbeteren. In hoofdstuk 3 hebben we 
een systematische zoektocht in PubMed uitgevoerd om de biochemische mechanismen 
te onderzoeken die betrokken zijn bij dopaminerge medicijn-effecten, met daarin mee-
genomen de beschikbaarheid van biomarkers in het bloed die hieraan gerelateerd zijn. 
Een veelvoud aan biochemische mechanismen bleek geassocieerd met dopaminerge 
medicijneffecten, zoals de neurotransmitter, the nitric oxide, en de kynurenine systemen. 
Daarnaast bleken de neuro-endocriene en metabole systemen te reageren op toediening 
van dopaminerge medicijnen. Hoewel dit deels toe te schrijven is aan de beperkte selec-
tiviteit van veel dopaminerge medicijnen, lieten ook de selectieve medicijnen een breed 
effectenpatroon zien. Met uitzondering van prolactine vonden we in deze literatuurstudie 
geen biomarkers die de relatie tussen medicijneffecten in het brein en biomarkers in het 
bloed beschreven. Bovendien liet deze studie zien dat farmacologische effecten over het 
algemeen statisch worden geëvalueerd (dosis-respons relatie op één tijdspunt), zonder de 
tijdsdynamiek mee te nemen die van groot belang is voor de dosis-effect relatie. 
Op basis van deze twee hoofdstukken hebben we drie eigenschappen bepaald waaraan 
een PK/PD-metabolomics methode-ontwikkeling aan moet voldoen om onze vragen te 
beantwoorden:
1. Een longitudinale analyse van een systeem-biomarker respons met meerdere dose-
ringsniveaus 
2. Simultane analyse van medicijnconcentraties en medicijneffect in het bloed en de 
hersenen
3. Een integratie van PK/PD principes in multivariate analyse van metabolomics data
Sectie II – De dynamische respons van het neuro-endocriene systeem om 
dopamine D2 medicijneffecten te bestuderen
Een van de manieren om biomarkers in het bloed te vinden is om de respons van het 
neuro-endocriene systeem op toediening van CNS medicijnen te bestuderen. Het 
neuro-endocriene systeem verbindt het neurale systeem met het endocriene systeem, en 
bestaat uit de hypothalamus, de hypofyse en verschillende verder afgelegen endocriene 
organen. Neurale projecties vanuit de hypothalamus naar de hypofyse, zoals de tubero-
infundibulaire dopamine (TIDA) neuronen, worden aangestuurd door neuro-chemische 
stoffen zoals dopamine, serotonine en acetylcholine. Deze neuronen geven een signaal 
aan de hypofyse (door bijvoorbeeld dopamine uit te scheiden) om van daaruit de uit-
scheiding van hormonen (bijvoorbeeld prolactine) in het bloed te reguleren. Daarnaast 
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kunnen neuronen die hun cellichaam in de hypothalamus hebben ook neuro-peptiden 
(zoals oxytocine) uitscheiden vanuit hun eind-voeten die zich in de hypofyse bevinden. Het 
principe van deze neuro-endocriene mechanismen is al vaker gebruikt om dopaminerge 
medicijneffecten te bestuderen met behulp van prolactine als biomarker. 
Hoewel het vaak toegepast is, met bewezen nut in biomarker-gedreven medicijnontwik-
keling, heeft een single-biomarker benadering nadelen. Zoals we zagen in hoofdstuk 3, 
veroorzaken dopaminerge medicijnen een veelvoud aan effecten op het neuro-endocriene 
systeem. Anticiperend op een breder in vivo farmacologisch profiel, willen we een multi-
biomarker benadering ontwikkelen dat de dynamische respons van het neuro-endocrine 
systeem op dopaminerge medicijntoediening beschrijft. In hoofdstuk 4 hebben we de 
haalbaarheid van deze benadering onderzocht met behulp van de dopamine D2 antagonist 
remoxipride. Interessant genoeg lieten allen adrenocorticotropic hormone (ACTH) en 
prolactine een respons zien, terwijl brain-derived neurotropic factor, follikelstimulerend 
hormoon, groeihormoon, luteïniserend hormoon, schildklier stimulerend hormoon 
en oxytocine niet reageerden op remoxipride. Het aantal neuro-endocriene hormonen 
dat een effect liet zien na toediening van de dopamine D2 agonist quinpirole was ook 
laag, zoals we laten zien in hoofdstuk 5, hoewel nu ook groeihormoon en schildklier 
stimulerend hormoon een effect lieten zien. Overwegende dat het dopaminerge systeem 
biologisch verbonden is met meer neuro-hormonen en neuro-peptiden dan het aantal dat 
wij identificeerden in onze studies, is het waarschijnlijk dat de onderliggende biologische 
netwerken een bepaalde veerkracht hebben als het gaat om dopaminerge verstoring door 
remoxipride en quinpirole. Daarnaast suggereert de afwezigheid van het effect van de 
antagonist remoxipride op groeihormoon en schildklierhormoon dat er geen endogene 
dopaminerge stimulatie van deze hormonen plaatsheeft. Gegeven de hogere affiniteit van 
quinpirole voor de D2 receptor, in vergelijking met endogeen dopamine, lijkt het waar-
schijnlijk dat alleen hoge mate van D2 receptor activatie van invloed is op de uitscheiding 
van deze twee hormonen. Vervolgstudies met meerdere dopamine agonisten en antago-
nisten zijn nodig om de gevonden biomarkers te valideren.
Met behulp van PK/PD modelleren zijn de potenties (mate van activiteit van een medicijn) 
van quinpirole en remoxipride op de verschillende hormonen bepaald. Een belangrijke 
vraag is hoe deze geïnterpreteerd moeten worden. Er zijn twee factoren die de potentie van 
medicijnen beïnvloeden: receptor affiniteit (mate van bindingsvermogen aan de receptor) 
en signaal transductie efficiëntie (mate van doorgeven van een signaal na binding aan de 
receptor). In het geval van remoxipride laten we zien dat de receptor activiteit bepalend 
kan zijn voor verschillen in potenties tussen de verschillende biomarkers. Prolactine en 
ACTH lieten allebei een effect zien met een verschillende potentie voor remoxipride. 
Prolactine is welbekend als biomarker voor dopamine effecten. De ACTH respons betreft 
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waarschijnlijk een off-target effect, aangezien de verhoging van ACTH concentraties in 
het bloed niet verklaard kan worden met een dopamine effect – de ACTH concentraties 
zouden dan verlagen. Mogelijk kan dit effect verklaard worden met een adrenerg mecha-
nisme, aangezien de ratio van de potenties (EC50,ACTH/EC50,PRL) vergelijkbaar is aan de ratio 
van de receptor affiniteiten (ki,α2/ki,D2) (hoofdstuk 4). Terwijl dit voorbeeld laat zien dat de 
receptor affiniteit bepalend kan zijn voor het verschil in potenties, laten we in hoofdstuk 5 
zien hoe signaal transductie de verschillen kan verklaren. Met behulp van vergelijking (1) 
hebben we de relatie tussen quinpirole concentraties en hormoon effecten beschreven. 
Hierin namen we aan dat de affiniteit (kA) gelijk was bij ieder hormoon, terwijl het maxi-
male effect (Em) en de signaaltransductie efficiëntie parameter (τ) verschillend waren tus-
sen de hormonen. Onder deze aannames kon deze vergelijking de effecten van quinpirole 
op de hormoonspiegels goed beschrijven. Een interessante observatie in hoofdstuk 5 was, 
bovendien, dat de signaaltransductie efficiëntie beschreven kon worden aan de hand van 
de dopamine D2 receptor expressie op de hormoon-uitscheidende cellen in de hypofyse 
(vergelijking (2)). Dit laat zien dat de signaal transductie efficiëntie gedreven kan worden 




τ = τ0 * eslp * receptor expression  (2)
Naast het effect van eenmalige toediening van quinpirole op de hormoonspiegels, hebben 
we in hoofdstuk 5 ook de effecten onderzocht van langdurige toediening. Dit kan belang-
rijk zijn voor medicijnen die bedoeld zijn om langdurig gebruikt te worden, zoals anti-
parkinson D2 agonisten. Inderdaad kan het effect van D2 agonisten over tijd veranderen als 
gevolg van sensitisatie en tolerantie mechanismen, zoals eerder aangetoond in ratten. In 
onze studies zagen we de basale bloedspiegels van ACTH en prolactine veranderen na acht 
dagen van toediening. Bovendien veranderden niet alleen de basale spiegels, maar ook de 
potentie van quinpirole om schildklier stimulerend hormoon te beïnvloeden. Biologische 
terugkoppelingsmechanismen kunnen dus, als gevolg van langdurige toediening van 
quinpirole, zowel de basale biomarker spiegels als de farmacologische gevoeligheid van 
biomarkers veranderen. In tegenstelling tot de neuro-endocriene biomarkers, lieten de 
biogenic amines en aminozuren geen specifieke verandering zien als gevolg van langdurige 
toediening, zoals we in hoofdstuk 7 laten zien. Dit suggereert dat de systemen onderlig-
gend aan deze biomarkers veerkrachtiger zijn dan het neuro-endocriene systeem als het 
gaat om langdurige blootstelling aan quinpirole. 
In de hoofdstukken 4 en 5 hebben we aangenomen dat de neuro-hormonen aangestuurd 
werden vanuit het brein. Aangezien de hypofyse niet beschermd wordt door de bloed-
hersen-barrière, is deze ook blootgesteld aan medicijnconcentraties in het bloed. Hoewel 
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we in hoofdstuk 4 op basis van model selectie criteria konden aantonen dat de prolac-
tine respons op remoxipride waarschijnlijk hoofdzakelijk vanuit de hersenen aangestuurd 
wordt, konden we dit niet aantonen voor ACTH. Ook voor het effect van quinpirole op de 
verschillende hormonen konden we dit niet aantonen in hoofdstuk 5. In het geval van 
quinpirole namen we aan dat het effect op de neuro-endocriene hormonen hoofdzakelijk 
in het brein geïnitieerd werd, vanwege het feit dat de vrije medicijnconcentraties in het 
brein 5 keer hoger zijn dan in het bloed. De huidige afwezigheid van simultane medicijn 
en dopamine concentraties in hersenen en bloed, beperkt de mogelijkheden tot het 
ontwikkelen van den model dat de invloed van CNS medicijnen op beide niveaus tegelijk 
beschrijft. 
Samenvattend beschrijven deze hoofdstukken studies die een longitudinale analyse van 
een neuro-endocriene systeem-biomarker bevatten met meerdere doseringsniveaus 
van een D2 agonist en een D2 antagonist. Door PK/PD modellering toe te passen op deze 
data kregen we kwantitatief inzicht in de neuro-endocriene respons op dopaminerge 
medicijnen, en konden we deze relateren aan medicijn-specifieke en biologisch systeem-
specifieke farmacologische eigenschappen. 
Sectie III – De dynamische respons van biochemische systemen om 
dopamine D2 medicijneffecten te bestuderen
In dit deel van het proefschrift hebben we de multi-biomarker benadering uitgebreid van 
een neuro-endocrien platform met 15 hormonen en peptiden naar een metabolomics 
platform met 76 aminozuren en biogenic amines. Er bestaan verschillende statische me-
thoden om tijdsafhankelijke en multi-biomarker (bijv. metabolomics) data te analyseren. 
Zo is clusteren een gebruikelijke methode om de belangrijkste longitudinale patronen 
in een multivariate dataset te identificeren. In onze data, echter, wilden we niet alleen 
de tijdsdimensie, maar ook de dimensie van dosering en plaats van bemonstering (zoals 
bloed en brein) bestuderen. Al eerder is een multivariate methode ontwikkeld, ANOVA-
simultaneous component analysis (ASCA), die dit mogelijk maakt. Met deze methode 
worden de onafhankelijke variabelen (tijd, dosering etc.) als categorische data behandeld. 
Hoewel dit goed werkt in het geval deze categorieën zich relatief lineair tot elkaar ver-
houden, wordt het problematisch wanneer dit niet het geval is. In onze data waren de 
monstertijden en de verschillende doseringen erg niet-lineair, waardoor deze methode het 
identificeren van de onderliggende dynamiek zou beperken. Belangrijker nog, geen van 
de bestaande methoden om multivariate dynamische patronen te analyseren integreerde 
farmacologische principes. Om die reden besloten we een methode te ontwikkelen die 
om kan gaan met niet-lineaire tijds- en doserings-patronen, en die PK/PD concepten 
integreert in de multivariate data analyse. In hoofdstuk 6 hebben we tijdsafhankelijke bio-
genic amine en aminozuur patronen gemeten na toediening van verschillende doseringen 
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van de D2 antagonist remoxipride. Vervolgens hebben we een drie-stappen benadering 
gebruikt – i) het beschrijven van alle individuele biomarkers met een turnover model; ii) 
het clusteren van de metabolieten op basis van hun farmacologische parameters; iii) het 
beschrijven van de clusters met een turnover model. Hiermee konden we zes verschillende 
PK/PD patronen identificeren, met in vivo potenties van 0.0027, 0.019 of 0.12 μM, wat 
suggereert dat er meerdere biochemische systemen beïnvloed worden door remoxipride. 
Hoewel we niet kunnen zeggen of deze verschillen gerelateerd zijn aan off-target effecten 
of verschillen in signaaltransductie efficiëntie, kunnen we met dit model wel iets zeggen 
over de therapeutische range op basis van een systeem-effect. Van de 44 metabolieten die 
we robuust genoeg konden meten, werden er 18 geïdentificeerd als potentiële biomarker 
voor verdere validatie. 
Hoewel dit een stap voorwaarts was van een volledig empirische, data-gedreven methode, 
miste dit model nog een belangrijk element; er was geen component dat de biomarker 
respons in het brein beschreef. Helaas was toentertijd de methode om biogenic amines en 
aminozuren in de extracellulaire vloeistof van het brein (via microdialyse) nog niet robuust 
genoeg om te gebruiken voor onze modellen. Na optimalisatie van deze methode konden 
we in hoofdstuk 7 biogenic amines en aminozuren simultaan meten in bloed en brein. 
Met onze modelleringsmethoden konden we nu de plaats van medicijnwerking  bepalen; 
een belangrijke stap vooruit. Met betrekking tot deze uitbreiding van de methode doen 
we drie belangrijke observaties. Allereerst, hoewel de concentraties van quinpirole in het 
brein 5 keer hoger zijn, lijken veel effecten te ontstaan buiten het brein. Ten tweede blijken 
veel van deze effecten over de bloed-hersen-barrière heen te getransporteerd te worden 
om alsnog een respons in het brein te veroorzaken. Als derde, hoewel een veelvoud aan 
biochemische responsen in de hersenen waargenomen worden als gevolg van quinpirole 
toediening, worden maar een enkele van deze responsen over de bloed-hersen-barrière 
getransporteerd om vervolgens in het bloed potentieel te kunnen functioneren als bio-
marker. 
Tegen de verwachting in, namen we een heel aantal aminozuren en biogenic amines waar 
die verlaagd waren na toediening van remoxipride (antagonist), maar ook na quinpirole 
(agonist). Mogelijk kan dit verklaard worden met off-target effecten. Zo heeft remoxipride 
hoge affiniteit voor de sigma receptor, en zou het op deze manier de opname van ami-
nozuren kunnen reduceren. Verder onderzoek is echter nodig om de onderliggende ver-
klaring te achterhalen. Bovendien benadrukt deze observatie het belang van uitbreiding 
van deze studies naar meerdere dopaminerge medicijnen. Hiermee is het mogelijk om te 
identificeren welke effecten specifiek zijn voor interactie met de dopamine receptor. 
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Kortom, in hoofdstuk 6 en hoofdstuk 7 hebben we een methode ontwikkeld dat de 
farmacologische principes die onderliggend zijn aan de relatie tussen medicijn dosering 
en biochemische systeem-respons te kwantificeren. Hiermee hebben we de in vivo 
concentratie-effect relaties, de plaats van werking, en potentiele biomarkers in het bloed 
bepaald. 
Perspectieven van de PK/PD-metabolomics methode in CNS 
medicijnontwikkeling
De PK/PD-metabolomics methode heeft potentie om de vroege inzichten tijdens het 
traject van medicijnontwikkeling te vergroten op een data-gedreven en integrale manier. 
Metabolomics analyse kan eenvoudig toegevoegd worden aan de standaard set van analy-
ses die worden gedaan in (pre-)klinische studies op een relatief goedkope manier, afgezet 
tegen de kosten van een laat-klinische mislukking van een medicijn. In tegenstelling tot de 
huidige selectiecriteria van nieuwe medicijnen gedurende de vroege ontwikkeling, veelal 
op basis van affiniteit voor een enkele receptor, is het mogelijk beter om te selecteren op 
basis van een affiniteitsprofiel voor meerdere receptoren, zoals blijkt uit literatuur. PK/
PD-metabolomics zou een manier kunnen zijn om de relatie tussen zo’n in vitro affiniteits-
profiel en de in vivo systeem-effecten verder te bestuderen om uiteindelijk te komen tot 
een model dat de systeem-effecten kan voorspellen op basis van een affiniteitsprofiel. 
Hoe dan ook zal PK/PD-metabolomics van waarde zijn voor het ontdekken van nieuwe 
biomarkers, samen met hun farmacologische karakterisering. Bovendien kunnen op deze 
manier al vroegtijdig potentiele biomarkers in het bloed geïdentificeerd worden in relatie 
tot hun respons in het brein. Dit is van grote waarde, gezien de beperkingen van bemon-
stering van het menselijk brein. Uiteindelijk kan PK/PD-metabolomics zo de basis vormen 
van de schaling van medicijneffecten van dieren naar mensen om zo richting te geven aan 
de doseringsbepaling in de first-in-human studies. 
Algemene conclusie
Het doel van deze studies was om een methode te ontwikkelen die de relatie tussen 
medicijndosering en de dynamische systeem-biomarker respons kan beschrijven, en die 
biomarkers in het bloed identificeert die iets vertellen over medicijneffecten in het brein. 
Hiervoor hebben we de PK/PD-metabolomics methode ontwikkeld die de belangrijkste 
biomarker patronen beschrijft in termen van farmacologisch relevante parameters zoals 
EMAX en EC50. Voor het neuro-endocriene systeem, waar we veel a priori biologische kennis 
van hebben, konden we een model ontwikkelen om de verschillen in hormoonrespons te 
verklaren met behulp van receptor expressie niveaus van de D2 receptor. De combinatie 
van deze responsen zijn daarmee uniek voor stimulatie van de D2 receptor. Daarnaast 
hebben we laten zien dat met PK/PD-metabolomics, in combinatie met tijdsopgeloste me-
tabolomics data in het brein en het bloed, de plaats van werking van medicijnen bepaald 
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kan worden, en biomarkers in het bloed gevonden kunnen worden die iets zeggen over 
effecten in het brein. Met haar positie tussen data-gedreven multivariate methodes en 
mechanistische systeem-farmacologie modellen, kan PK/PD-metabolomics kwantitatieve 
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